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General introduction, aim, and outline of the thesis
The complexity of the elastic fiber system and its 
relation with the pathogenesis of emphysema
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Abstract
Elastic fibers are elastic entities abundantly present in the extracellular matrix of 
the lung. The main components of the elastic fiber are elastin and microfibrils, 
the latter primarily consisting of fibrillin-1. In addition to fibrillin-1, a large array of 
other proteins, such as EMILINs, fibulins, LTBPs, lysyl oxidases, and MAGPs, 
are associated with the microfibrils. Despite the fact that elastic fibers play a 
dynamic role in postnatal alveolarization and are responsible for pulmonary 
resilience, our understanding of elastic fiber associated-proteins in the lung is 
only just beginning. In this review, the most abundant elastic fiber associated- 
proteins are addressed, including their expression, pulmonary location, and 
proposed biological function. Next, the consequence of genetic defects in these 
components will be associated to a developmental emphysematous phenotype 
and an early-onset adult emphysematous phenotype in the lung, as 
characterized by irreversible enlargement of the alveoli and a compromised 
elastic fiber. These genetic defects not only underscore the important role of 
elastic fiber associated-proteins in lung development and hereditary 
pathologies, but also serve as a valuable resource in the research to 
understanding the etiology and pathogenesis of smoking-related adult 
emphysema.
Introduction
The extracellular matrix is an intricate coherence of macromolecules, forming a 
connective network in organs like bone, cartilage, blood vessels, lung, skin, 
muscle, tendon, and ligament. By varying the type, amount, and organization of 
the various macromolecules, the extracellular matrix is adapted to the functional 
requirements of the tissue. For instance, the matrix in bone is calcified and 
organized in such a way that bone is a rather inelastic, rigid structure (1). In 
contrast, lung, which undergoes over a billion cycles of stretching and relaxation 
over a lifetime, needs to be both strong and elastic in order to function. This 
elasticity is brought about by a system of elastic fibers that form a fine and 
highly branched network throughout the respiratory tree. Clearly outlined elastic 
fibers are observed in the alveolar septa, bronchiole, pleura, and blood vessels 
of the lung. More specifically, one or two elastic fibers are observed in a 
transverse section of the alveolar septa, whereas the alveolar endtips have a 
focal accumulation of elastic fibers (2). The elastic fibers endow the lung with 
the required resilience for expansion and recoil (3). The driving force of this 
resilience is entropic in origin; stretching decreases the entropy of the elastic 
fiber components and generates a (passive) driving force for elastic recoil by a 
spontaneous return to maximal entropy (4-6).
Assembly of elastic fibers
Pulmonary elastic fibers are composed of two morphologically distinguishable 
components (2;7-9); an outer mantle consisting of tubular microfibrils with a 10­
12 nm diameter and an inner core of amorphous elastin intertwined by stretches 
of microfibrils (figure 1). Assembly of the elastic fiber takes place in the 
infoldings of the cell membrane (10). In these infoldings, microfibrils are the first 
visible components, grouped in small bundles near the plasma membrane (5). 
These bundles of microfibrils take the shape and orientation of the presumptive 
elastic fibers and act as a scaffold for elastin deposition (3;11-13). Elastin is 
secreted into the extracellular space as a soluble precursor protein called 
tropoelastin (14;15). In the lung, tropoelastin is synthesized by chondroblasts, 
smooth muscle cells, (myo)fibroblasts, and mesothelial cells (16), and mRNA 
levels of tropoelastin in these cells peak at vascularization and alveolarization 
(17). Secreted tropoelastin is deposited onto the microfibrillar scaffold and is 
aligned in the right position for the formation of cross-links (5). Cross-linking is a 
critical feature in the assembly of the elastic fibers. Tropoelastin contains 
numerous lysine residues which participate in the cross-linking of elastin (15). 
Enzymes from the lysyl oxidase (LOX) family catalyze the oxidative deamination 
and condensation of the lysyl side chains of the tropoelastin protein thereby 
forming areas of amorphous, insoluble, elastin between the microfibrils (5, 18). 
These amorphous areas gradually coalesce and form the central elastin core. 
The majority of microfibrils are displaced to the outer regions of the fiber, a 
position they retain throughout mature life (5). The LOX family consists of five 
members, one LOX and four LOX-like proteins (LOXL-1, -2, -3, and -4) (18;19).
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In the murine and human lung, mRNA for LOX, LOXL-1, and LOXL-2 is found 
(20). In addition, protein expression of LOX and LOXL-1 overlap in murine lung 
and is predominantly localized to the alveoli, bronchus and bronchioles (21). Of 
the LOX family, LOX and LOXL-1 are the two members involved in elastin 
cross-linking and, therefore, localize to most tissues rich in elastic fibers (21­
24).
MF coat
B
Figure 1, Ultrastructural composition o f pulmonary elastic fibers. A schematical representation 
of the elastic fiber under the electron microscope (A). Two morphologically distinguishable 
components are observed; an outer mantle of microfibrils and an inner core composed of 
amorphous elastin aggregates intertwined by microfibrils. Transmission electron microscopy of 
pulmonary elastic fibers (B and C) clearly reveals a mantle of transversally cut, dot-like microfibrils 
lying around an amorphous white core of elastin with small regions of microfibrils in between. MF = 
microfibrils, E = elastin, EA = elastin aggregates.
Microfibrils
Structural analysis of isolated microfibrils have revealed a 56 nm beaded 
periodicity, a marked appearance that gave the microfibrils the name “beads- 
on-a-string” (25-30) (Figure 2).
Figure 2, Ultrastructural appearance o f pulmonary fibrillin-1 microfibrils. A schematically 
representation of the fibrillin-1 molecule and its assembly into a microfibril (A), highlighting the 
assembly into beaded microfibrils with a variable periodicity. Tapping mode atomic force microscopy 
of pulmonary microfibrils (B and C) revealed the typical “beads-on-a-string” appearance. A line scan 
along a microfibril (D) indicated an axial mass distribution of ~ 57 nm which correlates well with the 
predicted molecular folding. Figure 2A reproduced from Kielty et al. Phil Trans R Soc Lond B 2002.
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The microfibrils have an apparent complexity and may contain 34 or more 
different proteins (31). Proteins present in the microfibrillar component can be 
located to the microfibrils or can appear at the elastin-microfibril interface.
These microfibrillar proteins can have a structural function or they can be 
involved in the process of elastic fiber assembly by regulating tropoelastin 
deposition onto the microfibrils. The most important microfibrillar proteins will be 
introduced below, with an emphasis on their predicted location and function in 
the elastic fiber. Besides the major microfibrillar proteins described in this 
review, some other proteins are also predicted to be associated with the 
microfibrils (31). Because we have a particular interest in microfibrillar proteins 
involved in pulmonary dysfunction, this review only describes a certain subset of 
microfibril associated-proteins.
Fibrillin
The most abundant type of microfibrillar proteins are the fibrillins, especially the 
fibrillin-1 isoform (domain-structure depicted in figure 3) (32-34). Indeed, 
ultrastructural analysis predicted up to eight fibrillin-1 molecules in a cross­
section of the “beads-on-a-string” microfibrils (25;30;34;35). In the lung, fibrillin- 
1 is localized to elastic fibers in the bronchioles, alveolar septa, and blood 
vessels (33;36), and mRNA expression in murine lungs peaks during 
alveolarization (17). Fibrillin-1 is the major integral microfibrillar molecule. The 
assembly of fibrillin-1 into a microfibril is a multistep process in which the 
molecules are predicted to form a parallel head-to-tail alignment. Subsequent 
molecular folding and alignment of known transglutaminase-induced crosslinks 
result in the first structural changes. Further intramolecular folding eventually 
results in the typical “beads-on-a-string” structure (25;37;38) (figure 2 A).
MAGPs
The family of microfibril associated-glycoproteins (MAGPs) consist of MAGP-1 
(39) and MAGP-2 (40). MAGP-1 mRNA is localized in murine (41) and human 
lung (42), whereas MAGP-2 mRNA has been, so far, only localized in murine 
lung (43). Localization of MAGP-1 and -2 in bovine lung tissue by means of 
immunohistochemistry shows staining of the elastic fibers in bronchioles, 
pulmonary blood vessels, interlobular septa, and parenchymal tissue (44). 
MAGP-1 is possibly the best candidate for an integral microfibril molecule, as it 
localizes to the “beads” of the microfibrils as shown by immunogold labeling 
(45) and can be detected by mass spectrometry in purified microfibrils (46). In 
contrast to the widespread microfibrillar localization of MAGP-1, MAGP-2 has a 
restricted localization and can only be found in microfibrils of the ligament, skin, 
aorta, and kidney (44). The restricted tissue localization and developmental 
patterns of MAGP-2 suggest that it is a structural component of some, but not 
all, microfibrils. Immunogold labeling of microfibrils from nuchal ligament points 
out that MAGP-2 is localized to the “beads” and interbead region of the 
microfibrils (47). Besides an integral microfibrillar protein, MAGP-2 may also be 
important in the interaction between microfibrils and cells, particularly via 
binding to the integrin surface receptors (48). The localization of MAGP-1 and 
MAGP-2 to the microfibrils and their binding with fibrillin-1 (49;50) suggests that
they may function as molecular cross-linkers, stabilizing fibrillin monomers in a 
folded conformation within the microfibrils (47;51).
non Ca2+ binding 
EGF-like module
hybrid 
domain
ICa2+ binding EGF-like module
Figure 3, Domain-structure of human fibrillin-1. Fibrillin-1 compromises 47 epidermal growth 
factor (EGF)-like domains, 43 of which are calcium binding. The EGF-like domains are interspersed 
by seven TGF-binding protein domains (TGFp-like domains) and two hybrid domains that have 
similarities to both EGF-like domains and the TGFp-like domains. There are 14 putative 
glycolysation sites and a potentially flexible proline-riche region (31). Figure 3 is reproduced from 
the university of Southhampton (www.bionmr.soton.ac.uk).
EMILINs
Five family members of the “elastin microfibril interface located protein” 
(EMILIN) family have been identified viz. EMILIN-1, -2, -3, -4 (also known as 
multimerin), and -5 (52-54). Members of the EMILIN family have been identified 
in murine lung by mRNA expression (55;56). So far, only EMILIN-1 has been 
located to elastic fibers, more specifically to the interface between amorphous 
elastin and microfibrils (57). EMILIN-1 deposition peaks early in elastogenesis, 
even preceding the appearance of elastin (58). In vitro, the process of elastic 
fiber assembly is markedly affected by the addition of EMILIN-1 antibodies (57). 
Both observations point to EMILIN-1 as an important molecule in elastic fiber 
assembly.
Fibulins
The family of fibulins consists of fibulin-1, -2, -3, -4, and -5 (59;60). In the 
murine lung, fibulin-1 (61), -2 (61), and -5 (62;63) mRNA is present. In the 
human lung, mRNA for fibulin-1 (64;65) ,-2 (65), -3 (66), and -4 (66;67) is 
present. By means of immunohistochemistry, fibulin-1 has been localized to 
elastic fibers of the alveoli, blood vessels, and the connective tissue 
surrounding bronchiole of the human lung. In addition, infiltrated alveolar 
macrophages as well as the basement membrane and smooth muscle of the 
bronchiole in the human lung are positive for fibulin-1 (64). In murine lung, 
fibulin-1 is found in alveolar septa, basement membrane zones of bronchiole, 
and arterial walls (66). Fibulin-3 and -4 are localized to the basement 
membrane of the murine bronchiole and blood vessels (66) and fibulin-5 to 
murine alveolar septa and blood vessels (63;68). Radioimmunoassay have 
indicated various amounts of all five isoforms in adult murine lung (69). All five 
members of the fibulin family bind, with varying degrees, to tropoelastin in solid
13
G
eneral introduction, aim
, and 
outline 
of the 
thesis
14
C
ha
pt
er
 
1
phase assays (69). Ultrastructurally, fibulin-1 associates with the amorphous 
elastin core, but not with microfibrils (64). In contrast, fibulin-2 not only binds to 
tropoelastin, but also with a high affinity, to fibrillin-1 (70). The ability to bind 
both tropoelastin and fibrillin-1 may indicate that fibulin-2 serves to anchor 
tropoelastin to the microfibrils. This suggestion is in agreement with electron 
microscopy, which locates fibulin-2 at the interface between elastin and the 
microfibrils (70). Fibulin-3 displays little interaction with elastin or fibrillin-1 
(69;71), and its precise location in elastic fibers is unknown. Like fibulin-2, 
fibulin-4 binds to fibrillin-1 with high affinity (71) and may also function as an 
anchor between elastin and the microfibrils. Ultrastructurally, fibulin-4 is 
localized to microfibrils in mouse perichondrium (69). Like fibulin-2, the 
presence of fibulin-5 is located at the interface between elastin and the 
microfibrils (72) where it binds, amongst others, to fibrillin-1 (71), elastin, and 
integrins (73). Because of its binding to integrin, fibulin-5 is implicated as a 
bridging molecule between elastic fibers and the surrounding cells.
LTBPs
The family of latent TGF-p binding proteins (LTBPs) compromises four 
isoforms, LTBP-1, -2, -3, and -4 (74-78). All LTBP isoforms are expressed in the 
human lung, as indicated by mRNA expression analysis (79). Intracellular, all 
isoforms, except LTBP-2, sequester TGF-p in a latent complex that is secreted 
into the extracellular space (80-82). Besides their role in the targeting of TGF-p, 
LTBPs are molecules that are broadly distributed in the extracellular matrix (79). 
A major fraction of the secreted LTBPs does not contain TGF-p, suggesting that 
LTBPs can also be structural components of the extracellular matrix (83- 
85).LTBP-1 has been localized to the microfibrils (86-89) and binds with high 
affinity to fibrillin-1 (86;87). Based on the absence of immunolocalization of 
LTBP-1 in isolated beads-on-a-strings, LTBP-1 does not seem to be an integral 
molecule of the microfibrils (86). Instead, binding studies have suggested that 
the LTBP-TGF-p complex is cross-linked to components in the matrix other than 
microfibrils, like fibronectin, and that interaction of this complex with fibrillin-1 
has a stabilizing function (86). This suggestion is consistent with data that 
predict the transglutaminase-mediated cross-links, that immobilize the latent 
complex to the extracellular matrix (90), to be placed at the LTBP’s N-terminus 
(82;91;92). LTBP-2 is localized to microfibrils in nuchal ligament. Extraction of 
LTBP-2 from this tissue indicates that LTBP-2 associates strongly with the 
microfibrils, suggesting that LTBP-2 may be a structural molecule of the 
microfibrils (93). The LTBP-4 C-terminus is reported to bind to fibrillin-1, 
whereas binding of LTBP-3 to fibrillin-1 has not been reported (86). Electron 
microscopy of LTBP-3 and -4 on elastic fibers is lacking, and hence the location 
of both isoforms in elastic fibers and their biological role is unknown. Figure 4 
schematically summarizes the proposed function, location, and binding partners 
of the above introduced microfibrillar components and the ultimate assembly of 
these components into an elastic fiber.
O ---- - 0 — 0
Figure 4, proposed schematic model o f elastic fiber assembly. (1) Microfibrils, composed o f 
fibrillin-1, MAGP-1, and LTBP-2, act as a scaffold for tropoelastin aggregates that are cross-linked 
by lysyl oxidases. (2) A number o f m icrofibrillar components are involved in the process o f elastic 
fiber assembly by regulating tropoelastin deposition onto the microfibrils. Some o f them anchor 
tropoelastin to the microfibrils (fibulin-2 and -4), others bridge the microfibrils to the surrounding 
cells (LTBP-1, MAGP-2 and fibulin-5). (3) The amorphous elastin aggregates gradually coalesce 
and form the central elastin core. The majority o f m icrofibrils are displaced to the outer regions of 
the fiber. TE = tropoelastin, MF = microfibrils, FN = fibronectin.
A changing role for microfibrils
Microfibrils were initially regarded as structural elements of the extracellular 
matrix (94). However, over the years, accumulating research has appointed a 
key role for microfibrils in the extracellular regulation of growth factors, such as 
TGF-p and bone morphogenetic proteins (BMPs) (95;96). Members of the TGF- 
p superfamily, including BMPs, are multifunctional cytokines that regulate tissue 
development and homeostasis via modulation of a large number of biological 
phenomena such as cell proliferation, cell migration, cell death, development, 
inflammation, immunity, hematopoiesis, and tissue remodeling (97-100). TGF-p 
is secreted in the extracellular space as a latent complex consisting of the 
cytokine non-covalently bound to the latency associated propeptide (LAP), 
which in turn is covalently bound to LTBP-1, -3, or -4 (86;95;101;102). This
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large latent complex (LLC) not only promotes the targeting of TGF-p to the 
extracellular matrix, primarily by interaction of LTBPs with fibrillin-1 and 
fibronectin (see LTBPs), but also keeps TGF-p in an inactive state. TGF-p can 
be released from the LBTP-complex and thereby activated by reactive oxygen 
species, proteases, thrombospondin-1, and integrins (103) (figure 5). Other 
members of the TGF-p superfamily, such as BMPs, are suggested to be 
targeted to the extracellular matrix. By immunohistochemistry, the BMP-7 
complex localizes to fibrillin-1 and the prodomain of BMP-7 directly interacts 
with the N-terminus of fibrillin-1 (104). Recently, the propeptides of BMP-2, -4, 
and -10 have also been shown to bind to the fibrillin-1 N-terminus (105). In 
addition, immunohistochemistry locates BMP-4 to fibrillin-1 microfibrils in 
various fetal mouse tissues, including blood vessels and skin (105).
H ' t g f - I L
Fibrillin-rich
microfibrils
Figure 5, the large latent complex (LLC). The diagram shows the binding of the LLC , composed 
of LAP, TGF-p, and LTBP-1, to the extracellular matrix and the microfibrils. Once TGF-p is released 
from this LLC it becomes active. Figure adapted from Ramirez et al. Cell. Mol. Life Sci. 2007. LLC = 
large latent complex, ECM = extracellular matrix, LAP = latency associated propeptide.
Elastic fibers in lung development
Airway branching and alveolarization are critical processes in normal lung 
development, therefore the involved genes are tightly regulated in the correct 
spatiotemporal sequence. Elastic fibers are primarily assembled during the late 
fetal and early neonatal phase of development. Because this assembly 
coincides with the postnatal development of alveoli (alveolarization), elastic 
fibers are proposed to play a regulating role in alveolarization (16;106). Just 
before birth, the alveolar ducts and sacs are complete (saccular phase), forming 
a template for postnatal alveolarization. During this alveolarization, elastic fibers 
concentrate in the tips of the small buds that protrude from the primary septa.
As these buds increase in height they subdivide the air sacs into smaller alveoli. 
Further lengthening and thinning of these secondary septa ultimately forms the 
elaborate network of septa and alveoli (16;106).
Elastic fibers and developmental emphysema
Pulmonary adult emphysema is a pathological process defined as an abnormal 
permanent enlargement of the alveoli through irreversible destruction of the 
alveolar septa (107) (figure 6).
Normal Emphysema
% . 
fci. A ' V
\ f
, L V
bronchioli
distended
Figure 6, Morphological characteristics of emphysema. Compared to normal lung tissue (A), 
emphysematous lung tissue (B) is identified under the microscope by enlarged alveoli caused by 
destructed alveolar septa, as also schematically presented.
Emphysema leads to chronic respiratory failure including a fall in blood oxygen 
levels (hypoxemia), a rise in carbon dioxide levels (hypercapnia), shortness of 
breath, and a reduced life expectancy. The molecular mechanism(s) leading to 
emphysema has/have an enormous complexity. In the emphysematous lung a 
myriad of pathological changes are observed, including a protease/anti­
protease imbalance (108), inflammation (109-111), an excess of free radicals 
and oxidants (112), and apoptosis (113-115). Although there is experimental
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support for all of these theories, the pathogenesis of adult emphysema still 
remains elusive and important disease-causing pathways are only beginning to 
be understood. The loss of elasticity, caused by destruction of elastic fibers 
(2;116-118), is the hallmark of emphysema (119-121). Therefore, a possible 
approach to obtain more insight into, and perhaps to reveal a primary disease- 
causing pathway in, the pathogenesis of emphysema is to study genes that are 
involved in elastic fiber assembly. Genes that are implicated in both elastic fiber 
assembly and emphysema may be particularly instructive for the discovery of 
pathogenic mechanisms for emphysema. In the following pages, murine and 
human genetic defects in elastic fiber-associated proteins will be described that 
are reported to interfere with normal lung development. The pulmonary 
phenotype of these genetic models is often described by an enlargement of the 
alveoli, caused by an embryonic arrest in the saccular phase and a resulting 
perturbation of alveolarization. Since enlargement of the alveoli is a 
characteristic of emphysema, this specific pulmonary phenotype is called 
developmental emphysema.
Mice Models
Elastin
Mice lacking the elastin gene have a defective lung development. At birth, the 
alveoli are enlarged and surrounded by thin alveolar septa. This developmental 
emphysema is caused by an arrested alveolarization (122). Likewise, mice with 
a 63 % reduction in expressed elastin have developmental emphysema, as 
characterized by enlarged alveoli (123).
Lysyl oxidases
Mice lacking lysyl oxidase (LOX) die just after birth due to large aortic 
aneurysms or diaphragmatic collapses (20;124). A further examination of the 
LOX deficient mice reveals developmental emphysema as characterized by 
enlarged alveoli that are decreased in number at E18.5 and P0 (figure 7). This 
increase in alveolar size is most likely caused by a defective septation of the 
alveoli. As can be expected, in vitro analysis revealed that the cross-links within 
elastin are reduced and that elastic fibers appear fragmented, clumped and 
nearly devoid of amorphous elastin (125). LOX like protein 1 (LOXL-1) deficient 
mice have enlarged alveoli, indicative of developmental emphysema. A 
decrease in the number of elastin cross-links in the lung, skin, uterus, and aorta 
results in elastic fibers that are fragmented and reduced in amount (24).
Fibrillin
Mutations in the gene encoding fibrillin-1 results in developmental emphysema 
in mice. Homozygous mice harboring a targeted deletion of 6 kb in the fibrillin-1 
gene (Fbn1 mgA mice) die within three weeks after birth (126). Upon 
histological analysis, these mice have vascular dissections and developmental 
emphysema, as characterized by enlarged alveoli.
Figure 7, Developmental emphysema is LOX deficient mice. Compared to wild type mice (a, c), 
LOX deficient mice (b, d) have enlarged alveoli at E18.5 (b) and P0 (d). Arrowheads indicate 
bronchioles (a, b) and various sites of atelectasis (collapsed lung tissue; c, d). Figure reproduced 
from Maki et al. Am J Pathol 2005.
A detailed study of the pulmonary phenotype of the mgA mice revealed a lack of 
secondary septa which indicates that the alveolar enlargement is due to a 
perturbation of alveolarization. A marked dysregulation of TGF-p signaling has 
been shown to be causative for this lack of septation, since perinatal 
antagonism of TGF-p rescues the developmental emphysematous phenotype 
(127). Tight skin mice (Tsk/+ mice) are heterozygous for a tandem duplication of 
30-40 kb in the gene encoding fibrillin-1, resulting in the production of normal 
levels of a mutant protein. Tsk/+ mice show developmental emphysema the first 
month of their life (128-131). The emphysematous phenotype is characterized 
by alveolar enlargement and thinning and destruction of the alveolar septa. The 
elastic fibers of these mice appear fragmented (131). Finally, a ~75% reduction 
of the amount of fibrillin-1 (mgR mice (132)) also results in developmental 
emphysema in mice, as seen by enlarged alveoli (127; 133). This 
emphysematous phenotype is, however, not evident until 6 months of age and 
is accompanied by destructive changes, inflammation, and an increased 
expression of matrix metalloproteases. In agreement with the data in mgA mice 
models, the emphysematous phenotype in mgR mice is associated with a 
marked dysregulation of TGF-p signaling (127).
MAGPs
Disruption of the MAGP-1 gene in mice results in adiposity, bone lesions, 
delayed wound healing, and diathesis. On the other hand, elastic tissues such 
as the skin, lung, and aorta appear normal. MAGP-1 deficient lungs have proper 
alveolar and airway structure, with no indications of developmental emphysema 
(134). So far, MAGP-2 deficient mice have not been described.
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EMILINs
Mice disrupted at the EMILIN-1 gene locus do not reveal a clear phenotype and 
only in aorta and skin - not in lung- an altered histological morphology was 
found with transmission electron microscopy (135).
Fibulins
In fibulin-1 deficient mice, the development of the lung is delayed as seen by 
thickened alveolar septa and unexpanded alveoli one day after birth (136). 
Fibulin-2 deficient mice do not display any gross abnormal phenotype in the 
lung or any other organ. Besides that, no defects in elastogenesis were 
reported (137). Mice deficient for fibulin-3 show herniations and an early aging 
phenotype characterized by loose skin. No lung problems are manifested, which 
is in agreement with histological results that indicate that elastic fibers in skin 
are fragmented, but unaffected in the lung (138). Fibulin-4-/- mice generated by 
gene targeting manifest severe lung defects at P1 (139). Upon histological 
analysis, the distal airspaces appear markedly enlarged and are similar to an 
emphysematous phenotype. This emphysematous phenotype corresponds to a 
deficiency in elastic fibers, as the fibulin-4 deficient mice do not assemble 
elastic fibers in lung. Instead, electron microscopy in aorta revealed visible 
elastin aggregates near the cell membrane. Inactivation of the fibulin-5 gene in 
mice results in dilated alveoli from two weeks of age. The alveoli are further 
enlarged and disrupted upon aging, ultimately leading to severe developmental 
emphysema. Upon histological analysis it is shown that the elastic fibers in the 
alveolar septa are fragmented, disrupted, and disorganized (72;73).
LTBPs
A mouse model lacking LTBP-1 is characterized by craniofacial abnormalities 
and a reduced biological activity for TGF-p (140). An altered phenotype for the 
lung is, however, not reported. Disruption of the LTBP-2 gene in mice leads to 
early embryonic lethality, suggesting that LTBP-2 is very important in 
embryogenesis (141). No histological analysis was performed on organs. LTBP- 
3 deficient mice are lethargic and dyspneic, suggesting respiratory failure. 
Indeed, histological analysis of the lungs reveals a decreased amount of septa 
6 days after birth and a progressive enlargement of the alveoli with age which 
can by described as severe developmental emphysema (figure 8). Despite 
these severe manifestations, the morphology of the elastic fibers in these LTBP- 
3 deficient mice appears unaltered, suggesting that this phenotype is not 
derived from a defective elastogenesis. Instead, the manifestations might be 
derived from a decreased TGF-p activity, an event that may prevent normal 
lung differentiation (142). Disruption of the gene encoding for LTBP-4 leads to 
an emphysematous phenotype characterized by enlarged alveolar spaces 
surrounded by thin, dysplastic, and frequently incomplete septa at 6-8 months. 
This developmental emphysema is already present at birth, and worsens with 
time. The LTBP-4 deficient mice lack normal elastic fibers, since they appear 
fragmented and condensed. In addition to a defective elastic fiber, the 
deficiency is also associated with a reduced deposition of TGF-p in the 
extracellular matrix (143).
Figure 8, Developmental emphysema in LTBP-3 deficient mice. Compared to wild type mice 
(wt), LTBP-3 deficient mice (LTBP-3 -/-) have enlarged alveoli at 6, 10, and 23 days after birth. 
Arrows indicate the initial budding septa. Figure reproduced from Colarossi et al. Am J Pathol 2005.
Genetic defects in men, associated with emphysema
In humans, genetic defects in fibrillin-1, fibulin-4, and fibulin-5 have been 
described with a pulmonary phenotype resembling emphysema. The 
emphysematous phenotype evolves shortly after birth, in weeks to months, and 
is therefore suggestive of developmental emphysema.
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Fibrillin-1
In men, mutations in the gene encoding fibrillin-1 give rise to Marfan syndrome, 
an autosomal dominant disorder with pleiotrophic manifestations in the skeletal, 
cardiovascular and ocular system (144-146). Mutations for fibrillin-1 are found 
throughout the gene and, to date, over 500 fibrillin-1 mutations are correlated to 
Marfan syndrome (147;148). The mutations can affect different kind of fibrillin-1 
processes like synthesis, trafficking, and incorporation into the extracellular 
matrix (149-157). All mutations are, however, predicted to result in an 
impairment of microfibril function, ultimately leading to fragmented and 
disoriented elastic fibers (158-160). The most prominent characteristics of 
Marfan syndrome are lens dislocation, spinal curvature, joint hypermobility, and 
aortic dilatation. In addition, a large number of other manifestations in skin, 
lungs, and skeleton are linked to Marfan syndrome (145). Emphysema, ranging 
from developmental to early-onset adult, is one of these less abundant 
manifestations and has been noticed in a number of patients with Marfan 
syndrome. In an autopsy study, four young infants with Marfan syndrome, 11 
weeks to 10 months of age, displayed developmental emphysema, as indicated 
by overdistended air spaces and shortened alveolar septa (161). Necropsies on 
four infants with Marfan syndrome, 5 weeks to 9 months of age, also indicated 
developmental emphysema in all four patients. The pulmonary elastic fibers in 
these infants appeared irregularly thickened, interrupted, and clumped (162). In 
addition, mutations in exon 24-32 of the FBN1 gene give rise to neonatal 
Marfan syndrome (163-165). This type of Marfan syndrome is already 
diagnosed at birth and is by far the most severe form of Marfan syndrome. It 
displays some of the most abundant characteristics of Marfan syndrome, but, in 
contrast to other forms of Marfan syndrome, developmental emphysema is 
common (163-165).
Fibulin
A homozygous missense mutation in the fibulin-4 gene is associated with 
recessive cutis laxa syndrome, which is characterized by inelastic skin, arterial 
tortousity, and diaphragmatic hernia. Besides cutis laxa, a young patient with 
this mutation revealed developmental emphysema at 9 months of age (166). A 
homozygous missense mutation in the fibulin-5 gene in men results in 
autosomal recessive cutis laxa syndrome including emphysema in a Turkish 
family. In one of the patients, a CT scan of the thorax reveals developmental 
emphysema in the anterior segments of both lungs at the age of 6 months. The 
elastic fibers of these patients appear poorly developed and abnormal with a 
marked granular appearance (167).
Limitations of the genetic models
As described above, genetic defects in elastin, LOX, LOXL-1, fibrillin-1, fibulins, 
and LTBPs manifest itself by developmental emphysema in men and/or mice. 
Data illustrate the complex biology of elastic fibers and indicate that the elastic 
fiber is not only a structural entity of the pulmonary extracellular matrix, but also
modulates critical signaling events and cellular interactions. Besides that, they 
underscore that elastic fiber associated-proteins play an important role in lung 
development. It is tempting to extrapolate these data to the pathogenesis of 
adult emphysema, especially since loss or destruction of the elastic fibers is a 
hallmark of this disease. However, it has to be taken into account that the 
disease-causing mechanisms of developmental emphysema and adult 
emphysema are not completely comparable. Both developmental emphysema 
and adult emphysema are characterized by a morphological appearance of 
enlarged alveoli. However, the mechanisms ultimately leading to these 
morphological aberrations are quite different. In developmental emphysema the 
alveolar enlargement is caused by a perturbation of alveolarization. Due to a 
defective assembly of the elastic fiber, septa fail to form and protrude from the 
buds and the air sacs are not subdivided in alveoli. The observed alveolar 
enlargement is therefore not a true enlargement of the alveoli but rather 
represents a lung that is arrested in the embryonic saccular phase. A notion 
endorsed by the fact that the emphysematous phenotype of arrested 
development, described in the previous section, manifests itself shortly before 
or after birth. For instance, the murine defects of developmental emphysema 
manifest itself weeks after birth. In the described mouse models there is, 
however, one exception. The mgR mice, only expressing 20-25% of normal 
fibrillin-1, develop late onset emphysema that is evident from 4 to 6 months of 
age. This emphysematous phenotype not only evolves later in life, but is also 
characterized by enlarged alveoli and destruction of the alveolar septa by 
peribronchial inflammation and matrix metalloproteases overexpression (127). 
Thereby, this model not only recapitulates the pathological characteristics of 
adult emphysema, defined by an enlargement of the alveoli through irreversible 
destruction of the alveolar septa, but also the molecular mechanisms, such as 
inflammation, apoptosis, and proteolytic activity, underlying adult emphysema.
Elastic fibers and adult emphysema
Besides genetic mouse models and genetic defects in humans with 
developmental emphysema, literature describes a subset of elastic fiber 
associated-genes that have been implicated in human hereditary syndromes 
that include, early-onset, adult emphysema as part of their phenotype. Although 
hereditary, the described emphysema does not result from a pulmonary arrest 
in the embryonic saccular phase and perturbation of alveolarization. The 
emphysematous phenotype is rather described by an early enlargement of the 
alveoli through a destruction of the alveolar septa by certain destructive 
changes. Besides that, the emphysematous phenotype evolves later in life, up 
to years after birth and most often in adulthood. Mutations in elastin, fibrillin-1, 
and fibulin-5 are described to lead to adult emphysema (as described below). 
These mutations affect the elastic fiber in two ways. First, they interfere with the 
normal deposition of the mutated protein in elastic fibers, for instance by partial 
incorporation of the mutated protein in elastic fibers and partial cellular retention 
(168). Second, they render the mutated protein more susceptible for proteolytic 
degradation.
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Elastin
In men, mutations in the elastin gene are causative for a number of cases of 
cutis laxa, a rare inherited syndrome characterized by loose inelastic skin 
(169;170). Besides a progressive loosening of the skin, adult emphysema is 
observed in some cutis laxa patients with an elastin mutation. In one study, a 45 
year old woman with a predicted heterozygous frame shift mutation in the 
elastin gene was diagnosed with adult emphysema, clinically attributed to a 
smoking habit, as analyzed by a CT scan. The mutation was inherited in an 
autosomal dominant way to her 19 year old son, who probably had panlobular 
adult emphysema as analyzed by a high resolution CT scan (171). In another 
case (168), a woman with cutis laxa was diagnosed for adult emphysema by the 
age of 36. The emphysema was progressive and culminated in respiratory 
failure with hypercapnia, hypoxemia, and hart failure upon aging. Her daughter 
was diagnosed for adult emphysema by the age of 23. This early-onset adult 
emphysema was caused by a partial tandem duplication in the gene for elastin, 
aggravated by a heavy smoking habit and an a-1 antitrypsin M/Z genotype. In 
these two patients, histological analysis indicated elastic fibers with an 
abnormal morphology that appeared clumped and fragmented. Ultrastructurally, 
elastin failed to associate to the microfibrils. In a third case, a single base 
substitution in the terminal exon of the elastin gene resulted in moderate adult 
emphysema in a 41 year old patient with a history of heavy smoking (19 pack 
years). Upon histological analysis, the elastic fibers in the skin appeared 
normal, but the mutation is reported to increase the proteolytic susceptibility of 
the elastic fiber (172).
Fibrillin
As described in the pages above, mutations in the gene encoding fibrillin-1 give 
rise to Marfan syndrome, an autosomal dominant disorder with pleiotrophic 
manifestations like emphysema (145). In one study, three out of four autopsied 
Marfan syndrome patients, 19, 23, and 44 years of age, displayed emphysema 
upon microscopic examination, as indicated by dilated alveoli and ruptured 
septa (173). In addition to this study, chest radiography detected adult 
emphysema in 5 patients with Marfan syndrome, ranging from 21 years to 64 
years (174).
Fibulin
The same homozygous missense mutation in fibulin-5 reported before (167) 
resulted in cutis laxa in two members of an Iranian family (175). At the age of 
12, one of the patients was diagnosed as having emphysema. Elastic fibers 
were reduced and abnormal. The other patient died at an age of 2 because of 
pulmonary infections and it was surmised that he was also afflicted with cutis 
laxa.
Outlook
Smoking is the main risk factor for emphysema, nearly 90% of emphysema 
patients have a history of smoking. Despite the clear correlation between 
smoking and adult emphysema, only 15% of smokers actually attract clinical 
adult emphysema (176). One of the most compelling questions in the 
pathogenesis of adult emphysema is why one smoker can be more susceptible 
to the development of adult emphysema than another smoker? This enigma 
suggests that, besides smoking, constitutional factors may significantly affect 
the susceptibility towards adult emphysema. The possibility that adult 
emphysema results from combined external factors, like smoking, and 
hereditary factors dates back to the early 1800s (177;178). Since then there 
have been numerous reports that imply a genetic predisposition for adult 
emphysema (179-186) Over the years, a few genetic polymorphisms have been 
correlated to adult emphysema (187-191), a good candidate gene for adult 
emphysema has, however, not yet been identified. The hereditary elastic fiber 
defects reported in this review to be associated to developmental and adult 
emphysema might be instructive in the search to candidate genes for smoking- 
related adult emphysema. Such scientific impulses are specially needed since 
emphysema is predicted to become the third leading cause of death and fifth 
leading cause of disability in the world by 2020 (192). Nevertheless, an open 
vision has to be maintained in the study to genetic phenotypes. The genetic 
defects described in mice and men resulting in an emphysematous phenotype 
are due to mutations in a single gene (monogenic). However, emphysema is a 
multifactorial disease that, apart from external factors, could be due to 
mutations in more than one gene (polygenic). Since the completion of the 
Human Genome Project in 2003, such polygenic phenomena can be studied 
using a genome-wide association study (GWAS) screening for genetic 
variations across the whole genome.
Aim and outline of this thesis
The hereditary elastic fibers defects leading to developmental emphysema and 
early-onset adult emphysema described in this chapter can drive future 
research to the role of elastic fiber associated-molecules in the pathogenesis of 
adult emphysema. In this respect, this thesis is mainly focused on the main 
microfibrillar component viz. the structural and regulatory protein fibrillin-1. The 
aim of this thesis was to study fibrillin-1 in relation to the pathogenesis of adult 
smoking-associated emphysema. The experimental outcome may not only 
result in more insight into the processes leading to emphysema, but is also 
valuable for the identification of candidate genes involved in the predisposition 
to the disease. In chapter 1 an overview is given of the hereditary elastic fiber 
defects, including fibrillin-1 deficiencies leading to an emphysematous 
phenotype. In chapter 2, we describe the extracellular expression of fibrillin-1 in 
human lung specimens with varying degrees of microscopical emphysema. The 
expression of fibrillin-1 and other elastic fiber associated-molecules such as
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elastin, emilin-1, and fibulin-2 in emphysematous specimens is described in 
more detail in chapter 3, which also addresses the growth factor TGF-p. 
Chapter 4 further deals with the regulatory role of fibrillin-1, giving special 
attention to the growth factor TGF-p and some of the processes, regulated by 
this cytokine, such as apoptosis and inflammation. The role of fibrillin-1 in the 
biomechanics of the elastic fiber is described in chapter 5. Chapter 6 describes 
the extracellular matrix deposition of fibrillin-1 in cultured fibroblasts derived for 
patients with emphysema. To investigate the possibility that fibrillin-1 is a 
candidate gene for smoking-related emphysema, we present a DNA genotyping 
study in chapter 7. Finally, a summary of the studies and future directions are 
given in chapter 8.
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Abstract
Parenchymal destruction, air space enlargement, and loss of elasticity are 
hallmarks of pulmonary emphysema. Although the basic mechanism is 
unknown, there is consensus that malfunctioning of the extracellular matrix is a 
major contributor to the pathogenesis of emphysema. In this study, we analyzed 
the expression of the elastic fiber protein fibrillin-1 in a large number (n = 69) of 
human lung specimens with early onset emphysema. Specimens were 
morphologically characterized by the Destructive Index, the Mean Linear 
Intercept, and the Panel Grading. We observed a strong correlation (p < 0.001) 
of aberrant fibrillin-1 staining with the degree of destruction of lung parenchyma 
(r = 0.71), air space enlargement (r = 0.47), and emphysema-related 
morphological abnormalities (r = 0.69). There were no obvious correlations with 
age and smoking behavior. Staining for three other extracellular matrix 
components (type I collagen, type IV collagen, and laminin) was not affected. 
The aberrant fibrillin-1 staining observed in this study is similar to that observed 
in Marfan syndrome, a syndrome caused by mutations in the gene encoding 
fibrillin-1. Strikingly, emphysema is noticed in a number of Marfan patients. This, 
together with the notion that disruption of the fibrillin-1 gene in mice results in 
emphysematous lesions, makes fibrillin-1 a strong candidate to be involved in 
the etiology and pathogenesis of emphysema.
Introduction
Pulmonary emphysema is a progressive lung disease that is defined by an 
abnormal permanent enlargement of air spaces distal to the terminal 
bronchioles, accompanied by destruction of their walls and without obvious 
fibrosis (1). The prevailing theory is that emphysema develops through an 
imbalance between the proteolytic activity, due to proteases released from 
inflammatory cells, and the antiproteolytic defense of the lung. This 
protease/anti-protease imbalance results in the destruction of lung extracellular 
matrix and eventually leads to emphysema (2). Another theory is the 
oxidant/anti-oxidant concept, which postulates that an excess of oxidants and 
free radicals in the lung directly promotes tissue damage and emphysema (3). 
Firm evidence for either of these concepts is lacking and consequently the 
pathogenesis of emphysema is still an area of intense investigation.
The pathogenesis of emphysema is characterized by the loss of elasticity. The 
network of elastic fibers is an important structural element in lung parenchyma 
and is to a major extent responsible for the elastic recoil properties of the lung 
(4;5). Elastic fibers are composed of 10-12 nm microfibrils located in and 
around amorphous elastin (6-8). Elastin, the major component of elastic fibers, 
has attracted much attention in emphysema research. However, evidence that 
associates elastin to the pathology of emphysema is lacking although an amino 
acid substitution in the elastin gene has been associated with chronic 
obstructive pulmonary diseases, which include emphysema, in one family (9). 
Therefore, other molecules present in the elastic fiber may play important roles 
in the process of emphysema.
Fibrillin-1 is the major component of the microfibrillar part of the elastic fibers, 
though many other components, including fibulins (10-12), microfibril-associated 
glycoproteins (13-15), and EMILINs (16-18), are present. A number of 
observations has associated fibrillin-1 with developmental emphysema. In man, 
developmental emphysema has been noticed in patients with Marfan syndrome, 
an autosomal disorder caused by mutations in the gene encoding fibrillin-1 (19­
27). In mice, disruption of the fibrillin-1 gene results in developmental 
emphysema. The tight skin mouse, characterized by a tandem duplication in of 
30-40 kb in the gene encoding fibrillin-1, develops emphysematous lesions that 
are in many ways similar to those observed in humans (28-32). In addition, mice 
harboring a targeted deletion of 6 kb of the fibrillin-1 gene also display 
emphysematous lesions (33). Both Marfan syndrome and the two mouse 
models share a mutated form of fibrillin-1 that gives rise to developmental 
emphysema. It is however unknown if fibrillin-1 also plays a role in the onset of 
adult emphysema.
This study reports on the role of fibrillin-1 in early onset emphysema in adult 
humans. A major problem in the research to the onset of emphysema is the 
large time span between the initiation of the degenerative disease process and 
its clinical manifestations. At time of clinical diagnosis, the process of 
parenchymal destruction is already in an advanced state, impeding the 
identification of initiating molecular events. Detailed morphological analysis of
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lung parenchyma allows for early identification of emphysema, especially since 
the definition of emphysema is based on morphological parameters. Therefore, 
we used lung specimens from patients without clinical emphysema, but with 
microscopical emphysema as defined by destruction of the alveolar wall and 
enlargement of the airspaces (34). Based on our data a new concept for the 
onset of emphysema is proposed.
Materials and Methods
Lung tissue
Lung specimens were obtained from patients undergoing a lobectomy or 
pneumonectomy, for a localized malignant process, at the University Lung 
Center Nijmegen. All subjects were studied according to the guidelines of the 
Medical Ethical Committee of the Radboud University Nijmegen Medical Center. 
Specimens were sampled distantly from the tumor, or in an unaffected lobe. 
Upon histological analysis, specimens did not show any sign of the underlying 
disease. Lung function tests were performed before surgery. Lung function data 
for all patients studied were within normal range, according to ERS standards 
(35).
Tissue processing
Small tissue specimens were taken from resected lung lobes. Each specimen 
was cut into pieces of equal size. One part was immersed in phosphate 
buffered saline (PBS) and inflated under vacuum (13 kPa) for 20 min using a 
routine water stream-driven device (water aspirator) in order to restore alveolar 
dimensions (36). This part was used for immunohistochemistry (see below). The 
other -adjacent- part was similarly inflated in PBS containing 4% formalin, 
embedded in paraffin, and used for morphological analysis (see below).
Morphological analysis
Three morphological parameters were used to characterize human lung 
parenchyma and establish the severity of emphysema: the Destructive Index 
(DI, a measure for early parenchymal destruction) (37), the Mean Linear 
Intercept (MLI, a measure for air space enlargement) (38), and the Panel 
Grading (PG, morphological grading of emphysematous lesions) (39). 
Hematoxylin and eosin (Sigma-Aldrich, St. Louis, USA)-stained sections (5 ^m) 
were used.
Destructive Index (DI): Using a microscopic point count technique, the 
DI was evaluated. Microscopic fields devoid of large bronchiole, large blood 
vessels, collapsed tissue, or extensive fibrosis were selected. For each lung 
specimen, an average of 5 different sections was used, and representative non­
overlapping fields were selected. Alveoli lying underneath the counting points 
were evaluated for the presence of destruction. Destruction was defined on the 
base of one or more of the following criteria; (a) at least two alveolar wall 
defects, (b) at least two intraluminal parenchymal rags in alveolar ducts, (c)
clearly abnormal morphology, or (d) classic emphysematous changes (37). The 
percentage of all the points falling into these categories was computed to yield 
the DI. Generally, 750 points were analyzed per specimen with maxima up to 
5000 points. A DI value of 0-30% is considered normal (37).
Mean Linear Intercept (MLI): The MLI is a measure for airspace 
enlargement. To determine the MLI, the same images as described above were 
used. A transparent sheet with 10 horizontal and 11 vertical lines was laid over 
the images and intercepts of alveolar walls with these lines were counted. 
Values were corrected for tissue shrinkage by measuring the dimensions before 
and after histological processing. The correction factor was 0.82, which is in 
accordance with earlier studies (40). 2500 Intercepts were counted per 
specimen with maxima up to 18000 intercepts.
Panel Grading (PG): The degree of emphysema in the images 
described above was analyzed by comparing the images with a panel of 
reference images. The grading ranged from 0% (normal tissue) to 100% 
(complete destruction). The PG value was expressed as an average percentage 
of severity of the lesions. The average number of measured slides per 
specimen was 6.
Study group
69 lung parenchymal specimens, derived from patients without clinical 
emphysema, were selected on the basis of the three morphological parameters 
(DI, MLI, and PG). All of the 69 specimens studied were derived from patients 
with a history of smoking, ranging from 10 to 100 pack years. The 
characteristics of this study group are depicted in table 1. Specimens originating 
from patients who had never smoked and had values within the normal range 
were used as a control (n = 7). Specimens originating from patients with other 
pulmonary diseases (large cell carcinoma (n = 2) and sarcoidosis (n = 2)) were 
studied to evaluate the specificity of the data.
Immunohistochemistry
All incubations were performed at room temperature, unless stated otherwise. 
Cryosections of 2 ^m were cut and endogenous peroxidase was blocked with 
0.3% (v/v) H2O2 in PBS for 1 h. Subsequently, sections were washed in PBS 
and incubated for 30 min with 1% (w/v) bovine serum albumin (BSA, fraction V, 
Sigma-Aldrich, St. Louis, USA) in PBS (block buffer). Sections were incubated 
overnight with mouse anti-fibrillin-1 (mAb 1919, raised against bovine zonular 
fibrils, Chemicon International, Temecula, USA) diluted 1:1000 in block buffer. 
After three washes in PBS, primary antibody was detected with a biotinylated 
horse anti-mouse IgG antibody (Jackson Immuno Laboratories, West Grove, 
USA) for 1h, followed by enhancement with the Avidin-Biotin-Peroxidase 
Complex (Vectastain ABC Elite kit, Vector Laboratories INC., Burlingame, USA) 
for 1.5h. After three washes in PBS, sections were incubated with 
diaminobenzidine substrate (DAB) (Sigma-Aldrich, St. Louis, USA), enhanced 
with nickel. After a final wash in PBS, sections were counterstained with 
hematoxylin (Sigma-Aldrich, St. Louis, USA) and mounted in entellan (Merck, 
Darmstadt, Germany). Using the method described above, three other
41
A
berrant fibrillin-1 
expression 
in 
early 
em
physem
atous 
hum
an 
lung: 
a 
proposed 
predisposition 
for em
physem
a
42
C
ha
pt
er
 2
antibodies were used, viz: rabbit anti-laminin (L9393, Sigma Immuno 
Chemicals, St. Louis, USA; 1:100 dilution), a rabbit antibody against bovine type 
I collagen (Chemicon International, Temecula, USA; 1:100 dilution), and a goat 
antibody against human type IV collagen (1340-01, Southern Biotechnology 
Associates, Birmingham, USA; 1:100 dilution). Biotinylated donkey anti-rabbit 
IgG and donkey anti-goat IgG (Jackson Immuno Laboratories, West Grove, 
USA) were used to detect the primary antibodies. All sections were randomly 
coded, and immunoreactivity was scored independently by two observers using 
a semi-quantitative scale ranging from 0 (linear staining, no fragmentation) to 6 
(punctuate staining, extensive fragmentation).
Statistics
Results were calculated with SPSS 11.0 (SPSS Inc., Chicago, USA) using 
Spearman’s 2-sided ranked correlation and plotted in a scatter diagram.
Table 1, Characteristics of the three study groups (normal, moderate, and 
high degree of microscopical emphysema) & morphological data of the 
specimens studied
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3
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Study group
Age (Yr) 60±9 61±8 65±6
Pack years 29±9 38±20 39±21
FEV1 (% pred) 74±15 82±19 77±17
FEV1/VC (% pred) 82±1 91±1 78±2
Kco (% pred) 81±26 82±22 75±19
TLC (% pred) 93±23 95±17 102±13
RV/TLC (% pred) 105±21 106±21 108±18
Morphological data specimens
DI (%) 25±10 58±8 83±7
MLI (jm ) 290±41 319±43 394±55
PG (%) 31±11 57±9 78±8
All values are means ± SD. Abbreviations: DI, Destructive Index; MLI, Mean Linear Intercept; PG, 
Panel Grading; FEVi, forced expiratory volume in 1 second; % pred, percentage of predicted value; 
VC, vital capacity; Kco, diffusion capacity for CO; TLC, total lung capacity; RV, residual volume.
Results
Study group
As depicted in table 1, lung function of the 69 patients studied did not meet the 
GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria (41) for 
the diagnosis of emphysema. 69 lung specimens were morphologically 
characterized for their degree of microscopical emphysema using the 
Destructive Index (DI) as a marker for early parenchymal destruction, the Mean 
Linear Intercept (MLl) as a marker for airspace enlargement, and the Panel 
Grading index (PG) as a value for emphysematous lesions. Three groups were 
formed: normal specimens, specimens with a moderate degree of microscopical 
emphysema, and specimens with a high degree of microscopical emphysema 
(table 1).
General
To study fibrillin-1 expression, parenchymal lung specimens were stained with 
an antibody against fibrillin-1. In control specimens, fibrillin-1 was abundantly 
expressed in a characteristic fibrillar pattern (Figure 1A and B). Fibrillin-1 was 
identified in alveoli as elongated fibers meandering throughout the septa. No 
significant disruption of the linear fibrillin-1 staining was observed. In contrast, in 
specimens with a high degree of microscopical emphysema the linear fibers 
were (almost completely) fragmented and had a punctuate appearance (Figure 
2F).
Figure 1, Fibrillin-1 immunostaining in normal human lung parenchyma. Two cryosections, 
derived from a 21 year old patient who had never smoked and had no aberrant morphological 
parameters, were incubated with an antibody against fibrillin-1 (A, B). Bound antibody was 
visualized with biotinylated anti-mouse IgG followed by DAB incubation. Note the abundant fibrillar 
fibrillin-1 staining which meandered throughout the alveolar septa. (Bar = 50 |jm).
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Figure 2, Fibrillin-1 immunostaining. Cryosections derived from a normal lung specimens (63 
years, DI = 18%, MLI = 231 |jm, PG = 12%) (A, D), a specimen with a moderate degree of 
microscopical emphysema (58 years, DI = 60%, MLI = 273 jm , PG = 52 %) (B, E), and a specimen 
with a high degree of microscopical emphysema (68 years, DI = 87%, MLI = 317 jm , PG= 85%) (C, 
F) were incubated with an antibody against fibrillin-1. Bound antibody was visualized with 
biotinylated anti-mouse IgG followed by DAB incubation. Note the parenchymal destruction and 
airspace enlargement in specimens with a moderate/high degree of microscopical emphysema (B, 
C). Compared to the lung specimens with no manifestations of alveolar destruction (D), where an 
abundant and branched fibrillin-1 staining was seen, a reduced fibrillin-1 staining was apparent in 
lung specimens with moderate manifestation of alveolar destruction (E). The staining showed 
fragmented fibers (arrows) instead of elongated fibers. In specimens with severe manifestations of 
alveolar destruction, fibrillin-1 staining was markedly reduced and had a dot-like or punctuate 
appearance (F, arrows). (Bar = 50 jm  for A-C and 12,5 jm  for D-F).
Next to fibrillin-1, we studied other extracellular matrix components viz: type IV 
collagen, laminin (both confined to basement membranes), and type I collagen. 
Laminin and type IV collagen showed a typical linear basement membrane 
staining (Figure 3D-F and G-I), whereas type I collagen was present as a typical 
fibrillar staining (Figure 3A-C). Staining for these extracellular matrix 
components did not reveal any differences in abundance or distribution for all 
specimens examined (Figure 3).
Aberrant fibrillin-1 staining is associated with early parenchymal destruction 
The Destructive Index (DI) reflects the degree of parenchymal destruction and 
is considered the most sensitive marker for early emphysematous lesions. Lung 
specimens characterized by a low DI (normal lung specimens), indicating no
Figure 3, Type I Collagen, type IVcollagen, and laminin immunostaining. Cryosections derived 
from a normal lung specimen (63 years, DI = 18%, MLI = 231 |jm, PG = 12%) (A, D, G), a specimen 
with a moderate degree of microscopical emphysema (58 years, DI = 60%, MLI = 273 jm , PG = 52 
%) (B, E, H), and a specimen with a high degree of microscopical emphysema (68 years, DI = 87%, 
MLI = 317 jm , PG= 85%) (C, F, I) were incubated with an antibody against type I collagen (A-C), 
type IV collagen (D-F), and laminin (G-I). Bound antibody was visualized with biotinylated anti­
mouse IgG followed by DAB incubation. Note the fibrillar staining pattern for type I collagen and the 
liner basement membrane staining for type IV collagen and laminin. Type I collagen, type IV 
collagen, and laminin staining in specimens with a moderate or high degree of microscopical 
emphysema was similar to the staining in observed normal lung specimens. (Bar = 50 jm ).
parenchymal destruction, abundantly expressed fibrillin-1 (Figure 2D). This 
expression was comparable to the fibrillin-1 expression seen in control tissue 
(Figure 1). In lung specimens with moderate manifestations of parenchymal 
destruction (moderate degree of microscopical emphysema), fibrillin-1 
expression was moderately disrupted and slightly reduced (Figure 2E). Lung 
specimens, characterized by severe manifestations of parenchymal destruction 
(high degree of microscopical emphysema), displayed a markedly reduced and 
fragmented fibrillin-1 staining, characterized by a punctuate appearance (Figure
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2F). To semi-quantify the degree of fragmentation, we used an arbitrary scale 
from 0 (no fragmentation) to 6 (complete fragmentation). When the degree of 
fibrillin-1 fragmentation was plotted against the degree of parenchymal 
destruction, i.e. the DI, a significant correlation (p < 0.001) was observed 
(Figure 4).
Figure 4, Fibrillin-1 fragmentation as a function of the Destructive Index (DI). By means of an 
arbitrary scale ranging from no fragmentation (0) to maximal fragmentation (6), fibrillin-1 
fragmentation was plotted against the DI. A significant correlation was found between fibrillin-1 
fragmentation and DI (p < 0.001). The regression coefficient equals 0.71. Each point represents an 
individual patient.
Aberrant fibrillin-1 staining is associated with air space enlargement and 
emphysematous abnormalities
The Mean Linear Intercept (MLI) is a parameter for air space enlargement. The 
presence of fragmented fibrillin-1 staining was plotted against the MLI (Figure 5) 
and a significant correlation (p < 0.001) was observed. The Panel Grading value 
(PG) reflects the overall degree of emphysematous abnormalities. A significant 
correlation (p < 0.001) was observed between the amount of fibrillin-1 
fragmentation and PG (Figure 6).
Figure 5, Fibrillin-1 fragmentation as a function of Mean Linear Intercept (MLI). By means of 
an arbitrary scale ranging from no fragmentation (0) to maximal fragmentation (6), fibrillin-1 
fragmentation was plotted against the MLI. A significant correlation was found between fibrillin-1 
fragmentation and MLI and (p < 0.001). The regression coefficient equals 0.47. Each point 
represents an individual patient.
Figure 6, Fibrillin-1 fragmentation as a function o f Panel Grading value (PG). By means of an 
arbitrary scale ranging from no fragmentation (0) to maximal fragmentation (6), fibrillin-1 
fragmentation was plotted against the PG. A significant correlation was found between fibrillin-1 
fragmentation and PG (p < 0.001). The regression coefficient equals 0.69. Each point represents an 
individual patient.
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Aberrant fibrillin-1 staining is not associated with age 
The process of emphysema is age-dependent. Therefore, it may be assumed 
that the fibrillin-1 fragmentation is dependent on age. However, this appears not 
to be the case. When fibrillin-1 fragmentation was plotted against age (Figure 
7A), no significant correlation was observed. Fibrillin-1 fragmentation was 
present at the same level in all age categories. For instance, staining derived in 
a specimen from a young individual (42 years) with a high DI (70%) was highly 
fragmented, as was staining in a specimen from an older individual (68 years) 
with a high DI (87%) (Figure 7C and E). Likewise, a young individual (41 years) 
with a low DI (11%) displayed a normal fibrillin-1 staining, as did an older 
individual (78 years) with a low DI (23%) (Figure 7B and D).
Aberrant fibrillin-1 staining is not associated with smoking behavior 
The degree of clinical emphysema is strongly correlated with smoking behavior. 
However, when fibrillin-1 fragmentation was plotted against smoking behavior, 
as expressed in pack years (one pack year is equal to smoking one pack of 
cigarettes per day during one year), no correlation was detected (Figure 8).
Aberrant fibrillin-1 staining is not associated with other lung diseases 
To evaluate the specificity of the aberrant fibrillin-1 staining for the process of 
emphysema, specimens derived from patients with other lung diseases (large 
cell carcinoma and sarcoidosis) were immunostained for fibrillin-1(Figure 9, for 
large cell carcinoma). Fibrillin-1 expression in these specimens was abundant 
with a striking absence of fibrillin-1 fragmentation, indicating the specificity of 
our observations.
Discussion
In this study we showed that an aberrant fibrillin-1 staining in lung specimens 
was significantly associated with the three most important morphometric 
parameters for emphysema: the Destructive Index (alveolar destruction), the 
Mean Linear Intercept (air space enlargement), and the Panel Grading 
(emphysema-related morphological abnormalities). Since emphysema is 
defined by an abnormal permanent enlargement of air spaces and by 
destruction of their walls, characterization of the disease with morphological 
parameters like DI and MLI are a prerequisite to study the pathogenesis of 
emphysema. We collected lung specimens that had microscopical emphysema, 
as judged by morphometric analysis (34). Despite these morphological 
abnormalities, lung function test were still within normal range, indicating that 
the process of lung destruction is still in an early stage. Lung function tests are 
a useful tool to diagnose Chronic Obstructive Pulmonary Disease (COPD), a 
collective term including chronic bronchitis and
Figure 7, Lack o f correlation between fibrillin-1 fragmentation and age. A. Fibrillin-1 as a 
function o f age. By means of an arbitrary scale ranging from no fragmentation (0) to maximal 
fragmentation (6), fibrillin-1 fragmentation was plotted against age. No significant correlation was 
found between fibrillin-1 fragmentation and age. The regression coefficient equals 0.15. Each point 
represents an individual patient. B-E. Fibrillin-1 immunostaining in specimens from patients with 
sim ilar age, but different destructive indices. Cryosections derived from a young patient (41 years) 
with a low destructive index (DI, 11%) (B) and a young patient (42 years) with a high DI (70%) (C) 
were incubated with an antibody against fibrillin-1. Likewise, cryosections from an older patient (78 
years) with a low DI (23%) (D) and an older patient (68 years) with a high DI (87%) (E) were 
immunostained for fibrillin-1. Bound antibody was visualized with biotinylated anti-mouse IgG 
followed by DAB incubation. Note the abundant, helical, fibrillin-1 staining in the young patient and 
older patient with a low DI (A, D) and the small, dot-like fibrillin-1 structures (arrows) in the young 
patient and older patient with a high DI (B, E). (Bar = 50 |jm).
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Figure 8, Fibrillin-1 fragmentation as a function of smoking. By means of an arbitrary scale 
ranging from no fragmentation (0) to maximal fragmentation (6), fibrillin-1 fragmentation was plotted 
against smoking (expressed in pack years). No significant correlation was found between fibrillin-1 
fragmentation and smoking. The regression coefficient equals 0.07. Each point represents an 
individual patient.
Figure 9, Fibrillin-1 immunostaining in a lung specimen derived from large cell carcinoma. A
cryosection from non-emphysematous tissue (DI = 20%, MLI = 264 |jm, PG = 22%; age of patient: 
57 years, and 40 pack years), affected by large cell carcinoma was incubated with an antibody 
against fibrillin-1. The section contains alveolar fibrosis due to a desmoplastic reaction, and 
infiltrated cells. Bound antibody was visualized with biotinylated anti-mouse IgG followed by DAB 
incubation. Note the abundant fibrillin-1 staining which was present throughout the alveolar septa. 
(Bar = 50 jm).
emphysema. However, because lung function tests reflect airway obstruction 
and not loss of pulmonary parenchyma, the use of these tests to merely 
establish emphysema is controversial (42-44). Besides that, the relationship 
between lung function data and the morphological assessment of emphysema 
has been described as poor (45-48). Due to this insensitivity, lung functions 
tests are of limited value to identify the onset of emphysema. Therefore, clinical 
manifestations of emphysema are only evident in patients with a wide spread 
and advanced emphysema (46;49-55). Indeed, autopsy studies indicated that 
one-third of the lung can be affected by emphysema before respiratory function 
is impaired (56). The onset of emphysema is a process that can only be 
measured accurately by microscopic measurements. Therefore, this study used 
lung specimens from patients without clinical manifestations, but with 
morphological abnormalities indicative of early onset emphysema. This unique 
data set allowed us to analyze initiating molecular events in the pathogenesis of 
emphysema.
Our data suggests that fibrillin-1 is an important player in the onset of adult 
emphysema. This notion is underlined by the observation that staining for other 
extracellular matrix molecules (laminin, type I collagen, and type IV collagen) 
was not aberrant. The hypothesis that fibrillin-1 is a major player in the onset of 
emphysema is corroborated by other lines of research that have correlated 
fibrillin-1 with developmental emphysema. Mutated forms of fibrillin-1 are 
causative for developmental emphysema in mouse models (30;32). Tight skin 
mice, characterized by a tandem duplication of 30-40 kb in the gene encoding 
fibrillin-1(31), have an abnormal immunostaining for fibrillin-1 (29). Fibroblasts 
from these mice synthesize and secrete normal, as well as oversized, fibrillin-1 
protein (28;29). The resulting abnormal fibrillin-1 assembly results in 
emphysema that is in many ways similar to that observed in humans. 
Emphysematous lesions are also observed in another mouse model, harboring 
a targeted deletion of 6 kb in the fibrillin-1 gene (33). As a result, elastic fibers 
have less tensile strength resulting in mechanical collapse, overstretching, and 
fracturing. At such sites, influx of inflammatory cells is noted. In man, mutations 
in the fibrillin-1 gene are causative for Marfan syndrome, an autosomal disorder 
affecting the cardiovascular, skeletal, and ocular system (20;22;24). To date, 
over 500 fibrillin-1 mutations have been identified (57), mutations are found 
throughout the gene and result in a reduced fibrillin-1 synthesis, a delayed 
secretion, and thus an impaired fibrillin-1 deposition into the matrix. The 
fragmented fibrillin-1 staining observed in our lung specimens is similar to the 
fibrillin-1 staining observed in skin specimens from Marfan patients (58;59). 
Strikingly, developmental emphysema has been noticed in a number of Marfan 
syndrome patients, although studies are scarce. In one study, 3 out of 4 
autopsied cases (44, 23, and 25 years of age) displayed emphysema on 
microscopical examination, as indicated by dilatation of alveolar spaces and 
rupture of alveolar walls. Fragmented elastic fibers, with a granular appearance, 
and microfibrils were noticed (26). In another study, 4 out of 4 infants with 
Marfan syndrome had microscopic emphysema similar to that observed in older 
patients with emphysema but without Marfan syndrome (19). In yet another 
study, 4 out of 4 infants with Marfan syndrome had microscopical features of 
emphysema, with interrupted, fragmented, and clumped fibers that were not
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observed in 13 control infants (25). About 5% of the Marfan patients develop 
bullous emphysema, as detected by chest radiography (27). In neonatal Marfan 
syndrome, a severe form of the disease, emphysema is common (21;23). It 
should be noted that the presence of emphysema in patients with Marfan 
syndrome may very well be underestimated. Patients are generally not 
examined for emphysema/COPD. Before the use of beta-blockers and 
cardiovascular surgery, patients generally died in their late 30’s, an age at 
which clinical emphysema is generally not manifest.
The observation that fibrillin-1 fragmentation is not correlated with smoking 
behavior or age is intriguing. Smoking is considered the most important risk 
factor for emphysema, but, for unknown reasons, only 15% of smokers actually 
develop clinical emphysema (60). This paradox suggests that, besides smoking, 
another factor must be involved in the susceptibility for emphysema. Is there 
another risk factor for emphysema besides smoking? Familial aggregation, 
implying a genetic predisposition, has been observed for emphysema (61-64). 
This suggests that next to environmental causes, genetic influences are of 
importance for the susceptibility for emphysema. Clinical emphysema would 
thus result from combined external risk factors and intrinsic host factors. 
Emphysema has been associated with polymorphisms in genes encoding 
epoxide hydrolase (65),vitamin D-binding protein (66), and heme oxygenase 
(67). However, strong associations between these polymorphisms and the 
elastic recoil properties of the lung are lacking and correlations with protein 
levels in human lung have not been reported (68;69).
Our study presents data that correlate fibrillin-1 to the onset of adult 
emphysema. This, together with the notion that mutations in the fibrillin-1 gene 
may result in emphysematous lesions in man (Marfan syndrome) as well as 
mice, makes the fibrillin-1 gene a strong candidate for the predisposition of 
smokers to emphysema. The following hypothesis may now be put forward: a 
mutation in the gene encoding fibrillin-1 results in a (moderately) affected 
fibrillin-1 protein in the lung. Once the lung is challenged, e.g. by smoking, the 
affected fibrillin-1 will lead to defective elastic fibers and to the loss of elasticity, 
which is the major hallmark of emphysema. Due to the loss of elastic fibers, 
breathing will be compromised and clinical emphysema will develop.
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Abstract
We recently demonstrated an aberrant staining of fibrillin-1 in lung tissue 
specimens with emphysematous lesions. In this study, we have extended this 
observation by an elaborate analysis of the elastic fiber. Using domain-specific 
antibodies to fibrillin-1, and to other elastin fiber-associated molecules, lung 
tissue derived from patients without obvious clinical emphysema, but harboring 
various degrees of microscopical emphysematous lesions, was analyzed. In 
addition, the fibrillin-regulated growth factor TGF-p was studied. Electron 
microscopy and biochemical analysis of desmosin (a marker for elastin) were 
also performed. Results were compared to lung tissue derived from patients 
with clinical emphysema. Domain-specific antibodies recognizing the C- 
terminal, N- terminal, and middle part of fibrillin-1 showed aberrant staining 
patterns associated with increasing degrees of microscopical emphysema. 
Staining for elastin, EMILIN-1, and fibulin-2 was, however, not aberrant. TGF-p 
staining was markedly increased. On the electron microscopical, but not light 
microscopical level, initial elastic fiber degradation was noticed in specimens 
with microscopical emphysema. Lung specimens from patients with clinical 
emphysema also displayed fragmented fibrillin-1 staining and, in addition, 
displayed extensive degradation of the elastic fiber. The results suggest that 
fibrillin-1 anomalies and TGF-p overexpression are associated with initial events 
occurring during the emphysematous process. Based on these data and data 
from literature, a mechanism for emphysematogenesis is proposed.
Introduction
The network of elastic fibers composes an important structural element in 
human lung parenchyma, as it maintains the structural integrity of the alveolar 
wall and contributes to the elastic recoil properties of the lung as a whole. 
Pulmonary emphysema, a condition characterized by dilated respiratory 
airspaces and destruction of the alveolar septa, is correlated with a progressive 
loss of elastic recoil (1). Elastin, the major component of the elastic fibers (2), 
has attracted much attention in the research to emphysema, although firm 
evidence for a distinctive initiating role of elastin in the pathogenesis of 
emphysema is lacking (3;4). As a result, research is now focusing on the 
microfibrillar component of elastic fibers.
Microfibrils are 10-12 nm filaments formed through the polymerization of fibrillin 
molecules and other elastic fiber associated-proteins (5;6). Over the years, 
immunohistochemical and biochemical techniques have resulted in a rapidly 
expanding inventory of elastic fiber associated-molecules. Next to fibrillin, which 
is the major component of microfibrils, a large number of other elastic fiber 
associated-molecules are present including microfibril associated-glycoproteins 
(MAGPs) (7), latent TGF-p-binding proteins (LTBPs) (8), collagen (9;10), 
several proteoglycans (11), EMILIN (12), and fibulin (13). Despite the 
identification of various elastic fiber associated-proteins, the molecular 
complexity of the microfibrils is still poorly understood. Besides that, the 
biological role of most of these (glyco)proteins is not clear, although their 
importance for the lung is indicated by mouse knock-out studies. Mice lacking 
LTBP-3 (14), LTBP-4 (15), fibulin-4 (16), and fibulin-5 (17) display a 
(developmental) emphysematous phenotype.
Recently, we observed an aberrant fibrillin-1 staining in human lung specimens 
which had microscopical emphysema, which were derived from individuals 
without obvious clinical emphysema (18). The data indicated fibrillin-1 to be 
associated with the onset of emphysema, and suggested that fibrillin-1 
anomalies play a role in the disease process. Fibrillin-1 regulates growth factor 
availability, mediates cell attachment, and act as a scaffolding protein during the 
assembly of the elastic fiber (5). Giving these functions, it is conceivable that 
aberrant fibrillin-1 may have profound effects on the integrity of elastic fibers in 
the lung and may mediate the destruction of elastic fibers, a feature of 
emphysema. This hypothesis is corroborated by the link between mutated forms 
of fibrillin-1 and emphysema in men and mice. Some patients with Marfan 
syndrome, an autosomal dominant disorder characterized by a mutation in the 
gene encoding fibrillin-1 (19), develop emphysema (20-22). Mice harboring a 
mutated form of the fibrillin-1 gene, either characterized by a 30-40 kb tandem 
duplication or a 6 kb deletion, develop emphysematous lesions that are in many 
ways similar to those observed in men (23-25).
In this study, we made use of a unique set-up that allowed us to study the role 
of fibrillin-1 and other molecules in the onset of elastin breakdown and 
eventually emphysema (18). To this end, we used morphologically 
characterized lung specimens with microscopical emphysema, as determined
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by three morphological parameters; the Destructive Index (DI), Mean Linear 
Intercept (MLI), and Panel Grading (PG). In addition, we analyzed lung 
specimens from patients with severe clinical emphysema.
Materials and Methods
Materials
Unless stated otherwise, all chemicals were purchased from Merck (Darmstadt, 
Germany).Mouse monoclonal antibodies against fibrillin-1 (mAb 2502 against 
human fibrillin-1 N-terminal site, recognizing an epitope within region aa 45­
450; mAb 2499 against human fibrillin-1 C-terminal site, recognizing an epitope 
within region aa 2093-2871; and mAb 1919 against bovine zonular fibrils, 
recognizing an epitope within region aa 451-909) were obtained from Chemicon 
(Temecula, CA). A polyclonal antibody reactive with the C-terminus of human 
TGF-p1 was obtained from Santa Cruz Biotechnology (sc-146, Santa Cruz,
CA). Tween-20, 3,3'-diaminobenzidine (DAB), hematoxylin according to Mayer, 
mouse anti-bovine elastin (clone BA4), and bovine serum albumin (fraction V) 
were obtained from Sigma (St. Louis, MO). Vectastain ABC kit and biotinylated 
horse anti-mouse IgG were obtained from Vector (Burlingame, CA). Biotinylated 
donkey anti-rabbit IgG was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA). A monoclonal antibody reactive against human 
EMILIN-1 was a kind gift of Prof. Dr. Alfonso Colombatti (Aviano, Italy) and a 
polyclonal antibody reactive against human fibulin-2 was a kind gift of Dr. 
Takako Sasaki (Martinsfried, Germany). All experiments were performed at 
ambient temperature (22°) unless stated otherwise.
Study group
Morphological and lung function data are presented in Table 1. Lung specimens 
were obtained at the University Lung Center Nijmegen. All subjects were 
studied according to the guidelines of the Medical Ethical Committee of the 
Radboud University Nijmegen Medical Center. Lung function tests were 
performed before surgery and the tests were analyzed by an experienced 
physician (R. Dekhuijzen). Lung specimens were obtained from 3 patients with 
clinically established emphysema undergoing lung volume reduction surgery, 
and from 20 individuals without obvious clinical emphysema, but with a variable 
degree of microscopical emphysema. In the latter group, patients underwent a 
lobectomy or pneumonectomy for a localized malignant process and specimens 
were sampled distantly from the tumor, not showing any sign of the tumor or its 
potential consequences (e.g. obstruction pneumonia). Three morphological 
methods were used to analyze microscopical emphysema; the DI, MLI, and PG 
(26). Lung parenchymal specimens from this subset of 20 individuals were 
divided in three study groups characterized as specimens with a high degree of 
microscopical emphysema (DI ranging from 80 to 100%), specimens with a 
moderate degree of microscopical emphysema (DI ranging from 30 to 80%), 
and specimens harboring no degree of microscopical emphysema (also called
specimens without microscopical emphysema, DI ranging form 0 to 30%) (18). 
Please note that in this study specimens were selected based on morphological 
criteria, and that specimens from other parts of the lung may have different 
characteristics. The characteristics of the three study groups and the study 
group composed of specimens with clinical emphysema are depicted in table 1. 
The 3 patients undergoing lung volume reduction surgery showed severe 
airflow obstruction and a reduced diffusion capacity. In contrast, patients with 
no, moderate or high degrees of microscopical emphysema showed no obvious 
clinical or functional signs of COPD. Because two patients from the group 
harboring no degree of microscopical emphysema had severe obstructive 
pneumonia (as evaluated by RD), the mean FEV1 as a percentage of predicted 
was lower in this group. However, this does not reflect an obstruction according 
to the GOLD criteria, as the GOLD classification is only applicable in (smoking 
related) obstruction without other causes of airflow limitation, such as an 
(obstructive) tumor or obstructive pneumonia.
Immunohistochemistry
Tissue processing and immunohistochemistry were performed as described 
(18;26). The anti-fibrillin-1 2502 (N-terminus) antibody was analyzed on 5 ^m 
paraffin, using a 1:100 dilution. Other antibodies, not reactive with paraffin- 
embedded specimens, and MAb 2502 were analyzed on 5 ^m cryosections. 
MAb 2499 was diluted 1:100, MAb 2502 1:2000, MAb 1919 1:250, anti-elastin 
antibody BA4 1:50, anti-fibulin-2 1:50, and anti-emilin-1 1:50. To identify TGF-p, 
paraffin sections were stained o/n with 1:100 diluted anti-TGF-p antibody using 
the immunohistochemistry method described, with the inclusion of an antigen- 
unmasking step. Antigen unmasking was performed by incubating the sections 
in 10 mM citrate buffer pH 6.0 for 120 min at room temperature.
Visualization of elastin
Elastin was also visualized in paraffin sections (5 ^m) by an Elastin Von Gieson 
staining as described (27).
Transmission Electron Microscopy (TEM)
Human lung tissue was embedded in 1.5 % (w/v) agarose, fixed in 2% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), postfixed with 1 % (w/v) 
osmium tetroxide, dehydrated in an ascending series of ethanol, and embedded 
in Epon 812. Ultrathin sections (60 nm) were cut and picked up on formvar- 
coated grids, post stained with lead citrate and uranyl acetate, and examined in 
a JEOL 1010 electron microscope.
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Table 1, Characteristics of study group (no degree, moderate degree, and 
high degree of microscopical emphysema and clinical emphysema) & 
morphological data of the specimens studied.
All values are means ± SD. Abbreviations: FEV1, forced expiratory volume in 1 sec.; VC, vital 
capacity; % pred, percentage of predicted value; Kco, diffusion capacity for CO; DI, Destructive 
Index; MLI, Mean Linear Intercept ; PG, Panel Grading.
* = DI, MLI, and PG were not assessed due to the advanced parenchymal destruction of the 
specimens.
# = Low value reflects 2 patients with severe obstruction pneumonia.
Desmosine assay
Desmosine analysis on human lung tissue was performed according to 
published protocols (28;29).
Statistics
Results were subjected to statistical analysis using the Mann-Whitney U test for 
multiple comparisons. Statistical significance was regarded when p < 0.05.
Results
Region-specific antibodies confirm that emphysema is associated with an 
anomalous fibrillin-1 staining
To study fibrillin-1 deposition, parenchymal lung specimens were stained with 
region-specific antibodies directed towards the N-terminal, C-terminal and 
central part of the fibrillin-1 protein. The antibodies against the C-terminal and 
central part of fibrillin-1 were only reactive with cryosections. The antibody 
against the fibrillin-1 N-terminus, however, displayed a clear fibrillin-1 staining in 
both paraffin and cryosections. Because of the better morphological 
preservation of lung tissue in paraffin sections, the fibrillin-1 N-terminal staining 
in paraffin sections will be described first. Next, the fibrillin-1 staining pattern of 
the three region-specific antibodies will be compared in cryosections. The 
fibrillin-1 N-terminal antibody displayed an abundant staining in the alveolar 
wall, alveolar endtips (a structure rich in elastic fibers), and around blood 
vessels and capillaries (Figure 1). Fibrillin-1 was abundantly present in human 
lung tissue without microscopical emphysema (the group of specimens 
harboring no degree of microscopical emphysema), as seen by an intense 
staining for the fibrillin-1 N-terminus (Figure 1A, B). In specimens with a 
moderate degree of microscopical emphysema (Figure 1C, D), a reduced and 
fragmented staining was observed in the alveolar walls and endtips. Compared 
to specimens without microscopical emphysema, the fibrillin-1 staining had a 
more punctuate appearance instead of a striped and coiled appearance. In 
specimens with a high degree of microscopical emphysema (Figure 1E, F), the 
reduction in fibrillin-1 staining was more pronounced. Despite the reduced 
overall staining, small spots of fibrillin-1 staining remained in the alveolar walls 
and endtips. Lung specimens derived from patients with clinical emphysema 
were analyzed to study if the anomalous fibrillin-1 staining was also present in 
clinical end-stage emphysema. In these specimens, a markedly reduced and 
fragmented staining for fibrillin-1 was observed that was similar to that seen in 
specimens with microscopical emphysema (Figure 1 G, H). To study the 
anomalous fibrillin-1 staining in more detail, three region-specific antibodies 
(directed towards the fibrillin-1 N- terminus, C-terminus, and central region) 
were applied to cryosections. All region-specific antibodies revealed a similar 
aberrant fibrillin-1 staining in specimens with a moderate or high degree of 
microscopical emphysema (Table 2, and Figure 2 for the fibrillin-1 N-terminal 
and C-terminal antibody). Densely packed fibrillin-1 deposits were observed in 
the alveolar walls and endtips of specimens without microscopical emphysema
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(Figure 2A, B), whereas a markedly reduced, fragmented fibrillin-1 staining was 
observed in both the endtips and alveolar walls of specimens with a moderate 
or high degree of microscopical emphysema (Figure 2C-F).
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Figure 1, Immunostaining for fibriiiin-1. Sections of paraffin-embedded human lung specimens, 
characterized as specimens without microscopical emphysema (no degree of microscopical 
emphysema, A, B), with a moderate (C, D), or with a high (E, F) degree of microscopical 
emphysema, and specimens derived from patients with clinical emphysema (G, H) were incubated 
with mAb 2502 (reactive with the N-terminus of fibrillin-1). Compared to specimens without 
microscopical emphysema, where a strong and continuous fibrillin-1 staining was seen in the 
alveolar endtips (A) and the alveolar walls (B), a diminished fibrillin-1 staining in specimens with a 
moderate or high degree of microscopical emphysema was apparent (C-F). In addition, a 
fragmented instead of a striped appearance was observed (arrows). A comparable 
diminished/punctuate staining pattern was observed in specimens derived from patients with clinical 
emphysema (G, H). (Bar = 50 ^m).
Table 2, Summary of the degree of immunostaining for elastic fiber 
proteins in human lung specimens characterized as harboring no, a 
moderate, or a high degree of microscopical emphysema.
No Moderate High
Fibrillin-1 (C-term) + + + +/-
Fibrillin-1 (middle part) + + + +/-
Fibrillin-1 (N-term) + + + +/-
Elastin + + + + + +
Fibulin-2 + + +
EMILIN-1 + + + + + +
TGF-ß +/- + ++
All scores are averages (n = 6 for the group of specimens without microscopical emphysema (also 
called specimens harboring no degree of microscopical emphysema) and n = 7 for the group of 
specimens analyzed as having a moderate of a high degree of microscopical emphysema. 
Definitions: + +, strong reactivity (abundant linear staining); +, moderate reactivity (substantially 
reduced, occasionally interrupted, staining); +/-, weak reactivity (markedly reduced, non-linear and 
punctuated, staining). In case of TGF-p staining, a similar score was used, but without the linear/ 
non-linear indication.
Anomalous fibrillin-1 staining is not associated with an obvious anomalous 
staining o f other microfibrillar components
As fibrillin-1 associates with other elastic fiber-associated proteins, it may be 
anticipated that the anomalous fibrillin-1 staining in specimens with 
microscopical emphysema is associated with anomalous staining of other 
components such as fibulin-2 and EMILIN-1. When stained for EMILIN-1 
(Figure 3A, C) and fibulin-2 (Figure 3B, D), both specimens without or with a 
high degree of microscopical emphysema, displayed a typical fibrillar pattern in 
the alveolar walls and endtips. The staining was not affected by the degree of 
microscopical emphysema (Table 2).
Anomalous fibrillin-1 staining is not associated with loss of elastin or with 
aberrant elastin staining
The cross-linking amino acid desmosine is unique to elastin, and quantitative 
analysis of this amino acid is indicative for the amount of elastin in the 
extracellular matrix. No significant differences were observed between the three 
groups of specimens (p between 0.1-0.4) (Figure 4), suggesting that the amount 
of elastin was not affected by the degree of microscopical emphysema. In 
addition, localization of elastin by means of an Elastin Von Gieson (EVG) 
staining (Figure 5) and by immunohistochemistry (data not shown) did not 
reveal differences among the three groups of specimens. In specimens without, 
or with a moderate or a high degree of microscopical emphysema, elastin was 
abundant, as demonstrated by a striped elastin staining in alveolar endtips and 
by a coiled elastin staining in the alveolar walls (Figure 5A-D). In specimens 
derived from patients with clinical emphysema, however, elastic fibers were
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severely compromised as illustrated by clumps, rather than stripes, of elastin 
staining in the alveolar walls and endtips (figure 5E, F). To study, on the light 
microscopical level, if aberrant fibrillin-1 staining was associated with altered 
elastin staining, successively prepared sections, cut directly after one another, 
were stained for fibrillin-1 (N-terminal) and for elastin (EVG). In specimens with 
microscopical emphysema, no altered elastin staining was observed to be 
associated with an anomalous fibrillin-1 staining (Figure 5G-J).
Figure 2, Immunostaining for fibrillin-1 with domain-specific antibodies. Cryosections of 
human lung specimens, characterized as specimens without microscopical emphysema (no degree 
of microscopical emphysema, A, B), with a moderate (C, D) or with a high (E, F) degree of 
microscopical emphysema, were incubated with mAb 2499 (A, C, E) reactive against the C-terminus 
of fibrillin-1, and mAb 2502 (B, D, F), reactive against the N-terminus o f fibrillin-1. Antibody staining 
for both antibodies was abundant in specimens without microscopical emphysema (A, B). 
Specimens with a moderate (C, D) and high (E, F) degree o f microscopical emphysema displayed a 
diminished and fragmented staining. In the alveolar endtips, and the alveolar walls, small dots of 
fibrillin-1 staining remained. (Bar = 50).
Figure 3, Immunostaining for EMILIN-1 and fibulin-2. Cryosections of human lung specimens, 
characterized as specimens without microscopical emphysema (no degree of microscopical 
emphysema, A, B) or with a high degree of microscopical emphysema (C, D), were incubated with 
antibodies against EMILIN-1 (A, C) and fibulin-2 (B, D). Staining for both antibodies was abundant 
in both specimens. Staining for EMILIN-1 and fibulin-2 displayed a typical fibrillar pattern with a 
striped staining in endtips and the alveolar walls. (Bar = 50 |jm).
Figure 4, Quantitative desmosine analysis. Desmosine content in lung tissue without 
microscopical emphysema (no degree of microscopical emphysema), or with a moderate or high 
degree of microscopical emphysema was quantified by a radioimmunoassay. Desmosine content 
was expressed in picomoles desmosine per milligram protein (pM des/mg protein). Total desmosine 
content was not significantly different among the three groups (normal vs. moderate p = 0.35; 
normal vs. high, p = 0.12).
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Figure 5, Visualization o f elastin and co-localization with fibrillin-1. Elastin was visualized in 
paraffin sections by an elastin Von Gieson staining, which stained elastin purple/blue, using 
specimens without microscopical emphysema (no degree of microscopical emphysema, A, B), 
specimens with a high degree of microscopical emphysema (C, D), and lung specimens derived 
from patients with clinical emphysema (E, F). The elastin staining for specimens without or with a 
high degree of microscopical emphysema was comparable. Note the striped and coiled elastin 
staining in the alveolar endtips and walls of specimens without microscopical emphysema (A, B) 
and specimens with a high degree of microscopical emphysema (C, D). The elastin staining in 
specimens derived from clinical emphysema patients was markedly different and appeared as 
clumps or fragments in the alveolar endtips (E) and walls (F) (arrows). Co-localization of elastin and 
fibrillin-1 (G-J). In specimens without microscopical emphysema (G,I) there was a co-localization 
between elastin and fibrillin-1 staining. In specimens with a high degree of microscopical 
emphysema (H,J), fibrillin-1 was diminished and showed a punctuate staining, whereas elastin 
seemed unaffected. (Bar = 50 |jm).
Anomalous fibrillin-1 staining is associated with the onset of elastin degradation 
Transmission Electron Microscopy (TEM) was used to investigate if the 
anomalous fibrillin-1 staining could be associated with ultrastructural changes in 
the elastic fiber. In specimens without microscopical emphysema, elastin was 
identified by a solid amorphous component being electron translucent to 
moderately opaque (Figure 6A, C). In specimens with a high degree of 
microscopical emphysema, elastin had a heterogeneous morphology with 
locally dark-stained elastin, and with irregular and poorly defined rims (Figure 
6B, D). The irregular appearance of the outer regions gave the elastin 
component a porous appearance with clearly visible open spaces. The darker 
staining likely reflects a greater penetration of the uranyl and lead stains into the 
elastin core and is considered as a sign of incomplete crosslinking or proteolytic 
damage (30-32). The altered elastin morphology can be regarded as a sign of 
early elastin degradation, and is in line with the “moth-eaten” appearance of 
elastin fibers in specimens derived from emphysematous patients or animal 
models for emphysema (33-37). In contrast to elastin, the clusters of microfibrils 
lying within and around the elastin component appeared normal in specimens 
with a high degree of microscopical emphysema.
Anomalous fibrillin-1 staining is associated with an increased TGF-p staining 
Fibrillin-1 plays a key role in the extracellular targeting and activation of the 
growth factor TGF-p (38). It is suggested that fibrillin-1 regulates TGF-p 
availability through association with LTBP-1, a protein that sequesters TGF-p in 
a large latent complex (LLC) rendering it less prone to activation (39;40). To 
study if TGF-p plays a role in microscopical emphysema, parenchymal lung 
specimens were immunostained with an antibody that recognizes latent as well 
as active TGF-p (Table 2). Staining for TGF-p was sparsely present in alveolar 
cells from lung specimens without microscopical emphysema (Figure 7A), 
whereas staining was increased in specimens with microscopical emphysema 
(Figure 7B). TGF-p was predominantly located in alveolar walls and 
macrophages (Figure 7).
Discussion
Research to emphysema has been hampered by the large time span between 
theinitiation of the disease process and its clinical manifestations. At the time of 
clinical diagnosis, the process of parenchymal destruction is in an advanced 
state, impeding the identification of initiating molecular events. Therefore, this 
study used a unique collection of lung specimens from patients without clinical 
emphysema, but with microscopical emphysema, as judged by morphometric 
analysis. As described previously (18), this unique set-up allowed us to analyze 
components in an early stage of the development of emphysematous lesions. 
For comparison, lung specimens from patients with clinical emphysema were 
included in this study.
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Figure 6, Transmission electron microscopy o f specimens with or without microscopical 
emphysema. Alveolar endtips from specimens without microscopical emphysema (no degree of 
microscopical emphysema, A, C) and with a high degree o f microscopical emphysema (B, D) were 
analyzed. In specimens without microscopical emphysema, amorphous elastin appeared regular 
and electron lucent, whereas in specimens with a high degree of microscopical emphysema, elastin 
appeared locally darker with an irregular and porous outline. The microfibrils, lying within and 
around the elastin component, appeared normal in both sets o f specimens. E = normal appearing 
elastin, MF = microfibrils, IE = irregular elastin, and P = pores within elastic fibers. (Bar = 0.5 |jm).
No degree of High degree of
microscopical emphysema microscopical emphysema
Figure 7, Immunostaining for TGF-p. Specimens without microscopical emphysema (no degree of 
microscopical emphysema, A) or with a high degree of microscopical emphysema (B) were 
immunostained using a polyclonal antibody to TGF-p. Note that specimens with a high degree of 
microscopical emphysema (B) displayed a markedly increased TGF-p staining. (Bar = 50 jm ).
In an earlier study, we showed that microscopical emphysema is associated 
with a fragmented and reduced presence of one of the major microfibrillar 
components of the elastic fiber, fibrillin-1 (18). In this study we corroborated on 
these data by showing a similar association in specimens with microscopical 
and clinical emphysema using three region specific antibodies. In contrast to 
staining for fibrillin-1, staining for two other microfibrillar associated-components 
(EMILIN-1 and fibulin-2) was not aberrant. This may be explained by the 
location of EMILIN-1 and fibulin-2, which are not identified as integral 
components of the microfibrils, but are present at the interface between 
amorphous elastin and the microfibrils where they are suggested to regulate 
tropoelastin deposition (41;42). In fact, EMILIN stands for “elastin microfibril 
interface located protein”. Routine histology and desmosine analysis indicated 
that the amount and distribution of elastin, the non-fibrillar component that 
makes up 90% of the elastic fiber, was not affected in specimens with 
microscopical emphysema. In contrast, TEM analysis indicated that elastin was 
less compact and irregular in lung specimens with a fragmented fibrillin-1 
distribution. This loosening of elastin was identified as one of the first signs of 
elastin degradation, not yet visible by conventional methods like EVG staining 
(33-37). The rims of the elastin component appeared more electron dense in 
specimens with a high degree of microscopical emphysema, previously 
described as a result of proteolysis or incomplete cross linking of elastin (30­
32). In addition to an anomalous staining for fibrillin-1, an increased staining for 
TGF-p was observed in specimens with microscopical emphysema.
The most accepted theory for the pathogenesis of emphysema involves the 
protease/anti-protease imbalance (43), where excess protease activity 
participates in destruction of the lung parenchyma. The fragmented fibrillin-1 
staining and the initial elastic fiber degradation observed in our specimens with 
microscopical emphysema might be the result of an increased proteolytic 
activity leading to degradation of elastin and fibrillin-1, albeit to different 
degrees.There are a number of matrix metalloproteases (MMPs) which have 
been implicated in elastic fiber homeostasis and which are capable of disrupting 
fibrillin-1 molecules and microfibrils (44). Because there is substantial evidence 
of increased MMP expression in emphysematous lungs (45-48), the observed 
fragmented fibrillin-1 staining and initial elastic fiber degradation might be 
caused by an ongoing proteolytic activity. In addition, changes in the 
extracellular matrix of the lung, like an aberrant fibrillin-1 distribution, may 
provoke certain processes that can eventually contribute to the pathogenesis of 
emphysema. In the extracellular matrix, fibrillin-1 aids in sequestering TGF-p in 
a large latent complex rendering it less prone to activation (38-40;49). In 
literature it is speculated that perturbations in fibrillin-1 changes the large latent 
complex and activates TGF-p (39;50). We associated an anomalous fibrillin-1 
staining with an increased staining for TGF-p. Although this association does 
not directly indicate that the observed aberrancies for fibrillin-1 are responsible 
for the increased TGF-p staining, literature data shows that a targeted 
disruption of the fibrillin-1 (Fbn1) gene (mgA mice) results in activation of TGF-p 
and in airspace enlargement (50). Moreover, mice harboring a hypomorphic 
Fbn1 allele (mgR mice) show more active TGF-p in parenchymal lung tissue,
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and develop destructive emphysema at the age of 6 months (50). TGF-p is a 
multifunctional cytokine that regulates a plethora of processes such as cell 
growth, cell survival, cell differentiation, inflammation, immunity, hematopoeisis, 
and matrix synthesis (51-53). Increased expression of the isoformTGF-p1 has 
been associated with pulmonary fibrosis (54-57). However, increased 
expression of this isoform has also been implicated in the pathogenesis of 
COPD (50;58;59). The paradigm of these responses can be explained by the 
nature of context in which TGF-p is found. The effects of this cytokine are 
regulated by the activation and differentiation of the target cell, genetic 
background, the presence of other growth factors or stimuli in the local 
environment, and the composition of the extracellular matrix (60). Although 
speculative, but in line with our data, it is tempting to put forward the following 
hypothesis; aberrant fibrillin-1, possibly as a result of unleashed proteolytic 
activity or as a result of genetic factors, affects the normal regulation of growth 
factors/cytokines like TGF-p leading to a plethora of processes finally resulting 
into an emphysematous phenotype. This hypothesis is substantiated by 
observations in mice deficient in fibrillin-1 which show airspace enlargement as 
a result of dysregulation of TGF-p activation; airspace enlargement that can be 
prevented by the administration of neutralizing antibodies to TGF-p (50). 
Moreover, the phenotype of the tight skin mice, a genetic model for emphysema 
that is characterized by a tandem duplication in the gene encoding fibrillin-1, is 
also associated with an abnormal TGF-p activation (61). Further research on 
human lung specimens should clarify if there is indeed an association between 
aberrant fibrillin-1 and dysfunctional cellular signaling pathways of TGF-p that 
correlates with the pathogenesis of emphysema.
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Abstract
Recent data have drawn attention to the extracellular targeting and release of 
TGF-p by fibrillin-1, and its potential role in the pathogenesis of emphysema. 
Using antibodies to various proteins involved in the TGF- p signaling cascade, 
lung tissue derived from patients with microscopical emphysema was analyzed. 
Using immunohistochemistry, it was shown that, of the TGF- p isoforms, only 
TGF- p1 expression was increased together with phosphorylated smad-2, 
indicating an increase in TGF- p1 receptor-mediated down-stream signaling. 
Immunostaining for TGF- p receptor I was not affected. Specimens with 
microscopical emphysema showed an increase in apoptotic cells, and an influx 
of macrophages and T-lymphocytes. Analysis of elastolytic/proteolytic activity 
by a spectrometric assay and zymography did not reveal an increase in the 
activity of matrix metalloproteinases. Combining these data with data from 
literature, we propose that fibrillin-1 anomalies in human lung results in a 
perturbed matrix sequestration of TGF- p, thereby predisposing the lung to 
TGF- p induced pathogenetic processes like apoptosis and the influx of 
inflammatory cells, ultimately leading to emphysema.
Introduction
Emphysema is defined by an abnormal enlargement of airspaces distal to the 
terminal bronchioles that is accompanied by destruction of the septa (1).
Chronic Obstructive Pulmonary Disease (COPD), a collective term including 
chronic bronchitis and emphysema, is predicted to become the third leading 
cause of death and fifth leading cause of disability in the world by 2020 (2). 
Despite this growing global importance, emphysema is still a poorly defined 
disease at the molecular level. Over the past years, there have been several 
concepts for the pathogenesis of emphysema, including chronic inflammation, 
protease/anti-protease imbalance, oxidative stress, and apoptosis (3-9). 
Although it is conceivable that all these processes are involved in the complex 
pathogenesis of emphysema, the molecular pathology of emphysema is still 
elusive.
Recently, attention has been drawn to fibrillin-1 as an important player in the 
pathogenesis of smoking-related emphysema. Fibrillin-1 is an extracellular 
matrix protein that is the prime component of the microfibrils, which are 
structures ubiquitously found in elastic fibers (10;11). We have recently 
correlated anomalies in fibrillin-1 staining with microscopical emphysema in 
cigarette smokers (12). Since this aberrant fibrillin-1 staining was not found in 
cigarette smokers without microscopical emphysema, alterations in fibrillin-1 
were proposed as a possible predisposition for the development of smoking- 
related emphysema. In addition, we found that the aberrant fibrillin-1 staining 
was associated with an increased staining for TGF-p (13).
The question arises as to how fibrillin-1 anomalies can be related to an 
emphysematous phenotype. An explanation can be found in one of the many 
functions that fibrillin-1 exerts in the extracellular matrix. Data indicate that 
fibrillin-1 plays a key role in the extracellular targeting and release of TGF-p 
(14;15), a powerful growth factor that regulates tissue development and 
homeostasis via modulation of cell growth, inflammation, and matrix synthesis 
(16). It is suggested that fibrillin-1 regulates TGF-p availability through 
association with the latent transforming growth factor p binding protein 1 (LTBP- 
1) (17;18), a protein that sequesters TGF-p in a large latent complex rendering 
it less prone to activation (19;20). Increased TGF-p activity has been implicated 
in the pathogenesis of emphysema and COPD (21-23). It has been speculated 
that perturbations in extracellular matrix proteins, like fibrillin-1, destabilizes the 
large latent complex, thereby activating TGF-p (18;22). By combining these two 
observations, it may be hypothesized that anomalies in fibrillin-1, as seen in our 
specimens with microscopical emphysema (13), alter the extracellular matrix 
sequestration of TGF-p and thereby leading o active TGF-p. In turn, active TGF- 
p might ultimately lead to a molecular emphysematous phenotype, 
characterized by chronic inflammation, protease/anti-protease imbalance, 
oxidative stress, and apoptosis. In a recent study using a mouse model for 
emphysema (the tight-skin mouse), it was demonstrated that a mutation in the 
gene encoding fibrillin-1 results in oxidative stress and apoptosis (24).
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In this study, we used morphologically characterized human lung specimens 
with microscopical emphysema as determined by three morphological 
parameters: the Destructive Index (DI), Mean Linear Intercept (MLI), and Panel 
Grading (PG). This set-up has previously been proved to be a valuable method 
in the identification of molecular events in the pathogenesis of emphysema 
(12;13). These specimens with smoking-related microscopical emphysema 
have been associated with an aberrant distribution of fibrillin-1 and an increased 
expression of TGF-p (12;13). In this study, we localized various members of 
TGF-p signaling cascade, including TGF-p isoforms, receptors, and an internal 
signaling protein, and related observed changes to emphysema-associated 
processes such as apoptosis and inflammation.
Materials and Methods
Study group
Lung specimens were obtained at the University Lung Center Nijmegen as 
described (25), and were derived from patients undergoing a lobectomy or 
pneumonectomy for a localized malignant process. Specimens were sampled 
from an area distant from the tumor, not showing any sign of the tumor or its 
possible consequences (e.g. obstructive pneumonia). Lung parenchymal 
specimens (n = 13) were divided in two study groups characterized as 
specimens without (n = 6) or with (n = 7) microscopical emphysema. 
Microscopical emphysema was analyzed by three morphological methods; the 
DI, MLI, and PG (25). Inclusion of specimens in the microscopical emphysema 
subset was based on a DI ranging between 70-100%. Please note that 
specimens from other parts of the lung may have different characteristics. Some 
characteristics of the study group are depicted in table 1.
Tissue processing
Tissue processing was performed as described (25). Briefly, small tissue 
specimens were cut into pieces of equal size. One part was immersed in 
phosphate buffered saline (PBS) containing 4% formalin and inflated under 
vacuum (13 kPa) for 20 min, using a routine water stream-driven device (water 
aspirator) in order to restore alveolar dimensions (26). After embedding in 
paraffin, 5 ^m sections were cut for immunohistochemistry. The other, adjacent, 
part was stored at -80 °C for biochemical analysis.
Immunohistochemistry for proteins involved in TGF-p signaling 
5 ^m paraffin sections were dewaxed by xylene and rehydrated through graded 
alcohol series. For antigen unmasking, sections were incubated with 10 mM 
sodium citrate buffer pH 6.0 for 120 min at ambient temperature. Endogenous 
peroxidase was blocked with 1% hydrogen peroxidase in methanol for 30 
minutes. Thereafter, sections were blocked with 5% normal serum of the 
species in which the secondary antibody was produced. Sections were
Table 1, Characteristics of the study group & morphological data of the 
specimens studied.
No microscopical 
emphysema
microscopical
emphysema
Study group
N 6 7
Male/female 6/0 7/0
Age (Yr) 58 ± 6 67 ± 5
Pack years 30 ± 10 25 ± 6
FEVi (% pred) 68 ± 8# 79 ± 12
Kco (% pred) 86 ± 28 66 ± 25
Morphological data
DI (%) 18 ± 6 85 ± 11
MLI (jm ) 254 ± 38 368 ± 52
PG (%) 21 ± 8 79 ± 7
All values are means ± SD. Abbreviations: FEV1, forced expiratory volume in 1 sec. (post­
bronchodilatation); VC, vital capacity; % pred, percentage of predicted value; Kco, diffusion capacity 
for CO; DI, Destructive Index; MLI, Mean Linear Intercept; PG, Panel Grading.
# = Low value reflects 2 patients with severe obstruction pneumonia.
incubated with antibodies to TG F-pi, TGF-p2, TGF-p3, TGF-pRI, TGF-pRII 
(1:100, all from Santa Cruz Biotechnology, Santa Cruz, USA), Smad-2p (1:100, 
Cell Signaling Technology, Beverly, USA), and p-LAP (1:20, R & D systems, 
Minneapolis, USA) overnight at 4°C. After extensive washing in PBS, antibody 
binding was detected by the appropriate biotin-labeled secondary antibody 
(1:200, Jackson Immuno Laboratories, West Grove, USA) for 1 h at ambient 
temperature, followed by an enhancement with the Avidin-Biotin-Peroxidase 
Complex (Vectastain ABC Elite kit, Vector Laboratories Inc., Burlingame, USA) 
for 1h. Bound complexes were visualized with 3’,3’-diaminobenzidine substrate 
(DAB, Sigma-Aldrich, St. Louis, USA). Sections were briefly counterstained with 
hematoxylin (Sigma-Aldrich, St. Louis, USA) and mounted with entellan (Merck, 
Darmstadt, Germany). Staining was (semi)quantified in two ways. In case of a 
predominant cellular staining pattern (TGF-p1, TGF-p2, TGF-p3, TGF-pRI, and 
smad-2p), the number of stained cells was estimated by counting immune- 
positive cells in 8 non-overlapping fields (933 x 725 ^m each) of parenchymal 
tissue. In case of a predominant extracellular staining pattern (p-LAP), immuno- 
reactivity was scored using semi-quantitative criteria ranging from no staining to 
intense staining, as compared to control specimens.
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Apoptosis
Apoptotic cells were detected by a TUNEL assay.
TUNEL assay: DNA strand breaks were detected by an in situ cell death 
detection kit (Roche Diagnostics, Pensberg, Germany) following the 
manufacturer’s instructions. Briefly, after deparaffinization and rehydration, 5 
^m paraffin sections were pre-treated with microwave irradiation in 10 mM 
sodium citrate pH 6.0 for 5 min. Slides were immersed in TUNEL reaction 
mixture and incubated in a humid atmosphere at 37 °C for 60 min. After two 
PBS washes, slides were mounted in mowiol (Calbiochem, La Jolla, USA) and 
analyzed using a fluorescence microscope (Leica CTR600, Leica, Wetzlar, 
Germany). The number of apoptotic cells in the alveolar septa was estimated by 
counting stained cells in 8 non-overlapping fields (933 x 725 ^m) of 
parenchymal tissue. To identify which cell types were apoptotic, a double 
staining was performed with an immune fluorescence assay for epithelial or 
endothelial cells followed by a TUNEL assay. Briefly, after dewaxing and 
rehydration, 5 ^m paraffin sections were pre-treated with 10 mM sodium citrate 
pH 6.0 for 20 min at 95 °C. Non-specific antibody binding was blocked with 1% 
BSA (Sigma, St. Louis, USA) in PBS for 10 min. Sections were incubated for 1 
h with either mouse anti- human epithelial membrane antigen antibodies (EMA, 
1:100, Dakocytomation, Glostrup, Denmark) to identify epithelial cells, or mouse 
anti-human CD31 (1:100, Dakocytomation, Glostrup, Denmark) to identify 
endothelial cells. Bound primary antibodies were detected by alexa 594- 
conjugated goat anti-mouse IgG (1:100, Molecular Probes, Eugene, USA) for 
1h. After three PBS washes, TUNEL staining was carried out as described 
above, omitting the microwave pre-treatment.
Caspase-3 immunostaining: To identify caspase-3 positive cells, 5 ^m paraffin 
sections were immunostained for active caspase-3 (1:500, BD, Franklin Lakes, 
USA). Staining was performed using the method described above (see 
Immunohistochemistry for proteins involved in TGF-fi signaling), incubating the 
sections in 10 mM sodium citrate buffer pH 6.0 for 20 min at 95 °C for antigen 
unmasking.
Cell proliferation
Cell proliferation was assessed by staining 5 ^m paraffin sections with an 
antibody to human proliferating cell nuclear antigen (PCNA, 1:2500, Sigma- 
Aldrich, St. Louis, USA). Staining was performed using the method described 
above (see Immunohistochemistry for proteins involved in TGF-fi signaling ), 
incubating the sections in 10 mM sodium citrate buffer pH 6.0 for 20 min at 95 
°C for antigen unmasking. The number of proliferating cells was estimated by 
counting stained cells in 8 non-overlapping fields (933 x 725 ^m each) of 
parenchymal tissue.
Inflammatory influx
Inflammatory cells viz. macrophages (1:100, mouse anti-human CD68), 
neutrophils (1:100, mouse anti-human neutrophil elastase), and T-lymphocytes 
(1:100, mouse anti-human CD3, CD4, and CD8) (all antibodies were from
Dakocytomation, Glostrup, Denmark) were identified by immunostaining in 5 ^m 
paraffin sections using the method described above (see Immunohistochemistry 
for proteins involved in TGF-fi signaling). Antigen unmasking was performed by 
incubating the sections in 10 mM sodium citrate and pH 6.0 for 20 min at 95 °C. 
The number of inflammatory cells was estimated by counting stained cells in 8 
non-overlapping fields (933 x 725 ^m each) of parenchymal tissue.
Elastolytic activity
The elastolytic activity in lung parenchymal specimens was estimated by a 
spectrophotometric assay. To this end, ~ 50 mg (wet weight) of lung 
parenchymal tissue was homogenized with a polytron in RIPA buffer (50 mM 
Tris HCl, pH 7.6 containing 150 mM NaCl, 5 mM CaCl2, 1% Nonidet-P40 (USB 
corporation, Cleveland, USA), 2 mM PMSF and 5 mM NEM). Homogenates 
were stirred in an end-to-end rotor for one hour at 4 °C and spun down at 
10,000 x g for 15 min. Supernatant was collected and protein content was 
estimated by a Protein Bradford Assay (Bio-Rad Laboratories, Hercules, USA). 
Elastolytic activity was quantified by incubating insoluble Congo Red- 
conjugated elastin (Sigma-Aldrich), 20 mg/ml 0.2 M Tris-HCl, pH 8.8, with equal 
protein contents in supernatant. After 20 min of incubation at 37 °C, the 
suspension was centrifuged and the solubilised Congo Red products were 
measured in a spectrophotometer at 585 nm.
Gelatin zymography
To examine the activity of a subset of matrix metalloproteinases (MMPs), 10% 
SDS-PAGE gels containing 1 mg gelatin /ml were used. Each lane was loaded 
with 50 ^g of protein derived from the lung parenchymal extracts (see elastolytic 
activity) in non-reducing sample buffer. After electrophoresis, gels were washed 
twice with 2.5% Triton X-100 (BDH Chemicals, Poole, Great Brittan) for 15 min. 
After a final wash in 0.05 M Tris HCl, pH 8.0 containing 5 mM CaCl2, gels were 
incubated in 0.05 M Tris HCl, pH8.0 containing 5 mMCaCl2 and 5 mM ZnCl2 at 
37 °C for 4-72h. After incubation, gels were stained with 0.5% (w/v) Coomassie 
Brilliant Blue R250 (MP Biomedicals, South Chillicothe, USA) in a mixture of 
methanol, acetic acid, and MilliQ (5:1:4 respectively). Upon destaining in 5:1:4 
methanol/acetic acid/MilliQ, zones of enzymatic activity appeared as clear white 
bands against a blue background. Gels incubated in the presence of 20 mM 
EDTA, an inhibitor of MMPs, were used to indicate the specificity of the assay. 
Enzyme activity was quantified using software that measured the intensity of the 
bands (GeneTools, Syngene, Cambridge, UK).
Statistics
Results were subjected to statistical analysis using the Mann-Whitney U test for 
multiple comparisons. Differences were regarded significant when p < 0.05.
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Results
An increased staining for TGF-pi and smad-2p is associated with microscopical 
emphysema
Previous data from our group have indicated that TGF-p immunostaining is 
increased in a subset of specimens with microscopical emphysema (13). To 
study the role of TGF-p in more detail, a subset of parenchymal lung specimens 
with and without microscopical emphysema was immunostained with antibodies 
to various members of the TGF-p signaling cascade (results are as summarized 
in figure 1A). In all specimens, TGF-p1 (figure 1B and C), TGF-p2 (figure 1 D 
and E), and TGF-p3 (figure 1 F and G) were localized in the extracellular matrix, 
alveolar cells, and infiltrated alveolar macrophages. Only TGF-p1 staining was 
increased in specimens with microscopical emphysema, whereas TGF-p2 and 
TGF-p3 staining was similar in specimens with or without microscopical 
emphysema. In specimens without microscopical emphysema, staining for 
phosphorylated smad-2 (smad-2p, the activated form of smad-2) was sparsely 
present, whereas smad-2p staining in specimens with microscopical 
emphysema was abundant (figure 1H and I). In contrast to an increased 
expression of TGF-p1 and smad-2p, the expression of the N-terminal 
propeptide of TGF-p (latency associated protein (LAP)), and the TGF-p receptor 
I (TGF-pRI) was similar in both groups of specimens (figure 1A).
Immunostaining for the TGF-pRII was diffusely scattered throughout the 
specimens, and the low staining intensity made quantification impossible.
Increased TGF-pi and smad-2p staining is associated with increased apoptosis 
TGF-p1 plays a fundamental role in the homeostasis between cell growth and 
apoptosis; the cytokine can have either growth promoting or growth inhibiting 
effects (27). To determine the effect of the increased TGF-p1 and smad-2p 
staining, as seen in specimens with microscopical emphysema, lung specimens 
were immunostained for the proliferating nuclear cell antigen (PCNA), and 
assayed with the terminal deoxynucleotidyl transferase-mediated dUTP-biotin 
nick end-labeling method (TUNEL), to detect proliferation and apoptosis 
respectively. PCNA immunostaining, as indicated by a nuclear staining pattern, 
was sparsely present in specimens with or without microscopical emphysema, 
suggesting no major difference in proliferation among the two groups of 
specimens (figure 2).
On the other hand, a TUNEL assay indicated that the amount of apoptotic cells 
was significantly (p < 0.001) increased in specimen with microscopical 
emphysema (figure 3A-C). Since TUNEL staining is known to be positive in 
some necrotic cells, specimens were also immunostained for caspase-3, a 
down-stream effector of apoptotic events. Specimens with microscopical 
emphysema expressed caspase-3 in alveolar cells, whereas specimens without 
microscopical emphysema did not (results not displayed). Double labelling with 
an epithelial (epithelial membrane antigen (EMA)) and endothelial (CD31) cell 
marker was performed to determine the specific cell type undergoing apoptosis. 
Despite a few overlapping cells, the majority of TUNEL staining did not overlap
N o m ic ro sc o p ica l em ph y se m a m ic ro sc o p ica l em ph y se m a
Figure 1, Immunostainings for components o f the TG Fp signaling cascade. A. Overview of 
the (semi)quantification of immunostaining for TGF-p1, TGF-p2, TGF-p3, TGF-p RI, smad-2p, and 
p-LAP in paraffin-embedded human lung specimens, analyzed as specimens without (black bars) or 
with microscopical emphysema (white bars). In the case of a cellular staining pattern, reactivity was 
quantified by counting the stained cells. In the case of an extracellular matrix staining pattern, 
reactivity was scored semi-quantitatively. The average number of cells/staining intensity in 
specimens with microscopical emphysema was expressed as a fold of the average number of 
cells/staining intensity in specimens without microscopical emphysema, which was set at 1. Note 
that a significant increase was only observed for TGF-p1 and smad-2p. (*** = p < 0.001). B-I. 
Immunohistochemical detection of TGF-p1 (B, C), TGF-p2 (D, E), TGF-p3 (F, G), and smad-2p (H, 
I), as identified by a cellular staining pattern (arrows). An increase in the number of TGF-p1 and 
smad-2p positive cells was observed in specimens with microscopical emphysema (C, I) compared 
to specimens without microscopical emphysema (B, H). Staining for TGF-p2 and TGF-p3 in 
specimens without (D, F) or with microscopical emphysema (E, G) was similar. (Bar = 50 |jm).
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with CD31 staining, indicating that most endothelial cells were not apoptotic 
(figure 3D). On the other hand, overlapping TUNEL and EMA staining indicated 
that an appreciable amount of apoptotic cells were alveolar epithelial cells 
(figure 3E).
Figure 2, Immunostaining for PCNA, a marker for proliferation. Quantification of the 
immunostaining for PCNA in paraffin-embedded human lung specimens, analyzed as specimens 
without or with microscopical emphysema. Method of quantification was as indicated in Figure 1. 
Note the comparable number of positive cells in both groups of specimens.
Increased TGF-pi and smad-2p staining is associated with an influx of 
inflammatory cells
Besides regulating cell growth, TGF-p1 induces the influx of inflammatory cells, 
including macrophages, neutrophils, and T-lymphocytes (28-31). Therefore, the 
influx of these inflammatory cells was studied. Lung specimens with 
microscopical emphysema showed increased numbers of macrophages and 
lymphocytes in their parenchymal tissue (results are as summarized in figure 
4A), as identified by an increased number of cells that stained for CD68 (figure 
4 B, C), or CD3 (figure 4 D, E). Besides macrophages and T-lymphocytes, lung 
specimens with microscopical emphysema showed a tendency towards an 
increased number of neutrophils, but this effect was not statistically significant.
microscopical emphysema microscopical emphysema
TUNEL/CD31 TUNEL/EMA
Figure 3, Analysis of apoptosis by the TUNEL assay. A. Quantification of staining by the TUNEL 
assay in paraffin-embedded human lung specimens, analyzed as specimens without or with 
microscopical emphysema. Method of quantification was as indicated in Fig. 1. Note the significant 
increase in apoptosis in specimens with microscopical emphysema. (*** = p < 0.001). B-E. 
Immunohistological staining for apoptosis by the TUNEL assay indicated an increase in apoptotic 
cells (green stained nuclei) in specimens with microscopical emphysema (C), whereas specimens 
without microscopical emphysema showed considerably less apoptotic cells (B). Double staining 
(yellow) with an endothelial marker (CD31, red) and TUNEL (green) indicated that the majority of 
endothelial cells did not undergo apoptosis (D). The arrows indicate the location of the endothelial 
layer of the blood vessels. On the other hand, double staining (yellow) with an epithelial marker 
(EMA, red) and TUNEL (green) indicated apoptosis in an appreciable amount of epithelial cells (E). 
(Bar = 50 |jm).
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Figure 4, Immunostaining for neutrophils, macrophages, and T-lymphocytes. A. Quantification 
of immunostaining for neutrophils, macrophages, CD3+ T-lymphocytes, CD4 + T-lymphocytes, and 
CD8+ T-lymphocytes in paraffin-embedded human lung specimens, analyzed as specimens without 
(black bars) or with (white bars) microscopical emphysema. Method of quantification was as 
indicated in Fig. 1. Note the significant increase in macrophages, CD3+, CD4+, and CD8+ T- 
lymphocytes, and the tendency towards an increased influx of neutrophils in specimens with 
microscopical emphysema. (*** = p < 0.001, ** = p < 0.005, * = p < 0.05). B-E. Immunohistochemical 
detection of macrophages (B, C) and T-lymphocytes (D, E). CD68 (B and C) and CD3 (D and E) 
immunostaining displayed increased numbers of respectively macrophages and T-lymphocytes 
(arrows), in specimens with microscopical emphysema (C and E), as compared to specimens 
without microscopical emphysema (B and D). (Bar = 50 |jm).
Increased influx of macrophages is not associated with an increased elastolytic 
activity
Macrophages can be activated by a number of factors, including cigarette 
smoke, to release elastolytic enzymes like matrix metalloproteinase-2 (MMP-2), 
MMP-9, and MMP-12 (32;33). It may therefore be postulated that an increased
influx of macrophages, as observed in specimens with microscopical 
emphysema, results in an enhanced release of elastolytic enzymes. To detect 
the activity of elastolytic enzymes, protein extracts from lung parenchymal 
tissue were subjected to a suspension of insoluble Congo Red-conjugated 
elastin. Elastolytic enzymes are able to degrade the elastin, which can be 
measured by the amount of solubilised Congo Red dye in the supernatant. No 
significantly different levels of soluble Congo Red dye were detected in protein 
extracts derived from specimens with or without microscopical emphysema 
(Figure 5A). To examine the expression of active MMPs by another method, the 
protein extracts were subjected to gelatin zymography (figure 5B). In agreement 
with reported data, a subset of bands was seen that represent pro-MMP-2 (~72 
kDa), MMP-2 (-62 kDa), pro-MMP-9 (-92 kDa), and MMP-9 (-88 kDa), and 
MMP12 (-45 kDa) (34-37). Densitometric analysis indicated that the proteolytic 
activity was not significantly different in protein extracts derived from specimens 
with or without microscopical emphysema (figure 5C). Treatment of the extracts 
with EDTA, a known inhibitor of MMP activity, abolished the presence of bands 
(results not displayed).
Discussion
The interactions between TGF-p and the structural components of the 
extracellular matrix play a role in a number of pathogenic disorders of the 
extracellular matrix (38-40), including emphysema (21-23). Of the three TGF-p 
isoforms (TGF-p1, TGF-p2, and TGF-p3) and two TGF-p receptors (TGF-pRI 
and TGF-pRII), only TGF-p1 expression was increased in specimens with 
microscopical emphysema. This data is in agreement with reported literature 
that has described increased levels of TGF-p1 in lung specimens of patients 
with COPD, a collective term including chronic bronchitis and emphysema 
(21;23;41). Upon release of TGF-p1 from the large latent complex, the cytokine 
can initiate signaling by binding to the TGF-pRI /TGF-pRII complex thereby 
activating intracellular smad proteins, like smad-2, by phosphorylation (40). 
Therefore, the amount of phosphorylated smad-2 (smad-2p) is a measure for 
receptor-mediated TGF-p signaling (42). Our results indicate an increased 
smad-2p immunostaining in specimens with microscopical emphysema, which 
points to an increased TGF-p signaling as an early event in the process of 
human emphysema. In agreement with earlier research (42), we suggest that 
the increased TGF-p1 expression that we observe in specimens with 
microscopical emphysema results in binding to the TGF-p receptors and 
thereby initiates down-stream signaling via smad-2p.
Recent studies have provided evidence supporting a role for fibrillin-1, 
traditionally viewed as a structural matrix protein, in the regulation of TGF-p 
activity (14;15;43). Strikingly, two models of fibrillin-1 deficient mice correlate 
fibrillin-1-modulated bioactivity of TGF-p to emphysema (22). Mice harboring a 
targeted in-frame deletion of fibrillin-1 (mgA mice) have developmental
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Figure 5, Detection o f elastolytic/proteolytic activity by a spectrophotometric enzyme assay 
and gelatin zymography. A. Quantitative analysis of the elastolytic activity in extracts from 
specimens without and with microscopical emphysema. Elastolytic activity was assessed by 
measuring the absorbance at 585 nm of solubilised Congo Red, derived from Congo Red- 
conjugated elastin. No significant difference was detected between both type of specimens. B. 
Identification of proteolytic activity in extracts derived from specimens without or with microscopical 
emphysema using gelatin zymography. Zones of enzymatic activity appeared as clear white bands 
against a dark background. Clear bands indicate the presence of MMP-12 (~45 kDa), and a clear 
grouping of bands in the middle of the gel indicating the presence of pro-MMP-9 (~92 kDa), MMP-9 
(~88 kDa), pro-MMP-2 (~72 kDa), and MMP-2 (~62 kDa). Molecular weight standards (MW) are 
indicated by the arrowheads on the right. C. Band intensities were quantified by densitometric 
analysis and expressed in arbitrary units (AU). No significant difference in MMP activity between the 
two groups of specimens was detected.
emphysema, as characterized by defective distal airspace development, and 
show enhanced TGF-p activity (22). The emphysematous phenotype could be 
rescued by systemic administration of TGF-p-neutralizing antibodies. Mice 
harboring a hypomorphic fibrillin-1 allele (mgR mice), resulting in the production 
of about a quarter of the normal amount of fibrillin-1, develop late onset 
emphysema that is characterized by airspace dilatation accompanied by 
destructive changes. Similar to mgA mice, mgR mice have an enhanced TGF-p 
activity (22). In contrast to the developmentally impaired alveolarization in mgA 
mice, mgR mice recapitulate the pathological findings of human emphysema. 
Therefore, the authors proposed that abnormal or reduced levels of fibrillin-1 
perturb extracellular matrix sequestration of TGF-p, thereby predisposing the 
lung to apparently acquired phenotypes such as adult emphysema. The data 
reported here and addressing human emphysema fit within this hypothesis. 
Human specimens with microscopical emphysema are characterized by fibrillin- 
1 aberrancies (13), and showed an increased TGF-p1 signaling in association 
with apoptosis and influx of inflammatory cells (this study).
Macrophages play a pivotal role in emphysema, emphysematous patients have 
a 5- to 10-fold increase in their number, and a subsequent enhancement of the 
secretion of elastolytic enzymes (32;33;44). Despite a 3-fold increase in the 
number of macrophages, specimens with microscopical emphysema do not 
show an enhanced elastolytic activity. A possible explanation for this paradox is 
the increased TGF-p signaling; TGF-p suppresses the synthesis of 
macrophage-derived MMPs and increases the production of enzymes that 
inhibit MMPs (45). A lack of increase in MMP-activity, despite an increased 
influx of macrophages, has also been shown in the lungs of the tight skin 
mouse, a model for emphysema characterized by a tandem duplication of 30-40 
kb in the gene encoding fibrillin-1 (24). In this model, the aberrant fibrillin-1 
protein results in increased apoptosis and oxidative stress (24).
Increased levels of TGF-p1 can induce transcriptional responses, like 
apoptosis, leading to an emphysematous phenotype in fibrillin-1 deficient mgA 
and mgR mice (22). Can the increased levels of TGF-p1 and the downstream 
signaling via smad-2p that was observed in our study also be associated with 
transcriptional responses leading to an emphysematous phenotype? Many 
studies have demonstrated that excess TGF-p1 is a potent stimulator of 
epithelial apoptosis (22;27;46-50). Besides regulating apoptosis, TGF-p1 also 
induces chemotaxis of, amongst others, macrophages (28;29), T-lymphocytes 
(30), and neutrophils (31), most often at fM concentrations. Both apoptosis 
(5;44;51-55) and the influx of T-lymphocytes(54;56-58), neutrophils (56;58), and 
macrophages (56;58-60) have been reported as an early process in the 
pathogenesis of emphysema. In this study, we not only report an increased 
down-stream signaling of TGF-p1 that is associated with microscopical 
emphysema, but we also associate this increase with processes like apoptosis 
and inflammation.
Previously (13), we have associated aberrant fibrillin-1 staining and an increase 
in TGF-p1 to microscopical emphysema. Since the sequestration of TGF-p by
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fibrillin-1 is indispensable for tissue homeostasis, we proposed an initiating role 
for these molecules in the pathology of emphysema. The results reported here, 
combined with the outcome of the two strains of fibrillin-1 deficient mice (22), 
suggest that aberrations in fibrillin-1 lead to excess activation and down-stream 
signaling of TGF-p1, which upon transcriptional expression instigates cellular 
processes like apoptosis and inflammation, ultimately resulting in clinical 
emphysema (see fig. 6 for hypothetical scheme). Although this hypothesis is 
largely based on observational data, the hypothesis fits within the current 
opinion of fibrillin-1- mediated regulation of TGF-p.
Figure 6, Hypothetical mechanisms for TGF-p mediated emphysematogenesis. For details, 
see text.
The drug Losartan, an angiotensin II type I receptor antagonist and a known 
TGF-p antagonist, has been administered to mice with a heterozygous allele
C 1 0 3 9 G /+substitution in the gene encoding fibrillin-1 (Fbn1 ) (61), representing a 
mouse model of Marfan syndrome. Mutant mice show widening of the distal
airspace due to failure of alveolar septation and increased activation of TGF-p 
(61), representing developmental emphysematous lesions. Treatment with 
Losartan blunted fibrillin-1 induced TGF-p signaling (evidenced by reduced 
nuclear accumulation of smad-2p) in the aortic root, and partially restored 
normal lung morphology (61). These data are very promising and have recently 
resulted in the initiation of a clinical trial that studies the efficacy of losartan in 
treatment of emphysema in COPD patients (62).
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Abstract
Micromechanical properties of single elastic fibers and fibrillin-microfibrils, 
isolated from equine ligamentum nuchae using chemical and enzymatic 
methods, were determined with atomic force microscopy (AFM). Young’s moduli 
of single elastic fibers immersed in water, devoid of or containing fibrillin- 
microfibrils, were determined using bending tests. Bending the freely 
suspended elastic fibers by a tip-less AFM cantilever generated a force versus 
displacement curve from which the Young’s modulus was calculated. For single 
elastic fibers, Young’s moduli in the range of 0.3-1.5 MPa were determined, 
values not significantly affected by the presence of fibrillin-microfibrils. To 
further understand the role of fibrillin-microfibrils in vertebrate elastic fibers, 
layers of fibrillin-microfibrils were subjected to AFM nano-indentation tests.
From the slope of the force versus indentation curves, Young’s moduli ranging 
between 0.56 and 0.74 MPa were calculated. The results suggest that fibrillin- 
microfibrils do not contribute to a mayor extend to the mechanical properties of 
single vertebrate elastic fibers.
Introduction
Elastic fibers are essential structures that endow resilience to the extracellular 
matrix (ECM) by a passive, entropy-driven mechanism allowing stretching and 
recoil (1). In vertebrates, the elasticity of several tissues and organs such as 
blood vessels, skin, lung, ligaments and cartilage is provided by elastic fibers 
(2-4). Using macro-mechanical testing, the elasticity of these elastic fiber-rich 
vertebrate tissues has been a subject of study for years. The Young’s modulus 
of elastic fiber-rich tissue samples of purified dog or sheep aorta are in the 
range of 0.13-0.65 MPa (5). Similarly, Young’s moduli between 0.1-0.8 MPa 
have been calculated for purified pig aorta enriched with elastic fibers (6). The 
Young’s modulus of a single elastic fiber isolated from ligamentum nuchea was, 
for the first time, determined by a microtest apparatus attached to a polarizing 
microscope and was found to be around 1.2 MPa (7). The vertebrate elastic 
fibers contain at least two mayor morphological components: amorphous 
elastin, which accounts for 90% of the elastic fibers, and microfibrils, which are 
structures 10-12 nm in diameter (1,8). Fibrillin-1 is the major component of the 
microfibrils (3), although other, less abundant, molecules like microfibril- 
associated glycoproteins (MAGPs) (9-11), EMILINs (12-14), and latent 
transforming growth factor-p binding protein (LTBPs) (15-17) have been 
identified.
Fibrillin-microfibrils are considered necessary for the assembly of a functional 
elastic fiber. During elastic fiber formation, fibrillin-microfibrils appear first and 
serve as a scaffold for the deposition of tropo-elastin (8). Invertebrates lack 
elastin, and the essential elastic recoil of their tissue is provided by fibrillin- 
microfibrils, suggesting that invertebrate fibrillin-microfibrils are elastic (18-20). 
The Young’s modulus reported of the microfibrillar network is in the range of 
0.2-1.1 MPa (19-21). The question arises as to whether vertebrate fibrillin- 
microfibrils also have such mechanical properties, thereby playing a role in the 
mechanical properties of elastic fibers. Work on mammalian ciliary zonular 
filaments, a structure solely composed of fibrillin-microfibrils, gave insight into 
the mechanical properties of vertebrate fibrillin-microfibrils. X-ray diffraction and 
biomechanical testing of zonular filaments indicated that fibrillin-microfibrils 
have a Young’s modulus in the range of 0.19-1.88 MPa, similar in magnitude to 
invertebrate fibrillin-microfibrils and elastic fibers (22-24). Strikingly, using 
molecular combing, the Young’s modulus of single fibrillin-microfibrils from 
zonular filaments was estimated to be 78-96 MPa, which is two orders of 
magnitude higher than the modulus determined from tissue samples (25).
Based on these data, the authors suggested that fibrillin-microfibrils play a role 
in reinforcing vertebrate elastic fibers. Furthermore, recent work indicated that 
removal of fibrillin-microfibrils from the elastic fibers of porcine aorta resulted in 
a modestly (~ 10%) altered Young’s modulus, suggesting that fibrillin- 
microfibrils play a mechanical role in elastic fibers (6). To date, there is debate 
on how fibrillin-microfibrils contribute to the mechanical properties of elastic 
fibers and in what order of magnitude the Young’s modulus of fibrillin- 
microfibrils ranges.
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Since elastin is one of the most abundant proteins in human tissue, elastic 
fibers are regarded as highly suitable scaffolding material for tissue engineering 
applications. For the use of elastic fibers as a biomaterial, purity of the material 
is an important issue. Contamination with proteins may lead to unwanted 
immunological reactions. Efforts have been made to use purified intact elastic 
fibers as scaffolds in tissue engineering (26-29). The published work suggested 
that intact elastic fibers devoid of fibrillin-microfibrils are preferred for scaffold 
purpose (29). The mechanical properties of the purified elastic fibers devoid of 
or containing fibrillin-microfibrils should also be determined for an adequate use 
of these fibers in tissue engineering.
This study reports on the biomechanical properties of single purified elastic 
fibers. Highly purified elastic fibers, devoid of or containing fibrillin-microfibrils, 
were successfully extracted from equine ligamentum nuchae and subjected to 
an atomic force microscope (AFM). For the first time, micromechanical bending 
tests (30) were performed on single elastic fibers to determine the Young’s 
modulus. In addition, the Young’s modulus of fibrillin-microfibrils was 
determined using AFM-based nano-indentation. The contribution of fibrillin- 
microfibrils to the mechanical properties of the vertebrate single elastic fibers 
was evaluated using the combined results from bending and nano-indentation 
experiments.
Materials and Methods
All experimental procedures were performed at room temperature, unless 
stated otherwise.
Isolation of elastic fibers
Elastic fibers, devoid of or containing fibrillin-microfibrils, were isolated from 
equine ligamentum nuchea using a modification of previously published work of 
Daamen et al. (31,32). Ligamentum nuchae was pulverized under liquid 
nitrogen using a pulverisette sieve with 1 mm pores (Fritsch Pulverisette 19, 
Idar-Oberstein, Germany). The pulverized tissue was subjected three times to 
an overnight extraction at 4 °C with 10 vol. of 1 M NaCl containing 0.02% (w/v) 
NaN3. After each extraction step, insoluble material was recovered by 
centrifugation at 5000 x g at 4 °C for 20 min. After the last extraction step, the 
pellet was washed with demineralised water and resuspended in 10 vol. of 
ethanol. After 90 min, the suspension was filtered over a whatman filter paper 
(grade 6, Kent, United Kingdom). This procedure was repeated with 10 vol. of 
chloroform/methanol (2:1) for 90 min, 10 vol. of acetone for 30 min, and 10 vol. 
of ether for 30 min. The resulting residue was dried in a desiccator. The dried 
material was extracted with 15 vol. of 97% formic acid with 1% (w/v) cyanogen 
bromide for 24 h under N2 conditions. After extraction, the suspension was 
diluted with 45 vol. of demineralised water and centrifuged at 5000 x g at 4 °C 
for 15 min. The pellet was extensively washed with demineralised water. After
washing, the pellet was resuspended in 10 vol. of demineralised water and this 
suspension was divided in two parts. One half of the suspension was used to 
isolate elastic fibers devoid of fibrillin-microfibrils (method I) and the other half 
was used to isolate elastic fibers containing fibrillin-microfibrils (method II). 
Method I: After centrifugation, the pellet was resuspended in 5 vol. of 0.5 M Tris 
HCl pH 6.8 containing 4 M urea, 1 M p-mercaptoethanol, and 0.02% (w/v) NaN3 
and incubated overnight. This extraction step was repeated three times and 
after each step insoluble material was recovered by centrifugation at 5000 x g at 
4 °C for 20 min. The resulting pellet was washed for 6 times with 5 vol. of 
demineralised water. After centrifugation, the pellet was resuspended in 5 vol. 
0.1 M NH4HCO3, pH 8.2 containing 0.02% (w/v) NaN3 and 10,000 U trypsin (T- 
4665, Sigma, St. Louis, USA) and incubated for 4 h at 37 °C. The suspension 
was centrifuged and the pellet was washed with demineralised water, followed 
by three overnight extractions with 5 vol. 1 M NaCl containing 0.02% (w/v)
NaN3. The resulting pellet was washed with demineralised water and the end 
product was stored at -80 °C.
Method II: After centrifugation, the pellet was resuspended in 5 vol. 0.2 M Tris 
HCl pH 7.4 containing 0.05 M CaCl2, 0.02% (w/v) NaN3, and 500 U collagenase 
type VII (Sigma, St. Louis, USA), and incubated for 4 h at 37 °C. The 
suspension was centrifuged and the pellet was washed with demineralised 
water, followed by three overnight extractions with 5 vol. 1 M NaCl containing 
0.02% (w/v) NaN3. The resulting pellet was washed with demineralised water 
and the end product was stored at -80 °C.
Purity assessment
SDS-PAGE Gel electrophoresis: Per lane 500 ^g of elastic fiber preparations 
and 100 ^g of crude Ligamentum nuchae were analyzed under reducing 
conditions (5% p-mercaptoethanol) on a 10% (w/v) polyacrylamide gel. Proteins 
were visualized by silver staining using a 0.1% (w/v) AgNO3 solution. 
Transmission Electron Microscopy (TEM): Elastic fiber preparations were 
embedded in 1.5% (w/v) agarose, fixed in 2% (v/v) glutaraldehyde in 0.1 M 
phosphate buffer pH 7.4, post fixed with 1% (w/v) osmium tetroxide, dehydrated 
in ascending series of ethanol, and embedded in epon 812. Ultrathin sections 
(60 nm) were picked up on formvar-coated grids, post stained with lead citrate 
and uranyl acetate, and subsequently imaged using electron microscope (JEOL 
1010, Tokyo, Japan).
Scanning Electron Microscopy (SEM): Lyophilized elastic fiber preparations 
were mounted on stubs and sputtered with an ultrathin layer of gold in a Polaron 
E5100 SEM coating system. Specimens were studied with a SEM apparatus 
(JEOL JSM-6310, Tokyo, Japan) operating at 15 kV.
Immune Fluorescence Assay (IFA): Elastic fiber preparations were suspended 
in demineralised water and frozen in liquid nitrogen. 4 ^m cryosections were cut 
and incubated in 1% (w/v) bovine serum albumin (BSA, fraction V, Sigma, St.
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Louis, USA) in PBS to block nonspecific binding sites. Sections were incubated 
overnight at 4 °C with rabbit anti-bovine type I collagen (1:50, Chemicon, 
Temecula, USA), rabbit anti-human fibrillin-1 (1:500, derived to fibrillin-1 
fragment rF6H, kind gift of Dr. Dieter Reinhardt), and mouse anti-bovine elastin 
(1:500, clone BA-4, Sigma, St. Louis, USA) diluted in PBS containing 1% (w/v) 
BSA. After washing with PBS, bound antibody was detected with 1:100 diluted 
goat anti-mouse IgG Alexa 488 or goat anti-rabbit IgG Alexa 488 (Molecular 
Probes, Eugene, USA) in PBS containing 1% (w/v) BSA for 90 min. Sections 
were washed in PBS and mounted in mowiol (4-88, Calbiochem, La Jolla, 
USA).
Micromechanical bending tests of elastic fibers using AFM 
Quartz glass substrates with parallel micro-channels were prepared by reactive 
ion etching using a RIE Elektrotech system (Elektrotech Twin PF 340, UK). The 
width and depth of the channels were determined by AFM (home-built 
instrument) and SEM (LEO Gemini 1550 FEG-SEM, Oberkochen, Germany) 
measurements. Diluted suspensions of elastic fiber preparations, devoid of or 
containing fibrillin-microfibrils, were prepared by adding 15 mg of preparation I 
or II to 20 ml demineralised water. Glass substrates were incubated in the 
diluted suspension for 10 min, and dried overnight. A home-built AFM combined 
with an optical microscope was used for micromechanical bending tests. 
Bending experiments were performed using modified triangular silicon nitride 
cantilevers (coated sharp microlevers MSCT-AUHW, type F, spring constant k = 
0.5 N/m, Veeco, Cambridge, UK). The tip of the AFM cantilever was removed 
using focused ion beam (FIB) (FEI, Nova Nanolab 600 dual beam machine, 
Eindhoven, the Netherlands). The width of the tip-less cantilever was slightly 
wider than the fiber diameter, which facilitated the positioning of the cantilever 
above the fiber. The spring constant of each cantilever was calibrated by 
pushing on a pre-calibrated cantilever as described elsewhere (33). Before 
starting the measurement, the glass substrate containing the elastic fibers was 
immersed in 1 ml demineralised water and left to equilibrate for 15 min. 
Micromechanical bending tests were performed by bending the elastic fiber at 
the middle point of the channel using an AFM cantilever. Deflection versus 
piezo displacement curves were directly obtained from the micromechanical 
bending tests. From the results, forces versus displacement curves were 
derived to estimate the Young’s modulus of single elastic fibers. Local 
indentation of elastic fibers during bending was estimated by indenting the 
same fiber located on the glass surface.
Diameter of the elastic fibers in water
The diameter of the elastic fibers used in the micromechanical bending tests 
was determined by Scanning Electron Microscopy (SEM) (LEO Gemini 1550 
FEG-SEM, Oberkochen, Germany). The diameter of an elastic fiber in water 
was estimated from SEM images made with an environmental SEM system 
(Philips XL 30 ESEM-FEG, Eindhoven, the Netherlands) at water pressure of 
5.4 Torr and temperature of 5 °C.
Isolation of fibrillin-microfibrils
Fibrillin-microfibrils were isolated from equine ligamentum nuchea as described 
(34). Briefly, tissue was dissected into small pieces and incubated in 50 mM Tris 
HCl pH 7.4 containing 0.4 M NaCl, 10 mM CaCl2, type la collagenase (Sigma, 
St. Louis, USA), 2 mM PMSF, and 5 mM NEM for 18 h. Samples were 
centrifuged at 5000 x g at 4 °C for 5 min and the supernatant was size 
fractionated on a sepharose CL-4B column (Amersham, Piscataway, USA) in 
20 mM Tris HCl pH7.4 containing 0.4 M NaCl and 2 mM CaCl2 using a flow rate 
of 0.2 ml/min. The void volume contained fibrillin-microfibrils, as detected by 
dot-blot immunohistochemistry with rabbit anti-fibrillin-1 (1:500, fibrillin-1 
fragment rF6H).
Imaging of fibrillin-microfibrils using AFM
The void volume containing fibrillin-microfibrils was diluted 10 times in water. 
The diluted suspension of fibrillin-microfibrils was brought onto a cleaned glass 
substrate. After drying, the glass substrate was washed with demineralised 
water in order to remove any unbound material. The fibrillin-microfibrils were 
imaged by tapping mode in air using a home-built AFM system with V-shaped 
Si3N4 cantilevers (coated sharp microlevers MSCT-AUHW, type F, spring 
constant k = 0.5 N/m, Veeco, Cambridge, UK). A tapping frequency of ~ 120 
kHz and a tapping amplitude of ~ 400-600 nm were used.
Nano-indentation of fibrillin-microfibrils using AFM 
A suspension of fibrillin-microfibrils from the non-diluted void volume was 
brought onto a cleaned glass substrate to obtain multi-layers of fibrillin- 
microfibrils. After drying and washing with demineralised water, the fibrillin- 
microfibrils layers were imaged using AFM, as described above, to obtain 
information on the microfibrils morphology. Using an initial large scale image, 
the desired area for indentation was selected. Before starting the 
measurements, the glass substrate containing the fibrillin-microfibrils was 
immersed in 1 ml demineralised water and left to equilibrate for 15 min. Nano­
indentation was performed at different locations on the surface using the V- 
shaped Si3N4 cantilevers (coated sharp microlevers MSCT-AUHW, type C, 
spring constant k = 0.01 N/m, Veeco, Cambridge, UK) applying an AFM piezo 
displacement of 500 nm and a frequency of 10 Hz. The spring constant of each 
cantilever was calibrated by pushing on a pre-calibrated cantilever as described 
elsewhere (33). To obtain a force versus indentation curve, the sensitivity (S) of 
the applied method, i.e. the ratio between the bending of the cantilever and the 
deflection as measured by the quadrant detector, was derived from the force 
versus displacement curve using a glass surface. The Young’s modulus of 
fibrillin-microfibrils was calculated from the force versus indentation curve.
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Results and Discussion
Elastic fiber preparations
To visualize major contaminations (e.g. globular proteins), purified elastic fiber 
preparations, devoid of or containing fibrillin-microfibrils, were subjected to gel 
electrophoresis. Contaminants and elastin degradation products are soluble and 
will penetrate the gel, whereas the insoluble elastic fiber preparations will not. 
The consecutive extraction steps and the specific enzyme digestion used in 
method I and II successfully removed contaminants from the starting material, 
as indicated by the clear absence of protein bands (Figure 1A). Moreover, no 
signs of degradation products of elastin were present. Similarly, Scanning 
Electron Microscopy (SEM) revealed intact elastic fibers with a rather smooth 
surface (Figure 1B and C).
Figure 1. A. Gel electrophoresis of purified elastic fiber preparations. Note that, compared to the 
crude, starting material, Ligamentum nuchae (100 |jg, lane 1), purified elastic fibers devoid of (500 
|jg, method I, lane 2) or containing (500 jg , method II, lane 4) fibrillin-microfibrils did not contain any 
visible protein bands that indicate contamination or elastin breakdown. Elastic fiber preparations 
before purification with method I (500 jg , lane 3) or method II (500 jg , lane 5) still contained some 
protein bands, indicating that method I and II successfully removed the contaminations from these 
preparations. Molecular weight markers are indicated on the left in kDa. B-C. SEM images of 
purified elastic fiber preparations after purification with method I (B) and method II (C). Note the 
smooth and intact surface of the elastic fibers. (Bar = 10 jm ).
Transmission Electron Microscopy (TEM) and Immune Fluoresence Assay (IFA) 
were applied to detect collagen, fibrillin-1 containing microfibrils, and elastin in 
the elastic fiber preparations. Staining for elastin was abundant is elastic fiber 
preparations devoid of fibrillin-microfibrils (method I), whereas staining for type I 
collagen and fibrillin-1 was absent (Figure 2A and B for elastin and fibrillin-1). 
Elastic fiber preparations containing fibrillin-microfibrils (method II) displayed 
abundant elastin and fibrillin-1 staining (figure 2D and E). On the other hand, 
type I collagen was absent (data not shown). Please note that, although we 
used a polyclonal antibody recognizing denatured fibrillin-1, it can not be 
excluded that the loss of fibrillin-1 staining (Figure 2B) is due to a loss of the 
epitope by the enzymatic treatment used in method I. On the other hand, TEM 
analysis clearly indicated that method I resulted in elastic fibers devoid of 
fibrillin-microfibrils, as the abundant black dots, an indication of fibrillin-
microfibrils, were only found in the TEM images of elastic fibers containing 
fibrillin-microfibrils (Figure 2C and F). In conclusion, two elastic fiber 
preparations were prepared, one preparation contained pure, intact elastic 
fibers devoid of fibrillin-microfibrils (method I) and the other preparation 
contained pure, intact elastic fibers containing fibrillin-microfibrils (method II).
Figure 2. A-B, D-E. Fluorescence microscopy images of immunostaining of elastic fiber 
preparations. Elastic fibers devoid of fibrillin-microfibrils (method I) were immunostained for elastin 
(A) and fibrillin-1 (B). Likewise, elastin (D) and fibrillin-1 (E) were detected in elastic fibers containing 
fibrillin-microfibrils (method II). Note that in both preparations elastin was abundantly present, 
whereas fibrillin-1 was only present in elastic fibers purified by method II. (Bar = 50 |jm). C, F. TEM 
images of the elastic fiber preparations. Note that fibrillin-microfibrils, recognizable by the dot-like 
pattern, were only detected in elastic fibers purified by method II (F). E = elastin, FM= fibrillin- 
microfibrils. (Bar = 1 jm ).
Mechanical properties of single elastic fibers
Reactive ion etching afforded the glass substrates with well-defined micro­
channels with a width of 5 ^m -  10 ^m and a depth of 600 nm. After incubating 
the glass substrates with the diluted elastic fiber preparations, single elastic 
fibers spanning the micro-channels were selected for micro-mechanical AFM 
bending tests using an inverted optical microscope. SEM images clearly 
showed that the single elastic fibers were spanning the micro-channels of the 
glass substrate (Figure 3A). These fibers were bent with a tip-less cantilever 
along the fiber axis. With the piezo movement versus deflection curves obtained 
directly from the AFM bending data, the force (F) and the displacement (z) in 
the z-direction were calculated using the following equations:
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z = A -  D x S (eq. 1)
106
F  = D x S x k (eq. 2)
in which A is the piezo movement in the z-direction, D is the deflection 
measured (in Volts), S is the sensitivity of the cantilever, and k is the calibrated 
spring constant of the cantilever. A force versus displacement curve was 
obtained by plotting displacement (z) on the x-axis and force (F) on the y-axis.
By exerting a force on the elastic fibers at the middle point of the channel, a 
displacement from bending as well as a local indentation of the fiber was 
induced. In order to determine the modulus of an elastic fiber by bending, the 
displacement has to be corrected for this indentation. Local indentation can be 
estimated from the force versus displacement curve of indenting an elastic fiber 
on the glass surface (indentation curve in Figure 3B). For each force, the 
displacement resulting from only indentation was subtracted from the total 
displacement, as obtained by measuring at the middle point (bending curve in 
Figure 3B). This results in a curve representing only displacement from bending 
(Figure 3C). In the following the term displacement refers to displacement due 
to bending.
A linear force versus displacement curve was found for bending elastic fibers 
devoid of or containing fibrillin-microfibrils (Figure 3C). In the experiments, no 
difference was found in the force versus displacement curve after bending the 
fiber at the same position multiple times, which ensured the reproducibility of 
the measurements and indicated that no permanent deformation of the elastic 
fiber had occurred. The slope (dF/dx) of the force versus displacement curve 
was used to calculate the Young’s modulus. During the AFM manipulation, it 
became clear that the AFM cantilever was able to laterally move elastic fibers 
on the glass substrate. Therefore, elastic fibers were assumed to be supported, 
instead of being fixed at the two ends of the channel. The Young’s modulus of 
the elastic fibers can then be described by the linear elastic theory of isotropic 
materials, using the expression (35):
^  / 3 dFE = ------x ------ (eq.3)
48/ dx
1  T-% 4
in which I is the moment of inertia, equal to —m i
4
(elastic fibers were considered a rod with a circular cross-section with radius R), 
l is the length of the elastic fiber spanning the channel, and dF/dx is the slope of 
the force versus displacement curve obtained from bending experiments of the 
two elastic fiber preparations.
Displacement (nm)
Displacement (nm)
Figure 3. A. SEM image of an elastic fiber spanning a micro-channel in the glass substrate. (Bar = 2 
jmJ. B. Force versus displacement curves obtained from bending and indenting an elastic fiber 
immersed in water at the middle point of the channel (black squares) and indenting the same elastic 
fiber on the glass substrate (gray squares). C. Force versus displacement curve representing the 
bending of a fiber obtained after subtracting the displacement from local indentation.
The diameter of all the tested elastic fiber preparations was determined using 
SEM imaging of dry fibers. However, during the micromechanical bending test, 
the glass substrate containing the elastic fibers was immersed in water. This 
may lead to swelling of the elastic fibers, thereby affecting the diameter and the 
moment of inertia (I) in eq.3. Therefore, the diameter of an elastic fiber in the 
dry and in the hydrated state was estimated by environmental SEM imaging 
under high (5.4 Torr) and very low (0.6 Torr) water pressure (Figure 4). SEM 
images recorded at the high water pressure can be used to determine the 
dimensions of fully hydrated elastic fibers. By measuring the diameter of a large 
number of elastic fibers, the diameter of hydrated elastic fibers turned out to be 
1.1 times larger than the diameter of dry fibers.
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Figure 4. SEM images of elastic fibers devoid of fibrillin-microfibrils in dry state (0.6 Torr water 
pressure) (A) and in hydrated state (5.4 Torr water pressure) (B). Note the small increase in the 
diameter of hydrated elastic fibers as compared to dry fibers. (bar = 20 |jm).
Elastic fibers devoid of fibrillin-microfibrils had an average Young’s modulus of 
0.79 ± 0.17 MPa (mean diameter 3.9 ± 0.5 jm  (± SD)). Elastic fibers containing 
fibrillin-microfibrils had an average Young’s modulus of 0.9 ± 0.23 MPa (mean 
diameter 4.3 ± 1.1 jm  (± SD)). Statistically the difference between these ranges 
was not significant (Figure 5).
Figure 5. Average Young’s moduli of elastic fibers devoid of (black bars, n = 8, D = 3.9 ± 0.5 |jm) 
and containing fibrillin-microfibrils (gray bars, n = 9, D = 4.3 ± 1.1 jm ). The error in the Young’s 
modulus is presented as SD.
The Young’s moduli of single elastic fibers ranged between 0.3 and 1.5 MPa, 
which is comparable to the range stated in literature for single elastic fibers and 
tissues (18). Aaron et al. (7) were the first to study the mechanical properties of 
single elastic fibers from bovine ligamentum nuchae. Using a microtest 
apparatus, it was shown that the Young’s modulus of a single elastic fiber was 
in the range of 0.4-1.2 MPa. From macro-mechanical tests on elastin-rich tissue
strips, elastic fibers of purified dog or sheep aorta had Young’s moduli in the 
range of 0.13-0.65 MPa (5). Similarly, Young’s moduli between 0.1-0.8 MPa 
were obtained for elastic fibers in strips of purified pig aorta (6). The comparable 
Young’s moduli derived from our micromechanical AFM bending test and from 
macrotests/microtests of elastin rich tissue strips/single elastic fibers indicate 
that the applied purification procedure did not affect the mechanical properties 
of the elastic fibers. This finding is of major importance for the field of tissue 
engineering. Recent works suggested that purified intact elastic fibers, without 
fibrillin-microfibrils, are preferred for scaffold purposes (29). Therefore, efforts 
have been made to use purified intact elastic fibers as scaffolds in tissue 
engineering (26-29). For an adequate use of these fibers in tissue engineering, 
the purified elastic fiber preparation must meet two requirements. Firstly, it is 
required that the elastic fibers are highly pure, since contamination of the elastic 
fiber preparations with other proteins may lead to unwanted immunological 
reactions. Secondly, it is required that the mechanical properties of the purified 
elastic fibers are still within normal ranges, this in order to prevent scaffold 
tearing or overstretching. In this study we clearly demonstrate that highly 
purified elastic fibers were obtained that have mechanical properties 
comparable to elastin-rich tissue strips/single elastic fibers.
Although the value of Young’s modulus is well within stated ranges, it has to be 
noted that the spread in the value, as determined from our measurements, was 
considerable (0.3-1.5 MPa). This variance probably resulted from the 
assumption that the tested elastic fibers were circular in cross-section, as seen 
in Eq. (3). As reported previously (32), SEM imaging indicated that some elastic 
fibers had an irregular cross-sectional area.
Interestingly, no significant differences in the values of the Young’s modulus for 
the purified elastic fibers devoid of or containing fibrillin-microfibrils were found 
from our measurements. This result suggests that fibrillin-microfibrils do not 
influence the modulus of elastic fibers. However, it can not be totally debarred 
that the isolation steps applied in isolation method I have not affected the 
mechanical or elastic properties of fibrillin-microfibrils. Although the 
appearances of the fibrillin-microfibrils in the TEM and fluorescence 
micrsoscpoy indicate that the fibrillin-microfibrils have a normal appearance.
Fibrillin-microfibril preparations
In order to better explain the obtained results on the Young’s modulus for elastic 
fibers and to provide more insight in the mechanical properties of fibrillin- 
microfibrils, isolated fibrillin-microfibrils were prepared for micro-mechanical 
tests. Isolated fibrillin-microfibrils deposited on a glass substrate were imaged 
by AFM (Figure 6). As reported previously (36), AFM images displayed the 
typical “beads-on-a-string” structure for fibrillin-microfibrils. A distance between 
two beads of 65 ± 7 nm was determined from the images (Figure 6C).
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Figure 6. A. Tapping mode atomic force microscopy (AFM) height image of fibrillin-microfibrils 
deposited on a glass surface (Bar = 200 nm). B. Zoom in of tapping mode AFM height image of 
fibrillin-microfibrils. Note the typical fibrillin-microfibrils beads-on-a-string appearance (Bar = 100 
nm). C. Line scan along a fibrillin-microfibril. 6 repeats are shown as delineated by the arrows in 
image B. The mean distance between the beads was calculated to be 65 ± 7 nm.
Mechanical properties o f fibrillin-microfibrils
Because fibrillin-microfibrils are two to three orders of magnitude smaller than 
elastic fibers, poly(methyl methacrylate) (PMMA)-coated glass substrates with 
nano-channels of 100-200 nm in width, instead of 5-10 ^m, were prepared.
After incubating the PMMA substrate with a suspension of fibrillin-microfibrils, 
the substrate was subjected to tapping mode AFM imaging. However, AFM 
imaging at different positions of the substrate indicated that the fibrillin- 
microfibrils adhered to the bottom of the nano-channel instead of spanning the 
nano-channels. Therefore, micromechanical AFM bending tests could not be 
performed (data not shown). Efforts were made to make the PMMA substrate 
surface either hydrophilic by oxygen plasma treatment or positively charged by 
coating a layer of positively-charged protein. However, changing the surface 
properties of PMMA did not facilitate the spanning of the fibrillin-microfibrils over 
the channels.
Besides micromechanical AFM bending tests, AFM nano-indentation can also 
give insight into the mechanical properties of nano-size structures. Depositing 
high concentrations of fibrillin-microfibrils onto the glass substrate introduced 
the formation of microfibril layers with thicknesses of ~ 60-100 nm (Figure 7A). 
AFM nano-indentation tests of fibrillin-microfibrils were performed at several 
locations by approaching the AFM tip to the layered surface until a cantilever 
deflection was observed. A plot of the cantilever deflection versus the piezo 
movement in the z-direction was recorded for each indentation, and converted 
to a typical force versus indentation curve using Eq. 1 and 2. (Figure 7B). No 
difference was found in the force versus displacement curve after indenting 
multiple times at the same position, which ensured the reproducibility of the
measurements and indicated that no permanent deformation of the fibrillin- 
microfibrils had occurred.
Indentation (nm)
Figure 7. A. Contact mode AFM height image of fibrillin-microfibrils layers deposited on a glass 
surface (Bar = 200 nm). B. Typical force versus indentation curve obtained from nano-indentation of 
fibrillin-microfibrils layers. A relative Young's modulus (E*) of 0.86 MPa was calculated from fitting 
the experimental data to Eq. (4).
AFM nano-indentation tests have been used to determine the Young’s modulus 
of different biological samples (37;38) using the theory of Hertz (39) and the 
mechanics of Sneddon (40). The relationship between force and indentation is 
influenced by the geometry of the AFM tip. In this study, the radius of the tip 
was ~ 20 nm, which was in the same order as the indentation depth. Therefore, 
the tip can be assumed to be parabolic with a radius of curvature R at the apex. 
The force applied on the cantilever (F) as a function of the indentation (x) can 
then be described using the following expression:
A4R  7 7 *  1 5  /  A \F  = --------E  x 1 (eq. 4)
3
Where E* is the relative Young’s modulus, defined as:
1 i - v 2 i - v 2
A tip sample . _N
E *  =  < e q - 5)tip sample
In which usample is the Poisson ratio of the sample and utip the Poisson ratio of 
the tip. The experimental data of the force versus indentation curve could be 
fitted with Eq. 4 (Fig. 7B). An average E* of 0.74 ± 0.17 MPa (± SD) was 
calculated from several force versus indentation curves obtained from nano­
indentation at different locations of the sample. The Young’s modulus of the
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AFM tip (~ 200 GPa) is much higher than the Young’s modulus of the fibrillin- 
microfibrils in the hydrated state, therefore the 1/E* is further simplified to:
1 ^  1 - U *  (eq. 7)
sample
Using a typical Poisson ratio of 0-0.5 for elastic materials, the Young’s modulus 
(Esample) of fibrillin-microfibrils was estimated to be in the range of 0.56 ± 0.12 to 
0.74 ± 0.17 MPa (± SD).
It has to be considered that there are still some limitations in the method, 
influencing the accuracy of the determined Young’s modulus. For example, in 
the model the sample and the tip surface were assumed to be smooth, 
however, in practice they are usually rough. This uncertainty of the contact area 
will influence the measurements and can lead to deviations in the order of a few 
percent (41). However, the obtained value was still comparable to Young’s 
moduli previously estimated for vertebrate or invertebrate fibrillin-microfibrillar 
networks. The invertebrate microfibrillar network in abdominal lobster oarta had 
a modulus of ~ 1.06 MPa (19). Similarly, the Young’s modulus of fibrillin- 
microfibrils isolated from sea cucumber dermis was approximately 0.2 MPa 
(20), and the microfibrillar network in jellyfish had an estimated Young’s 
modulus of 0.9 MPa (21). In vertebrates, the Young’s modulus of bovine zonular 
filaments, a structure solely composed of fibrillin-microfibrils, was determined to 
be in the range of 0.19-1.88 MPa (22-24;42).
Recently, Sherrat et al. used a molecular combing technique to determine the 
Young’s modulus of fibrillin-microfibrils isolated from bovine zonular filaments 
(25). A Young’s modulus of 78-96 MPa was determined, a value nearly two 
orders of magnitude higher than the Young’s moduli reported in literature for 
microfibrillar networks as well as the values determined by us for isolated 
fibrillin-microfibrils. The authors imply that individual fibrillin-microfibrils act as 
relatively stiff elastic polymers, reinforcing the elastic fibers. However, our direct 
measurements on the mechanical properties of single elastic fibers devoid of or 
containing fibrillin-microfibrils did not show a reinforcing effect of these 
microfibrils. Recent published work by Megill et al. gives an explanation for this 
paradox (21). The authors suggest that the mechanical behavior of fibrillin- 
microfibrils must be fitted by a J-shaped model, instead of the linear model that 
was derived from the molecular combing experiments by Sherrat et al., Based 
on reinterpretation of the molecular combing experiments, Megill et al. suggest 
a Young’s modulus of 1 MPa for fibrillin-microfibrils, a value that is in range with 
our data. Besides that, it has to be highlighted that, compared to 
macromechanical tests, AFM is a very accurate method for determining the 
mechanical properties of micro- and nano-sized materials (43;44). Taken all this 
into account, we suggest that fibrillin-microfibrils have Young’s moduli in the 
range of 0.56- 0.74 MPa.
The finding that fibrillin-microfibrils had a Young’s modulus similar as that of 
elastic fibers can be brought up as a reason for the finding that the Young’s
moduli for single elastic fibers devoid of or containing fibrillin-microfibrils were 
not significantly different.
Conclusions
In the current study, an AFM-based mechanical technique was applied to study 
the micro-scale mechanical behavior of highly purified and intact elastic fibers 
devoid of or containing fibrillin-microfibrils and of isolated fibrillin-microfibrils. As 
determined from micro-mechanical bending tests, the Young’s moduli of single 
elastic fibers was in the range of 0.3-1.5 MPa, similar to the range stated in 
literature. Besides that, the Young’s modulus of single elastic fibers was not 
significantly affected by the absence or presence of fibrillin-microfibrils. As 
determined with nano-indentation tests, fibrillin-microfibrils had a Young’s 
modulus in the range of 0.56-0.74 MPa, which is comparable with the Young’s 
modulus of elastic fibers. From these data it is suggested that fibrillin-microfibrils 
do not significantly influence to the mechanical properties of single vertebrate 
elastic fibers.
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Abstract
The expression pattern of the elastic fiber protein fibrillin-1 in human lung 
specimens with morphological emphysema is altered, as identified by a reduced 
and fragmented fibrillin-1 staining. Because mutations in the gene encoding 
fibrillin-1 (FBN1) have been reported to result in an emphysematous phenotype 
in both patients with Marfan syndrome and knock-out mice models, FBN1 is 
proposed as a candidate gene that predisposes individuals to emphysema. In 
this study, we present preliminary data on the in vitro matrix deposition of 
fibrillin-1 in fibroblasts derived from patients with clinical emphysema. Instead of 
an organized 3-dimensional network, fibroblast derived from patients with 
clinical emphysema deposited a frayed and disorganized network of fibrillin-1 
fibers. Deposition of other extracellular matrix proteins such as LTBP-1, 
EMILIN-1, Type I collagen, and fibulin-1 was not altered. mRNA expression 
analysis did not indicate a significant down-regulation of the FBN1 gene. 
Although preliminary, the in vitro data from this study agrees with previously 
published data on fibroblast derived from patients with Marfan syndrome, 
describing a cellular phenotype of impaired matrix deposition of fibrillin-1. 
Combined with in situ data recently published by our group, it is suggested that 
fibrillin-1 plays an important role in the onset of emphysema.
Introduction
The 10-12 nm beaded fibrillin-containing microfibrils are a class of connective 
tissue elements with a widespread extracellular matrix distribution; they are 
particularly abundant in elastic tissues such as aorta, skin, ligament, and lung 
(1;2). The microfibrils are integral components of the elastic fibers and provide a 
scaffold for tropoelastin deposition. Besides providing structural integrity, the 
microfibrils also mediate cell attachment and regulate growth factor availability 
(3;4). The microfibrils have a complex ultrastructural appearance and are 
composed of different proteins, fibrillin-1 being a major component (1). In 
addition, a large number of other associated and integral molecules are present, 
including microfibril-associated glycoproteins (MAGPs) (5), latent TGF-p binding 
proteins (LTBPs) (6), EMILINs (7), and fibulins (8).
We recently described aberrant staining of fibrillin-1 in lung specimens derived 
from patient with microscopical emphysema, and reported on the associated 
dysregulation of TGF-p (9;10). Genetic disorders in men and knock-out mouse 
models for the microfibrillar proteins have highlighted their importance in 
extracellular matrix integrity and their distinctive role in connective tissue 
diseases (see reviews: (3;11)). Of all the microfibrillar proteins, genetic defects 
in fibrillin-1 have been described in most detail both in men and mice. In mice, 
four genetic models for fibrillin-1 (mgA, mgR, TSK and C1039G mice) have 
been described, all characterized by the presence of emphysema. Homozygous 
mice harboring a targeted deletion of 6 kb in the fibrillin-1 gene (mgA mice) die 
within three weeks after birth from vascular and pulmonary complications, 
including aneurismal dilatations, dissection of the aortic wall, and developmental 
emphysema (12). Mice with a 75% reduction of the amount of fibrillin-1 (mgR 
mice) die within 4-6 months after birth due to destructional changes leading to 
emphysema, mechanical collapse of the aortic wall, kyphosis, and overgrowth 
of ribs (13). In addition, heterozygous mice with a missense mutation (C1039G) 
in the fibrillin-1 gene live a normal life span but suffer from skeletal deformity, 
aortic dissection, and developmental emphysema (14). The tight skins mouse 
(TSK mice) is a genetic model characterized by a tandem duplication of 30-40 
kb in the gene encoding fibrillin-1. The homozygous mice are not viable and die 
in utero at 7-8 days of gestation (15). On the other hand, the heterozygous TSK 
mice are viable and develop hyperplasia of the skin, loose connective tissue, 
developmental emphysema, and increased growth of cartilage and bone 
(15;16). Mutations in the gene encoding fibrillin-1 in men are causative for 
Marfan syndrome, an autosomal disorder of the connective tissue with 
pleiotropic manifestations primarily affecting the cardiovascular, ocular, and 
skeletal system (17-19). Although studies are scarce, pulmonary dysfunction, as 
indicated by the development of emphysema, has been noticed in a number of 
patients with Marfan syndrome (20-25).
All of the murine and human genetic disorders described above can be 
associated with the development of emphysema. In line with these genetic 
disorders, the fibrillin-1 protein was recently linked to adult pulmonary 
emphysema (9;10); a condition characterized by destruction of the extracellular
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matrix (26). These observations suggest an important role for fibrillin-1 in the 
pathogenesis of adult early onset emphysema. To obtain more insight into the 
role of fibrillin-1 in the pathogenesis of emphysema, we studied this extracellular 
matrix component in primary lung fibroblasts derived from patients with clinical 
emphysema. Lung fibroblasts secrete many components of the microfibrils and 
the extracellular matrix (27), and present a good approach to study the linkage 
between emphysema and fibrillin-1.
Materials & Methods
Study group
Lung parenchymal specimens were obtained from 8 individuals characterized 
either as control individuals or patients with clinical emphysema. Classification 
of these specimens was based on clinical data and histological examination of 
lung tissue by an experienced pulmonary pathologist (WT). Patient 
characteristics are given in table 1. Control specimens (n = 4) were derived from 
individuals undergoing resective surgery for a pulmonary carcinoma.
Specimens were sampled distantly from the tumor and did not show any sign of 
the underlying disease. Upon histological analysis, no sings, either 
macroscopically or microscopically, of emphysema were observed. Specimens 
with clinical emphysema (n = 4) were derived from patients with clinically 
established emphysema undergoing surgery for lung transplantation. These 
patients had lung function tests indicative of severe airway obstruction; stage IV 
according to GOLD criteria (28). Histological analysis of the resected lung 
specimens showed both macroscopically and microscopically severe 
emphysematous lesions. The results of the lung function tests and the 
histological analysis are depicted in table 1.
Table 1, Characteristics o f the study group.
Control Clinical emphysema
N 4 4
Male/female 2/2 2/2
Age (Yr) 64 ± 9 57 ± 3
Pack years 62 ± 13 32 ± 7
FEV1 (% pred.) 101 ± 2 14 ± 3
FEV1/VC (%) 74 ± 3 42 ± 30
All values are means ± SD. Abbreviations: FEVi, forced expiratory volume in 1 second; % pred., 
percentage of predicted; VC, vital capacity.
Cells
Human lung fibroblast cultures were established from parenchymal lung 
specimens by a previously described explant technique (29). Fibroblasts were 
routinely maintained in Ham’s F12 medium supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, and 100 ^g/ml penicillin and streptomycin (all cell 
culture materials were purchased from Gibco, Grand Island, USA).
Immunofluorescence analysis
Cells (5.103 / 7 mm spot, passage 9), were grown on multispot slides (Cel-line, 
Portsmouth, USA) for up to 21 days. After 4, 7, 14, and 21 days of culture, 
slides were washed two times in PBS and fixed with icecold methanol. After 
blocking non-specific binding with 1% (w/v) bovine serum albumin (BSA, 
fraction V, Sigma, St. Louis, USA) in PBS, multispots were incubated with a 
primary antibody to fibrillin-1 (1:500; clone rF6H, kind gift of D. Reinhardt, 
Quebec, Canada), LTBP-1 and LTBP-2 (1:500, kind gift of C. Heldin, Uppsala, 
Sweden), EMILIN-1 (1:500; kind gift of A. Colombatti, Aviano, Italy), type I 
collagen (1:500, Chemicon, Temecula, USA), MAGP-1 and MAGP-2 (1:500, 
kind gift of M. Gibson, Adelaide, Australia), fibulin-1 and fibulin-5 (1:500, kind 
gift of T. Sasaki, Martinsreid, Germany), and elastin (1:500, Sigma) for 1 hour at 
room temperature. After washing with PBS, bound antibody was detected with 
1:100 diluted goat anti-mouse or goat anti-rabbit IgG Alexa 488 (Molecular 
Probes, Eugene, USA) for 60 min. Sections were washed in PBS and mounted 
in mowiol (4-88, Calbiochem, La Jolla, USA).
Quantitative PCR
Cells (1. 105 / 35 mm dish, passage 13) were allowed to grow for 96 h, after 
which the cells were detached with trypsin-ethylenediaminetetraacetic (EDTA) 
(PAA Laboratoires GmbH, Cölbe, Germany) and the suspension was 
centrifuged (100 x g). Total RNA was isolated from the cell pellet using the 
QIAshredder and RNeasy mini kit (Qiagen, Hilden Germany) with on column 
DNase I digestion (Qiagen). 1 ^g RNA was reverse transcribed using 50 ng 
random hexamer primers and the superscript III Reverse Transcriptase (10 U, 
Invitrogen, Carlsbad, USA). After the RT reaction, qPCR was prepared as 
follows: a primer mix of 3 ^l of each forward and reverse primer (4 pmol/^l) was 
added to 10 ^l Power SYBR®Green PCR Master Mix (Applied Biosytems, 
Scoresby, Australia) and 4 ^l cDNA. cDNA was amplified using the primers 
listed in table 2, designed with ‘primer 3’ (available via sourceforge.net) based 
on alignment of gene sequence. qPCR was performed on a ABI-PRISM 7000 
sequence detection system (Applied Biosystems, Foster City, USA) according 
to the manufacturer’s protocol. PCR conditions were as follows: 2 min at 50 °C 
and 10 min at 95 °C followed by 40 cycles of 15 sec at 95 °C and 1 min at 60 
°C, with data collection in the last 30 seconds. Efficiencies for all primer sets 
were determined using a standard curve of 6 serial cDNA dilutions. Primers 
were accepted if the deviation from the slope of the standard curve was less 
then 0.3 compared to the slope of the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) curve and if the melting curve showed only 1 product. 
The cycle threshold value (Ct) of the genes of interest was corrected for the Ct
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of the reference gene GAPDH. Relative mRNA expression was calculated by 2 
to the power of ACt. Gene expression in emphysematous fibroblasts was 
expressed as a fold of the relative mRNA expression in control fibroblasts, by 
arbitrarily setting the average value of the latter to 1.
Table 2, Primers used for qPCR.
Gene Forward primer Reverse primer
Fibrillin-1 atggaaggagctgcaaagatct gccgccaatggtgttaaca
LTBP-1 ggcagctaaagaccagtgtgaa ttcctgcactg cccatga
Type I collagen ctggttcggcgagagcat ccctggccgccatactc
EMILIN-1 cggtccccttcgacagagt cacgcctgtctctggatcataa
Fibuline-1 gggcatacatgcatcaacac agtaacccgtcttgcattcg
GAPDH ggtatcgtggaaggactcat accacctggtgctcagtgta
Statistics
Results were analyzed with the Student’s t-test and were considered significant 
if the p-value was < 0.05.
Results
Proteins deposited in the extracellular matrix
Immunofluorescence microscopy was used to evaluate the deposition of 
extracellular matrix proteins of primary lung fibroblasts. Fibrillin-1, LTBP-1, 
EMILIN-1, type I collagen, and fibulin-1 were located in the extracellular matrix 
deposited after 4, 7, 14, and 21 days of culture. After 4 days of culture, 
fibroblasts deposited an extracellular matrix that can be identified by patchy 
areas of short fibers that lie on top of the cells (figure 1A, E, and I for resp. 
LTBP-1, EMILIN-1, and Fibrillin-1). After 7 days of culture, the fibers were more 
homogeneously distributed, forming an intertwined and branched meshwork 
(figure 1B, F, and J). This meshwork extended throughout the cell layer at day
14 and 21, thereby forming a 3-dimensional network (figure 1C-D, G-H, and K­
L). Throughout day 4 to 21, immunoreactivity for fibrillin-1, LTBP-1, EMILIN-1, 
Type I collagen, and fibulin-1 could be detected in the extracellular matrix. On 
the other hand, antibodies to LTBP-2, MAGP-1, MAGP-2, fibulin-5, and elastin 
did not show reactivity in the matrix. These results do not indicate that LTBP-2, 
MAGP-1, MAGP-2, fibulin-5, and elastin are not synthesized by the fibroblasts, 
although this is a possibility. The results could also indicate that the epitope for 
the antibodies is not accessible.
day 4 day 7 day 14 day 21
Figure 1, Immunostaining of fibroblast cultures for LTBP-1, EMILIN-1, and fibrillin-1. Primary 
control lung fibroblasts (passage 9) were cultured for 4 (A, E, I), 7 (B, F, J), 14 (C, G, K), and 21 
days (D, H, L) (n = 1). The formed matrix was stained with an antibody to LTBP-1 (A-D), EMILIN-1 
(E-H), and Fibrillin-1 (I-L). Bound antibody was visualized by Alexa 488-conjugated goat anti-rabbit 
IgG or goat anti-mouse IgG. Note the short, patchy stained fibers at day 4 (A, E, I) and the 
intertwined, branched fibers at day 7 (B, F, J). Throughout day 41 (C, G, K) and day 21 (D, H, L), 
the stained fibers showed an increasing distribution leading to a 3-dimensional network. (Bar = 50 
Mm).
Deposition o f fibrillin-1 is aberrant in the extracellular matrix of fibroblasts 
derived from patients with clinical emphysema
To study if fibroblasts derived from clinical emphysema patients deposit 
aberrant fibrillin-1 in their extracellular matrix, the deposition of this protein was 
compared to control fibroblasts. Fibroblasts derived from control individuals 
deposited intensely stained fibrillin-1 fibers in the extracellular matrix, as seen 
by short intertwined and branched fibers at day 4 and 7 and by a 3-dimensional 
network at day 14 and 21 (figure 2A-D). Fibroblast derived from clinical 
emphysema patients also deposited an extracellular matrix with fibrillin-1 
containing fibers. However, an appreciable amount of the fibrillin-1 fibers had a 
different morphology and appeared clumped and fragmented at day 4 and 7. 
Furthermore, the meshwork of fibrillin-1 fibers did not appear as a 3­
dimensional network upon day 21, but was disorganized and frayed (figure 2E- 
H). The data suggest that the emphysematous fibroblasts deposited aberrant 
fibrillin-1 fibers. To exclude that the aberrancies were caused by an abnormal 
proliferation rate or by an abnormal deposition of extracellular matrix, the 
seeded multispot glasses were respectively stained with DAPI or with 
antibodies to other extracellular matrix proteins. Visualization of the cell’s nuclei 
with DAPI revealed no differences in relative cell number (data not shown).
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Besides that, other extracellular matrix proteins like LTBP-1, EMILIN-1, Type I 
collagen, and fibulin-1 were similarly deposited in control fibroblasts and 
fibroblasts derived from clinical emphysema patients (figure 3, representing 14 
days of culture).
Figure 2, Immunostaining for fibrillin-1 in fibroblast cultures from controls and patients with 
emphysema. Primary lung fibroblasts derived from control individuals (passage 9, A-D) or from 
patients with clinical emphysema (passage 9, E-H) were cultured for 4 (A, E), 7 (B, F), 14 (C, G), 
and 21 days (D, H) (n = 1). The cultured cells were stained with an antibody to fibrillin-1 and bound 
antibody was visualized by Alexa 488-conjugated goat anti-rabbit IgG. Note the intertwined and 
branched fibrillin-1 fibers deposited by control fibroblasts at day 4 (A) and 7 (B), forming a 3­
dimensional network at day 14 (C) and 21 (D). The fibrillin-1 fibers deposited by fibroblasts derived 
from emphysema patients appeared clumped and fragmented at day 4 (E) and 7 (F). An organized 
3-dimensional network was lacking upon longer incubations times, as seen by a disorganized and 
frayed fiber network at day 14 (G) and 21 (H). (Bar = 50 |jm).
Aberrant extracellular deposition of fibrillin-1 in emphysematous fibroblasts is 
not associated with a decrease in fibrillin-1 mRNA levels 
To study if the aberrant deposition of fibrillin-1 in the extracellular matrix of 
fibroblasts from emphysematous patients can be accounted for by a defect in 
synthesis the expression of FBN1 mRNA was evaluated using qPCR analysis. 
Using a primer set addressing the central part of the fibrillin-1 gene, comparable 
mRNA expression levels for fibrillin-1 in control and emphysematous fibroblasts 
were observed (figure 4). In addition, expression levels of a subset of other 
extracellular matrix genes, including LTBP-1, EMILIN-1, Type I collagen, and 
fibulin-1 did not show a significantly altered expression (p > 0,05) in 
emphysematous fibroblasts compared to control fibroblasts (figure 4).
Using Western Blot analysis an attempt was made to analyze the amount of 
intracellular and extracellular fibrillin-1, LTBP-1, EMILIN-1, Type I collagen, and 
fibulin-1. However, the expression of the various proteins within the study 
groups (either the group of control or emphysematous fibroblasts) was too 
heterogeneous.
emphysema
Figure 3, Immunostaining for TYPE I collagen, fibulin-1, LTBP-1, and EMILIN-1 in fibroblast 
cultures from controls and patients with emphysema. Primary lung fibroblasts derived from 
control individuals (passage 9, A, C, E, G) or from patients with clinical emphysema (passage 9, B, 
D, F, H) were cultured for 4, 7, 14, and 21 days (n = 1). Cells were stained with an antibody to type I 
collagen (A, B), fibulin-1 (C, D), LTBP-1 (E, F), and EMILIN-1 (G, H) and bound antibody was 
visualized by alexa 488-conjugated goat anti-rabbit or goat anti-mouse IgG. Pictures represent 14 
days of culture. Note that after 14 days of culture, type I collagen, fibulin-1, LTBP-1, and EMILIN-1 
fibers were abundantly present, forming an intertwined and branched network. No significant 
differences were observed between the fibers deposited by the fibroblast derived from control 
individuals or clinical emphysema patients. (Bar = 50 |jm).
Discussion
Fibrillin-1 is a crucial protein in elastic fiber assembly and once secreted by the 
fibroblast it, together with others proteins such as LTBPs, MAGPs, EMILINs, 
and fibulins, aggregates to from the scaffold for elastin deposition (3). During a 
lifetime, the lung undergoes over a billion cycles of stretching and relaxation of
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F igure  4, Q uantita tive  f ib rillin -1  mRNA ana lys is . qPCR analysis of RNA isolated primary lung 
fibroblasts (passage 13) derived from control individuals or emphysematous patients (n = 1 
(interassay) and n = 2/3 (intraassay)). No significant differences (p > 0.05) in the expression of the 
fibrillin-1 gene (FBN-1) were observed. mRNA levels of LTBP-1, type I collagen (type I COL), 
EMILIN-1 (EMN), and fibulin-1 (FBLN-1) also did not show a significant difference (p > 0.05) 
between control and emphysematous fibroblasts.
the elastic fibers, and it may be anticipated that anomalies in fibrillin-1 are 
associated with the pathological loss elastic recoil properties, as observed in 
emphysema. The lung fibroblast is primarily involved in the production of 
extracellular matrix components like fibrillin-1 (30), and consequently fibroblasts 
derived from patients with clinical emphysema present a suitable model for 
studies to the involvement of extracellular matrix molecules in the pathogenesis 
of emphysema (29;31).
This study indicates that the extracellular matrix deposited by cultured fibroblast 
derived from patients with emphysema contains fibrillin-1 fibers that appeared 
fragmented and clumped, resulting in a 3-dimensional network that was 
disorganized and frayed. This fragmented and frayed fibrillin-1 appearance 
resembles the fibrillin-1 staining pattern seen in human lung specimen derived 
from emphysema patients (9;10). In addition, comparable aberrant fibrillin-1 
fibers were also noted in the extracellular matrix laid down by fibroblasts derived 
from patients with Marfan syndrome and from bovine models for Marfan 
syndrome (32-34). This aberrant deposition of fibrillin-1 in the extracellular 
matrix is explained by the “dominant negative” mechanism (35-37). This 
mechanism explains that several unique missense, nonsense, and deletion 
mutations in FBN1 gene give rise to a defective fibrillin-1 molecule that 
interferes with normal fibrillogenesis by acting as a competitive inhibitor of 
normal microfibrillar assembly. It is suggested that the fibrillin-1 molecules are 
poorly assimilated into the extracellular matrix and inhibit multimer formation of 
fibrillin-1 (36;37).
The experiments in this study indicate that cells from affected and non-affected 
individuals express comparable amounts of fibrillin-1 mRNA. The data suggests 
that fibroblasts derived from clinical emphysema patient synthesize normal
amounts of fibrillin-1 and that the impaired matrix deposition of fibrillin-1 is not 
due to a down-regulation of the FBN1 gene. In the literature, a number of other 
biochemical features are associated with an impaired matrix deposition of 
fibrillin-1. A comprehensive study of 55 fibroblast lines from patients with 
Marfan syndrome indicated that there are five major causes leading to a 
disturbed fibrillin deposition in the matrix; 1) decreased synthesis and a normal 
fibrillin-1deposition in the matrix, 2) decreased synthesis and impaired fibrillin-1 
deposition in the matrix, 3) normal synthesis and mildly impaired fibrillin-1 
deposition in the matrix, 4) decreased secretion and severely impaired fibrillin-1 
deposition in the matrix, 5) normal synthesis, secretion and fibrillin-1 deposition 
in the matrix (36). The phenotypes described by Aoyama et al. are also 
observed in other studies analyzing fibroblast derived from Marfan patients (38­
40), most notably in fibroblast derived from Marfan patients that have developed 
emphysema (41). If we would like to reveal such a phenotype in emphysema 
patients, a larger cohort of emphysematous fibroblasts should be analyzed with 
[35S]cysteine labeled fibrillin-1 pulse chase studies (42) instead of conventional 
Western Blot analysis.
In summary, fibroblast derived from clinical emphysema patients displayed an 
abnormal deposition of fibrillin-1 in the extracellular matrix. What biochemical 
feature underlies this aberrant deposition remains unsolved. Although the 
number of fibroblast strains in this study is small, the in vitro data coincides with 
in vivo data published previously by our group (9;10) and strengthens the 
suggestion that fibrillin-1 plays an important role in the onset of emphysema. In 
agreement with earlier data, we suggest that a mutation in the gene encoding 
fibrillin-1 alters the structure of the protein and results in a (moderately) affected 
fibrillin-1 protein that abolishes normal aggregation into a complex meshwork of 
elastic fibers by the “dominant negative” mechanism. Once the elastic fibers in 
the lung encounter the detrimental effects of cigarette smoke a pathogenetic 
cascade is unleashed that predisposes the lung to emphysema.
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Recent published data from our group has indicated aberrant staining for 
fibrillin-1 in human lung specimens with (early) microscopical emphysema. The 
anomalous staining was similar to that observed in patients with Marfan 
syndrome, a syndrome caused by mutations in the gene encoding fibrillin-1 
(FBN1). In both men and mice, mutations in the FBN1 gene have been reported 
to result in emphysematous conditions. We therefore analyzed FBN1 as a 
candidate gene that predisposes individuals to emphysema. Using denaturing 
high-performance liquid chromatography (DHPLC), the FBN1 gene in lung 
specimens from 8 individuals with either no, or microscopical or clinical 
pulmonary emphysema was analyzed. The lung specimens derived from the 
latter two groups were characterized by an aberrant staining for fibrillin-1. 
Besides some previously reported polymorphisms, we detected a novel 
heterozygous exonic 6576C>T mutation in one patient with clinical emphysema. 
This silent mutation was predicted to induce a cryptic splice donor sequence 
within FBN1 exon 53 resulting in an in-frame deletion of 42 bases. Sequencing 
of the cDNA and analysis of the mRNA confirmed the mutation, but did not 
reveal a deletion in the FBN1 mRNA. In addition, mRNA analysis did not 
indicate a decreased expression of the FBN1 gene. In conclusion, we failed to 
detect a causative mutation in the FBN1 gene in lung specimens with 
emphysematous lesions and aberrant fibrillin-1 staining, but report on a novel 
single nucleotide polymorphism in one patient with clinical emphysema.
Introduction
Fibrillin-1 is the best characterized structural component of microfibrils, which 
are 10-12 nm tubular structures ubiquitously found in elastic fibers (1;2). Within 
the elastic fiber, microfibrils serve several functions; they shape and orientate 
presumptive elastic fibers by forming a scaffold for tropoelastin deposition (3) 
and they play a key role in the extracellular regulation of the growth factor TGF- 
p (4;5). The importance of fibrillin-1 in microfibril integrity and functioning has 
been highlighted by the notion that mutations in the gene encoding fibrillin-1 
(FBN1) give rise to heritable elastic fiber disorders, such as Marfan syndrome, 
familial ectopia lentis, Sphrintzen-Goldberg syndrome, and Weill-Marchesani 
syndrome (5).
The dominantly inherited elastic fiber disorder Marfan syndrome is caused by 
mutations in FBN1 (6;7), and, to date, over 600 FBN1 mutations have been 
identified, including missense mutations, splicing errors, deletions, nonsense 
mutations, and insertions (8) (see the Marfan Database at 
http://www.umd.necker.fr). All reported mutations lead to phenotypes with 
clinical manifestations such as ectopia lentis, aortic dilatation, dural ectasia, tall 
stature, arachnodactyly, and scoliosis (9). In a number of cases, Marfan 
patients, particularly patients with neonatal Marfan with FBN1 mutations in exon 
25-32, develop emphysema (10-16), a chronic progressive disorder 
characterized by enlargement of the alveoli accompanied by destruction of the 
alveolar septa (17). The association between fibrillin-1 and emphysema has 
also been demonstrated in several mouse models, including the tight skin 
mouse, and the mgA, mgR and C1039G mice models. Tight skin mice (18-22), 
characterized by a tandem duplication of 30-40 kb in the Fbn1 gene, develop an 
emphysematous phenotype that closely resembles human emphysema. In 
addition, mgA mice harboring a targeted deletion of 6 kb in the Fbn1 gene 
develop an emphysematous phenotype characterized by enlarged alveoli 
(23;24). In addition, the mgR mice, expressing 20 ~ 25% of normal fibrillin-1 
protein levels (25), also display an emphysematous phenotype characterized by 
alveolar enlargement (23). Heterozygous mice with a missense mutation 
(C1039G) in the Fbn1 gene (26) also display an emphysematous phenotype. 
Recently, we associated aberrancies in fibrillin-1 staining in the extracellular 
matrix to early events of emphysema (27;28). The aberrant fibrillin-1 staining 
was similar to the fibrillin-1 staining observed in specimens with Marfan 
syndrome (29;30). Combined with the notion that mutations in the FBN1/Fbn1 
gene give rise to emphysema in men and mice, we proposed FBN1 as a 
candidate gene involved in the process of emphysematogenesis (27). In this 
study, we analyzed lung specimens with aberrant fibrillin-1 staining and various 
degrees of emphysematous lesions (28) for mutations in the FBN1 gene, using 
denaturing high performance liquid chromatography (DHPLC). DHPLC is a 
simple and semi automated method and has been used to detect sequence 
variations in the FBN1 gene (31-33).
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Materials & Methods
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Specimens
Lung parenchymal specimens were obtained from 8 individuals analyzed as 
specimens with or without microscopical emphysema, or specimens derived 
from patients with overt (clinical) emphysema. All specimens were taken in 
accordance with the guidelines of the Medical Ethical Committee of the 
Radboud University Nijmegen Medical Center. Specimens without (n = 2) or 
with microscopical emphysema (n = 3) were derived from patients undergoing 
resective surgery for a pulmonary carcinoma. Specimens were sampled from an 
area distant from the tumor, not showing any sign of the tumor or its possible 
consequences (e.g obstruction pneumonia). Specimens without emphysema 
did not show an aberrant fibrillin-1 staining in the extracellular matrix of the lung 
parenchyma (28) (figure 1). Specimens with microscopical emphysema, as 
determined by morphometric analysis (27) (Destructive Index (DI), the Mean 
Linear Intercept (MLI), and the Panel Grading (PG)), displayed aberrant fibrillin- 
1 staining in the extracellular matrix of the lung parenchyma (28) (figure 1). 
Specimens with clinical emphysema (n = 3), derived from patients with overt 
emphysema undergoing surgery for lung transplantation, showed both 
macroscopically and microscopically severe emphysema combined with a 
strongly diminished fibrillin-1 staining in the extracellular matrix of the lung (28) 
(figure 1). The characteristics of the specimens are depicted in table 1. Please 
note that specimens were selected on basis of morphological characteristics.
Mutation screening
Genomic DNA was isolated from lung parenchymal tissue using the Qiagen 
DNeasy kit (Qiangen, Hilden, Germany) and was amplified exon-by-exon using 
previously reported intron-specific primers (32). PCR amplifications and 
denaturing-HPLC (DHPLC) were performed as described (32). Shortly, analysis 
was performed on a Wave® HPLC system containing a DNASep column 
(Transgenomic, Omaha, USA). Prior to DHPLC, 50 ^l aliquots of untreated PCR 
product were denatured at 95 °C for 3 min. followed by gradual re-annealing to 
35 °C over 45 min., allowing the formation of homo- and heteroduplexes. 5-15 
^l of re-annealed PCR products were automatically loaded onto the column kept 
at an oven temperature between 54-64 °C. PCR products were eluted from the 
column using a linear acetonitrile gradient. The elution of the PCR products was 
monitored with UV detection at 260 nm and analyzed using the Class-VP 
software version (Shimadzu). PCR products with abnormal elution profiles were 
directly sequenced. Splice site prediction software (www.umd.be) was used to 
determine the predicted effect of a nucleotide substitution on splicing.
Cell culture
Human lung fibroblast cultures were established using parenchymal lung 
specimens and a previously described explant technique (34). As a control the 
human fetal lung fibroblast cell line (CCL 153, American type culture collection, 
Manassas, USA) was used. The fibroblasts were routinely maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal calf 
serum and 100 jg/m l penicillin/streptomycin (all cell culture materials were 
purchased from Gibco, Grand Island, USA).
Table 1, Morphological data of the specimens (no microscopical, 
microscopical, and clinical emphysema) and characteristics of the study 
group.
No Microscopical Clinical
Morphological data
N 2 3 3
DI (%) 17 ± 1 93 ± 5 *
MLI (|jm) 279 ± 61 417 ± 46 *
PG (%) 27 ± 1 85 ± 3 *
Physiological data §
Age (Yr) 62 ± 9 66 ± 8 56 ± 5
Pack years 25 ± 4 58 ± 54 30 ± 15
FEV1 (% pred.) 75 ± 5 85 ± 10 23 ± 1
Kco (% pred.) 64 ± 7 74 ± 11 41 ± 20
All values are means ± SD. Abbreviations: FEV^ forced expiratory volume in 1 second; % pred., 
percentage of predicted; VC, vital capacity; Kco, diffusion capacity for CO; DI, Destructive Index; 
MLI, Mean Linear Intercept ; PG, Panel Grading. * = DI, MLI, and PG could not be assessed due to 
the advanced parenchymal destruction of the specimens. § = Please note that specimens were 
selected on basis of morphological data.
mRNA analysis
Total RNA was isolated from confluent cell layers or lung parenchyma tissue 
using a Qiagen RNeasy kit (Qiagen). The quality of the RNA was analyzed 
using the 260/280 ratio and the RNA Integrity Number (RIN). The RNA used for 
reverse transcription was characterized by a 260/280 ratio> 1.5, and a RIN> 8. 
One jg  RNA was reverse transcribed using oligo-dT primers and the 
Superscript First Strand Synthesis System (Invitrogen, Carlsbad, USA). cDNA 
was amplified using the primers reported in table 2, designed with ‘primer 3 
design’ (available via sourceforge.net) based on alignment of the fibrillin-1 gene. 
PCR amplifications were performed in a final volume of 50 j l  containing 1 j l  of 
cDNA, 1x PCR buffer (Roche, Basel, Schweiz), 25 mM MgCl2, 10 mM dTTP, 
dATP, dCTP, dGTP (invitrogen), 1 pmol/jl of each primer, and 1U of Taq DNA 
polymerase (Roche) with the following cycling profile: 5 min denaturation at 94 
°C and 35 cycles of denaturation at 94 °C for 1 min, annealing at 55-60 °C 
(table 2) for 1 min, extension at 72 °C for 2 min, followed by a final extension 
step at 72 °C for 5 min. PCR products were analyzed on a 2 % agarose gel 
according to standard procedures. For quantitative PCR analysis, the cycle
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threshold value (Ct) of the FBN1 gene (FBN1 C primerset) was corrected for the 
Ct of the reference gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Relative mRNA expression was calculated by 2 to the power of ACt.
no microscopical emphysema
microscopical emphysema
clinical emphysema
F igure  1, Im m unosta in ing  fo r  fibn lhn-1 . Sections of paraffin-embedded human lung specimens, 
characterized as specimens without microscopical emphysema (no microscopical emphysema, A, 
B), with microscopical emphysema (C-E), and specimens derived from patients with clinical 
emphysema (F-H) were incubated with mAb 2502 (reactive with the N-terminus of fibrillin-1). 
Compared to specimens without microscopical emphysema (A, B), where a strong and continuous 
fibrillin-1 staining was seen in the alveolar endtips, a diminished fibrillin-1 staining was seen in 
specimens with microscopical and clinical emphysema (C-H). In addition, in specimens with 
microscopical emphysema a fragmented instead of a striped appearance was observed (arrows). In 
one specimen derived from a patient with clinical emphysema, a comparable fragmented staining 
pattern was observed (arrow, F). The two other specimens (G, H) displayed an alveolar endtip that 
was nearly devoid of fibrillin-1 staining except for some fibrillin-loaden macrophages (arrowpoint). 
The 6576C>T mutation was observed in specimen G. (Bar = 50 |jm).
Sequence analysis of RT-PCR products
Amplified cDNA products were purified using the Qiaquick PCR purification kit 
(Qiagen) and sequenced by the Sanger method (35) using ABI PRISM BigDye 
Terminator V3.0 chemistry (Applied Biosystems, Foster City, USA) on an ABI 
PRISM 3730 analyzer (Applied Biosystems).
Table 2, Primers and conditions for RT-PCR and qPCR.
Name Primer sequence Exon Tm (C )
GAPDH F: GGTATCGTGGAAGGACTCAT - 59.6
R: ACCACCTGGTGCTCAGTGTA - 62.8
FBN1 A F: GGTTCCTATCGCTGCGAGTGTCC 52 64
R: CCTCATCTTTGCACATCCTACGG 54 62.4
FBN1 B F: GCACCTATATAAATGAATGTGCC 53/54 57.1
R: GTGCCAATGAGGTTCTTGC 55 56.7
FBN1 C F :ATGGACGAAT GCAAAGAACC 52 55.3
R: GCAGAGGATTCTGGGCAC 54 58.2
Results
A heterozygous 6576C>T mutation in the gene encoding FBN1 in a patient with 
clinical emphysema
DHPLC is a method that relies on the differential retention of homo- and 
heteroduplex DNA on a column. Heteroduplex DNA is formed when a mutant 
and wild type allele, differing in sequence, anneal. Therefore, DHPLC is a 
powerful method to detect heterozygous mutations, such as single base 
substitutions, small insertion, and deletions. DHPLC analysis revealed several 
heteroduplexes in the genomic DNA from the 8 lung parenchymal specimens. 
One known silent polymorphism in the coding sequence and 6 known 
polymorphisms in intronic sequences of FBN1 (table 3) were found. In addition, 
a novel heterozygous 6576C>T mutation in exon 53 of FBN1 was revealed in 
the genomic DNA from a 58 years old male patient with clinical emphysema 
(lung specimen displayed in figure 1G). This mutation has not been identified 
previously and was not present in 1000 control chromosomes. The 
heterozygous 6576C>T mutation is silent and changes the corresponding 
codon from TGC to TGT, both encoding cysteine. However, the C to T 
substitution is predicted to form a cryptic splice donor sequence within exon 53 
resulting in an in-frame deletion of 42 bases (figure 2).
The 6576C>T mutation does not represent a cryptic splice donor sequence 
To investigate the predicted in-frame deletion, total RNA was harvested from a 
fibroblast culture derived from the affected patient. As a control, the human fetal 
lung fibroblasts cell line was used. In addition, total RNA was harvested from 
lung parenchymal tissue from the affected patient and from 3 non-affected 
individuals. The RNA was subjected to a RT-PCR analysis using a primer pair 
spanning exon 52-54 of FBN1 (FBN1 A, table 2) and a primer pair for GAPDH 
(table 2). For GAPDH, one amplicon of 341 bp was observed for all samples.
137
M
utation 
analysis 
of the 
fibrillin-1 
gene 
in 
lung 
specim
ens 
from 
patients 
with 
pulm
onary 
em
physem
a
C
ha
pt
er
 
7
Table 3, Mutations and polymorphisms detected in this study.
138
No. Nucleotide change Location Reference
Mutations
1 6576C>T Exon 53 unpublished
Polymorphisms
1 1875T>C Exon 15 (44)
2 IVS17-46A>G Intron 17 (46)
3 IVS28 + 15 d e l l l l l A Intron 28 (46)
4 IVS40-35C>T Intron 40 (46)
5 IVS52 + 128G>A Intron 52 (47)
6 IVS 56 + 17G>C Intron 56 (46)
7 IVS60 + 113T>G Intron 60 (31)
Figure 2, 6576C>T mutation in exon 53 o f the FBN1 gene o f a patient with clinical 
emphysema. This figure illustrates the C to T substitution at position 6576 of exon 53 (indicated in 
red). The mutation is silent, replacing one cysteine codon by another. However, predictions 
indicated that the C to T substitution might result in the activation of a GT sequence as a cryptic 
splice donor sequence within exon 53. This would lead to an in-frame deletion of 42 nucleotides of 
exon 53.
For FBN1, an amplicon of 306 bp was observed for all specimens, including the 
sample derived from the patient harboring the mutation (figure 3). An additional 
band for fibrillin-1, 42 bp smaller, was not observed in RNA from the patient 
harboring the mutation, indicating that the predicted in-frame deletion has not 
occurred.
GAPDH FBN-1
M 1 2 3 4 5 6 M 1 2 3 4 5 6
400-------
300— w -------------------_ _ -  -  - - m
100— — •
bp
Figure 3, RT-PCR analysis of FBN1 mRNA from lung tissue and lung fibroblasts from patient 
with the 6576C>T mutation. RT-PCR analysis of total RNA isolated from lung parenchymal tissue 
(lane 1) and cultured fibroblasts (lane 6) from the patient carrying the 6576C>T mutation. RNA was 
also isolated from lung parenchymal tissue of 3 non-affected individuals (lanes 2 to 4), and from 
human fetal lung fibroblasts (lane 5). Amplification with GAPDH specific primers showed the 
expected 341 bp product for all samples. Amplification with primers spanning FBN1 exon 52 to 54 
(FBN1 A primer set) showed the expected product of 306 bp for all samples. Lane M represents the 
marker with the molecular sizes (bp) indicated on the left.
To verify these results, a specific primer pair (FBN1 B, figure 4A) was 
developed of which one primer was chosen such that it only hybridizes to the 
presumed mutant cDNA and gives rise to a product only if the 6576C>T 
mutation activates a cryptic splice donor sequence within exon 53 leading to an 
in-frame deletion of 42 bases. No amplicon was seen using this pair of primers 
(figure 4B), indicating that the 6576C>T mutation in one allele of the FBN1 gene 
of the patient with clinical emphysema does not result in the formation of a 
cryptic splice donor sequence in exon 53. Subsequent sequencing of exons 52 
to 54 confirmed the C>T transition in exon 53 in one fibrillin-1 allele of the 
patient carrying the mutation, but, in accordance with the RT-PCR analysis, did 
not show an in-frame deletion of 42 nucleotides (figure 5).
The 6576C>Tmutation is not associated with a decreased expression o f FBN1 
The heterozygous 6576C>T mutation might affect the transcription of the FBN1 
gene e.g. by altering the stability of the mRNA ultimately leading to a decreased 
expression of the fibrillin-1 protein. To study if the 6576C>T mutation resulted in 
a decreased transcription, total RNA harvested from lung parenchymal tissue 
from the affected patient and from 3 non-affected individuals (not carrying the 
6576C>T mutation) was subjected to quantitative PCR analysis. Relative mRNA
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expression levels for the FBN1 gene in the affected and the 3 non-affected 
patients was not significantly different (figure 6), indicating no decreased mRNA 
level due tot the 6576C>T mutation.
A B |E x o n  5 3
AT ACT GAT GAA TGT TOT G TT GGC AAT CCT TGT GGA AAT GGA ACC TGC
AAG AAT GTG A TT GGA GGT T T T  GAA TGC ACC g jC T  CAG GAG GGA TT T w
C-AC— --GGA- -A -T S-A T g-A gA  -TG -T-GA A -C 4 0 0 — —  —
3 0 0 — —  —
E x o n  5 4 1 0 0 — •
AT ATA AAT GAA TGT GCC CAG AAT CCT CTG CTC TGT GCC T T C  CGA TGT b p  *
GTG AAC ACT TAT GGG TC A  TA T GAA TGC AAA TGT CCC GTG GGA TAT
GTG CTC AGA GAA GAC CGT AGG ATG TGC AAA G
Figure 4, RT-PCR analysis of FBN1 mRNA using a primer spanning the predicted in-frame 
deletion. A. A specific forward primer (indicated in yellow) was developed spanning the predicted 
change that would occur if the 6576C>T mutation would lead to an in-frame deletion. The mutation 
is depicted in red, the 42 bases in-frame deletion is stroked through. The primer will only hybridize if 
the deletion occurs, resulting in an amplicon. B. RT-PCR analysis of total RNA isolated from lung 
parenchymal tissue from the patient carrying the 6576C>T mutation. No band was observed using 
the primer spanning the predicted deletion (lane 3), whereas specific bands were detected using 
FBN1 primers spanning exon 52-54 (lane 2, 306 bp product; FBN1 A primer set (see Table 2)), and 
GAPDH specific primers (lane 1, 341 bp product)). Lane M represents the marker with the 
molecular sizes (bp) indicated on the left.
G C A C  C T G Y G A G G A G G
Exon 53
Figure 5, Sequence analysis of amplified FBN1 cDNA. Sequencing of the amplified product, 
using primers spanning FBN1 exon 52 to 54 (FBN1 A primer set), of the patient carrying the 
6576C>T mutation revealed a heterozygous point mutation (Y) in exon 53. The Y corresponds to a 
C and a T nucleotide, both with a ~50% occurrence, and indicates a C>T nucleotide transition in 
one allele of FBN1 exon 53.
F igure  6, R e la tive  mRNA exp ress ion  o f  FBN1. Quantitative PCR analysis (FBN1 C primer set). 
RNA isolated from lung parenchymal tissue from the patient carrying the 6576C>T mutation, and 
from lung parenchymal tissue from 3 individuals without this mutation. No difference in the amount 
of mRNA was observed.
Discussion
Smoking is considered the most important risk factor for emphysema; about 
90% of emphysema patients are current smokers or have a history of smoking 
(36). However smoking alone does not completely account for the pathogenesis 
of emphysema, as illustrated by the observation that only 15% of cigarette 
smokers actually develop clinical emphysema (36). From this paradox it is 
suggested that, besides smoking, the genetic background of an individual plays 
a role in the susceptibility to emphysema. The implication for genetic risk factors 
is substantiated by the familial aggregation of emphysema (37-41). In previously 
published reports we have correlated fibrillin-1 to microscopical and clinical 
emphysema (27;28). Together with the notion that mutations in the FBN1 gene 
lead to an emphysematous phenotype in both men and mice, we have 
suggested FBN1 as a possible candidate gene for the genetic predisposition of 
emphysema (27). To test this hypothesis, we subjected 8 samples analyzed as 
human lung specimens with or without emphysematous lesions to DHPLC 
analysis, a method previously described to analyze FBN1 heterozygous 
mutations (31-33). Specimens with microscopical emphysema and specimens 
from patients with overt clinical emphysema revealed an aberrant fibrillin-1 
staining in the extracellular matrix of the lung parenchyma, whereas the control 
specimens did not (28) (figure 1).
Fibrillin-1 is a large glycoprotein with a multidomain modular structure 
comprising 47 epidermal growth factor (EGF) domains, 43 of which contain a 
consensus sequence that is required for calcium binding, seven TGF-p1-binding 
protein like domains, two hybrid domains, a proline-rich region and unique N-
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and C-termini (5). The EGF domains contain cysteine residues which form intra­
molecular disulphide bonds that stabilize the tertiary structure of fibrillin-1 (5). 
Mutations within the EGF domains of FBN1, particularly within the cysteine 
residues, represent the majority of Marfan syndrome-associated mutations (8).
In this study we revealed a patient with clinical emphysema harboring a 
heterozygous 6576C>T mutation in exon 53, a calcium binding EGF domain. 
The mutation is silent as both the TGC and TGT codon encode for cysteine, 
however, splice site prediction software indicated that the 6576C>T mutation 
might form a cryptic splice donor sequence within exon 53 resulting in an in­
frame deletion of 42 bases. Previous data from other groups have indeed 
indicated in-frame deletions and the skipping of consecutive exons for FBN1 in 
response to silent mutations (43) and missense mutations (43-45). Sequencing 
of the RNA from the patient harboring the mutation indicated that the 6576C>T 
was indeed present in about half of the mRNA corresponding to one allele of 
the FBN1 gene. On the other hand, RT-PCR and sequence analysis clearly 
indicated that an in-frame deletion of 42 bases was not present in exon 53 of 
the mutant allele. To exclude the possibility that the stable transcript from the 
wild type allele eliminates the detection of the trace amount of alternatively 
spliced product from the mutant allele, we performed RT-PCR analysis with a 
forward primer that would only hybridize with the mutant allele. In agreement 
with the other experiment, a cryptic splice donor sequences within exon 53 was 
not found. Quantitative PCR analysis revealed that the heterozygous 6576C>T 
mutation did not alter the amount of the mRNA coding for fibrillin-1, thereby 
excluding increased instability of the mutant mRNA or reduced DNA 
transcription. It is therefore that this observation, combined with the notion that 
the mutation is silent, suggests that the mutation is not directly associated with 
pulmonary emphysema. Previously published data from our group has indicated 
the association between aberrant fibrillin-1 staining and (microscopical) 
emphysema (27;28). The data from this study indicate that mutations in the 
FBN1 gene are not causative for the aberrant staining of fibrillin-1 protein. The 
6576C>T mutation merely represents a single nucleotide polymorphism (SNP) 
in the FBN1 gene that has not been identified before (8). However, this exonic 
SNP may be used in linkage studies addressing larger cohorts of patients with 
emphysema, and perhaps be used as a starting point to identify people at risk. 
Whether or not the 6576C>T SNP is involved in the process of emphysema 
remains to be clarified.
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Summary
Pulmonary emphysema is a progressive disease that affects the gas-exchange 
function of the lung through irreversible destruction of the alveoli (1). Due to 
cigarette smoking, the major risk factor for emphysema, this disease is 
predicted to become a worldwide epidemic in the coming years (2). The 
pathogenesis of emphysema is very complex and despite the growing global 
importance it remains underfunded. A growing number of molecular players 
have been associated with a large number of pathogenetic processes involved 
in emphysema (as reviewed in (3)). Besides that, recent studies of hereditary 
mice models that are prone to emphysema have uncovered elastic fiber 
components as possible new players in the pathogenesis of emphysema. In 
chapter 1, an overview is given on the present knowledge concerning the role 
of the different elastic fiber components in the pathogenesis of emphysema. 
Although all of the studies point to elastic fiber components as important players 
in the etiology/pathogenesis of emphysema, the question as to what is the 
initiator of the emphysematous processes and why some individuals are more 
prone to attract emphysema than others remains unanswered. The aim of the 
study presented here was to unravel the role of the major elastic fiber 
component fibrillin-1 in the pathogenesis of emphysema.
Study set-up
Although common, emphysema remains a poorly understood disease at the 
molecular level. Virtually all molecular insight into the pathogenesis of 
emphysema has come from studies in genetically manipulated mice. 
Unfortunately, the lungs of mice are notoriously resistant to the effects of 
chronic cigarette smoke. In the absence of genetic manipulation, the majority of 
mouse strains require a long exposure to cigarette smoke before an 
emphysematous phenotype develops. And even than, the emphysematous 
lesions that develop are mild and severe airway obstruction and destruction, 
such as observed in humans, can not be reproduced (4). In addition, the lungs 
of mice differ from humans in several functional ways. For instance, mice do not 
have respiratory bronchioles and their terminal bronchiole opens directly into 
alveolar duct (4). In this light, studying the emphysematous process in human 
lung is particularly instructive from the standpoint of uncovering pathogenetic 
mechanisms. Therefore, in chapter 2, 3, and 4 human lung specimens with 
morphological emphysema, as defined by destruction of the alveolar wall and 
enlargement of the airspaces, without obvious clinical signs of emphysema, as 
determined by lung function analysis, are studied. Although this set-up may 
seem controversial, one must be aware that lung function tests are a useful tool 
that correctly reflects airway obstruction, but not the loss of parenchymal tissue 
(5-7). As described elsewhere in this study, the relationship between lung 
function test and the morphological assessment of emphysema has been 
described as poor (8-11). The low sensitivity of the lung function test for the 
diagnosis of emphysema is probably due to the large time span between the 
initiation and the manifestation of the disease, meaning that at time of clinical 
diagnosis the process of parenchymal destruction is already in an advanced 
state. This is also indicated in an autopsy study; over 30% of the lung surface of
individuals with normal lung function tests proved to be affected by emphysema 
on microscopical examination (12). Therefore, the way of diagnosing 
emphysema in an early phase is to confine oneself to the definition of 
emphysema that states that emphysema is defined by an abnormal permanent 
enlargement of airspaces combined by destruction of their walls (1). In this 
study, lung specimens with enlargement of airspaces, as defined by an 
increased Mean Linear Intercept (MLI), and alveolar wall destruction, as defined 
by an enlarged Destructive Index (DI), were used as an unique set-up to study 
the pathogenetic process of emphysema in an early phase preceding clinical 
deviant lung function test.
Fibrillin-1 expression in human lung specimens
Using the study set-up described above, chapter 2 describes the expression of 
several elastic fiber components, viz. type I and IV collagen, laminin, and 
fibrillin-1 in lung parenchymal specimens with varying degrees of microscopical 
emphysema. In specimens with microscopical emphysema, the expression of 
fibrillin-1 was aberrant. The degree of aberrant fibrillin-1 expression was 
significantly associated with the three most important morphometric parameters 
of emphysema; the DI, MLI, and Panel Grading (PG). Chapter 3 describes a 
comparable aberrant fibrillin-1 expression in another subset of human lung 
specimens with microscopical emphysema. The expression of other important 
elastic fiber components, such as elastin, EMILIN-1 and fibulin-2 was not 
affected. In addition, lung parenchymal specimens from clinical (end-stage) 
emphysema patients display an aberrant fibrillin-1 expression that is in line with 
specimens with microscopical emphysema. Because our experimental set-up 
allowed for early detection of emphysema, the results presented suggest that 
fibrillin-1 is an important player in the onset of emphysema. This hypothesis is 
endorsed by a number of observations that have associated fibrillin-1 with 
developmental emphysema in mice and men (13-27). The question arises how 
fibrillin-1 anomalies are involved in the injurious cascade eventually leading to 
emphysema. In the elastic fiber, fibrillin-1 assumes both a regulatory and a 
structural role, which both could play a major role in the pathogenesis of 
emphysema.
Regulatory role of fibrillin-1
In the elastic fiber, fibrillin-1 regulates the activity of the growth factor TGF-p by 
sequestering the growth factor in an inactive complex (28-30). Previous 
research has speculated that perturbations in extracellular matrix proteins, like 
fibrillin-1, destabilize the large latent complex and activate TGF-p (29;14). In 
agreement with this hypothesis, chapter 4 describes a strongly increased 
down-stream activation of the isoform TGF-p1 in specimens with microscopical 
emphysema that have an aberrant fibrillin-1 expression. TGF-p is a multipotent 
cytokine modulating a plethora of processes, such as cell growth and matrix 
synthesis, which on first sight can be described as beneficial (31). On the other 
hand, TGF-p also modulates some disease-modifying processes such as 
inflammation and apoptosis (32-37). More particularly, defects in TGF-p function
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are associated with a number of pathological states, including emphysema 
(38;39;14). We associated the increase in TGF-pi signaling with 
emphysematous processes such as inflammation and apoptosis. A major 
challenge for future studies will be to prove that the perturbations in fibrillin-1 
actually do lead to TGF-p activation that, in turn, induces phenomena such as 
inflammation and apoptosis leading to pathogenetic disorders such as 
emphysema. In this light, it is interesting to note that two mice models 
displaying genetic fibrillin-1 anomalies develop emphysema that is instigated by 
an enhanced TGF-p activity (14). Perinatal administration of a polyclonal TGF-p 
neutralizing antibody rescues the emphysematous phenotype in these mice 
(14).
Structural role of fibrillin-1
Due to the loss of elastic recoil properties of the lung, an important hallmark for 
emphysema, attention has been drawn to the role of elastic fiber biomechanics 
in the pathology of emphysema. The idea that biomechanical failure of the 
elastic fibers plays a pivotal role in the progression of emphysema actually 
dates back to the 70s (40). Among the constituents of the elastic fiber, elastin 
appears to account for most of the viscoelastic mechanical properties of the 
lung (41). Although very controversial, the fibrillin-1 microfibrils are also thought 
to account for some of the biomechanical properties of the elastic fiber (as 
reviewed in (42)). However, Young’s moduli, a measure for elasticity, of fibrillin- 
1 microfibrils have been reported to be three to five times lower than elastin (43­
45) and two orders of magnitude higher than elastin (46). From our standpoint 
of view, it would be of importance to determine if fibrillin-1 microfibrils do impact 
elastic fiber viscoelasticity. As a result of biochemical changes in the elastic 
fiber, the biomechanical properties change correspondingly (47-49). One could 
speculate that if the composition of elastic fibers is altered, e.g. due to the 
aberrant fibrillin-1 expression as observed in our specimens with microscopical 
emphysema, corresponding changes in the biomechanical behavior take place. 
If fibrillin-1 indeed has some biomechanical properties that reinforce the elastic 
fiber, destruction of fibrillin-1 will weaken the biomechanical strength of the 
elastic fiber. In this situation, the mechanical force generated during normal 
breathing may become sufficient to promote elastic fiber failure and aggravate 
the lung dysfunction seen in emphysema. Unfortunately, the data presented in 
chapter 5 demonstrate that the absence or presence of fibrillin-1 microfibrils do 
not impact the elastic modulus of elastic fibers. In addition, the Young’s 
modulus of fibrillin-1 microfibrils are in the order of those for elastin, and thereby 
do not significantly impact the elasticity of the elastic fiber. As the data suggest 
that fibrillin-1 microfibrils do not play a significant role in elastic fiber 
viscoelasticity, their suggested impact on biomechanical failure in the 
pathogenesis of emphysema becomes obsolete.
Fibrillin-1 expression in human lung fibroblasts
Fibroblasts derived from patients with clinical (end-stage) emphysema allowed 
insight into the cellular processing of fibrillin-1 and, as described in chapter 6, 
indicated that the extracellular matrix deposition of fibrillin-1 was affected in
emphysematous fibroblasts. On the other hand, mRNA expression analysis 
indicated that this defective matrix deposition is not due to a down-regulation of 
the fibrillin-1 gene (FBN1). Although this chapter represent some preliminary 
data derived from only a small number of fibroblasts strains (n = 4), the data 
coincides with the data on human lung specimens presented in the previous 
chapters and strengthens the suggestion that fibrillin-1 plays an important role 
in the onset of emphysema.
Fibrillin-1; a candidate gene for emphysema?
Each puff of cigarette smoke contains approx. 5,000 toxic compounds including 
hydrogen peroxide, hydroxyl anion and organic radicals (50). In this light, it is 
not surprising that smoking is the main risk factor for emphysema; nearly 90% 
of emphysema patients are current smokers or have a history of smoking (51).
It is proposed that smoking induces a cascade of injurious processes eventually 
leading to the disappearing of structural elements, like fibrillin-1, and leaving the 
alveolar septa disrupted with a progressive decrease in capillary exchange area 
(52). Despite the fact that smoking is appointed as the main risk factor, the 
association between smoking and emphysema is paradoxical. For as yet 
unknown reasons, only 15% of cigarette smokers actually develop clinical 
emphysema (51). This paradox suggests that, besides smoking, other risk 
factors are involved in the susceptibility towards emphysema. Familial 
aggregation of emphysema has suggested that, next to environmental risk 
factors like cigarette smoke, genetic influences are of importance (53-56). The 
fibrillin-1 anomalies described in the previous chapters, combined with the 
notion that mutations in FBN1 lead to an emphysematous phenotype in both 
men and mice (13-27), suggest fibrillin-1 as a possible candidate gene for the 
genetic predisposition of emphysema. It is proposed that a mutation in the 
FBN1 gene “weakens” the fibrillin-1 protein in such a way that non-smokers will 
not be affected by the mutation. However, once the fibrillin-1 protein is 
challenged by the toxic compounds in cigarette smoke, irreversible damage is 
done that eventually leads to emphysema. In chapter 7, human 
emphysematous lung specimens with an aberrant fibrillin-1 staining were 
analyzed for heterozygous FBN1 mutations. Out of the 6 genomic DNA samples 
that were derived from patients with microscopical or clinical emphysema, only 
1 sample displayed a (novel) mutation (6576C>T). This mutation was, however, 
silent and did not affect the amino acid sequence or the amount of expressed 
mRNA.
General conclusion
In this study the expression of several elastic fiber components was studied in 
human lung specimens with morphological emphysema. Of the different elastic 
fiber components, the microfibrillar protein fibrillin-1 was found to be aberrant in 
specimens with microscopical emphysema, the fibrillin-1 staining in these 
specimens was fragmented and punctuate instead of linear and striped. In 
addition, we could associate this aberrant fibrillin-1 expression with a
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pertubation of the regulatory role of fibrillin-1; the regulation of the activity of the 
growth factor TGF-p. Based on the role of TGF-p as a multipotent cytokine that 
modulates disease- modifying processes such as inflammation and apoptosis, 
the following hypothesis is suggested: aberrations in fibrillin-1 lead to excess 
activation and down-stream signaling of TGF-p1, which upon transcriptional 
activation instigates cellular processes like apoptosis and inflammation, 
ultimately resulting in clinical emphysema. The question is how the fibrillin-1 
protein becomes aberrant. A pathogenetic mutation in the FBN1 gene that 
makes the fibrillin-1 proteins susceptible for e.g. the effect of cigarette smoking 
or proteases was not found. This observation undermines the suggestion that 
fibrillin-1 is a candidate gene in the pathogenesis of emphysema; a candidate 
gene that triggers a cascade of detrimental processes ultimately leading to 
airspace enlargement and a loss of elasticity. Despite the notion that fibrillin-1 
could not be pointed out as the primary initiator of emphysematogenesis, the 
aberrant fibrillin-1 expression observed in early-onset emphysematous 
specimens is indicative of an early involvement of this protein. An attractive 
hypothesis is that the (secondary) fibrillin- 1 anomalies are a trigger for injurious 
processes located in the airspace. The key-process triggered by the anomalous 
fibrillin-1 is the release and down-stream activation of TGF-p. In fact, the 
unleashed down-stream activation of TGF-p may reconcile all of the different 
processes previously associated with emphysema such as inflammation, 
apoptosis, and protease-imbalance. Although this hypothesis is tempting, this 
study only offers indirect experimental evidence. This study offers no direct 
insight on how fibrillin-1 staining in the lungs specimens becomes fragmented.
A potential explanation is the progressive destruction of fibrillin-1 by matrix- 
degrading proteases secreted by pulmonary resident cells and inflammatory 
cells upon exposure to cigarette smoke. In this light, the matrix metalloprotease 
(MMPs) have gained special interest in several publications (57-59). However, 
gelatinography studies (chapter 4) indicated no in- or decreased activity of the 
MMPs in human lung specimens with an aberrant fibrillin-1 expression. 
However, given the large numbers of proteolytic enzymes as well as their 
targets, the presence of a fibrillin-1 -degrading enzyme present in human lung 
specimens exposed to smoking can not be excluded.
Future perspectives
Chronic obstructive pulmonary disease (COPD), a collective term including 
chronic bronchitis and emphysema, is a worldwide health problem that is not 
only a burden for the individuals who carry the disease but also a burden for 
society. There is frequent contact with health care providers, a high rate of 
hospital admission, and an increased risk of premature death (4). The 
complexity of the pathology of emphysema is difficult to grasp and new players, 
as also presented in this study, are being discovered on an ongoing basis. The 
authors are of opinion that the elastic fiber components are of a special 
importance in the search to a genetic predisposition for emphysema. Elastic 
fiber components are not only an important structural constituent of the lung,
they also regulate a plethora of processes of which the sequestration of TGF-p 
has come to our special interest. Further work, preferable using human lung 
specimen, to better characterize and appreciate the importance of elastic fiber 
components and TGF-p in the pathogenesis of emphysema is of importance. 
Recently, the unleashed down-stream activation of TGF-p in mice models of 
emphysema has directed medical intervention (14) (see below). We feel that, in 
concordance with this study, the clinical effects and the mechanistic clarification 
of this medical intervention will guide future research on the pathogenesis of 
emphysema
Medical intervention of emphysema
There are no current treatments that stop the progressive nature of 
emphysema. Emphysema is characterized by a complex pathology that 
involves several processes, such as inflammation, apoptosis, and extracellular 
matrix destruction. These pathogenetic processes do not act in isolation, but 
rather converge and ultimately account for the destruction of alveolar structures. 
From this point of view, intervening this cascade by suppressing or inhibiting 
one of these pathogenetic processes might lead to an arrest of alveolar 
destruction and circumvent end-stage emphysema. One important point that 
must be taken into consideration is that the lung can initiate certain repair 
mechanisms, but that elastic fibers generally can not be regenerated . Despite 
the fact that elastin and the other extracellular matrix components can be 
resynthesized, deposition of these components does not result in the restoration 
of physiological functioning elastic fiber (60). The complicated temporal and 
spatial regulation of all elastic fiber components is probably difficult to 
recapitulate in adults (60). Therefore, pharmacological intervention should be 
aimed at a process early in the pathogenetic cascade preceding elastic fiber 
degradation. Suppression of inflammation by inhaling corticosteroids has 
proved to be not effective, not even at higher doses (61-63). Treating 
emphysema patients with phosphodiesterase (PDE)-4 inhibitor, a broad- 
spectrum inflammatory inhibitor, slightly suppresses inflammation (64).
However, the administration of higher doses of PDE-4 inhibitor is unfavorable 
due to the frequency of unwanted side effects like nausea and vomiting (64).
Our observation that TGF-p1 and fibrillin-1 are crucial players in the 
pathogenesis of emphysema opens the door for new therapeutic strategies. 
Prenatal administration of a TGF-p-neutralizing antibody in mice homozygous 
for a hypomorphic Fbn1 allele significantly reduced TGF-p signaling and 
prevented the emphysematous phenotype (14). Based on a recent report by 
Habashi et al. (65), TGF-p antagonists may represent a successful treatment for 
developmental emphysema in Marfan patients and perhaps also for smoking- 
induced adult emphysema. Recently losartan, an angiotesin II type 1 receptor 
antagonist used to decrease blood pressure, has come into play (65). A major 
benefit of losartan is its widespread clinical use for treatment of hypertension 
and prevention of strokes and its exceptional tolerance profile. In human and 
animal models of chronic renal insufficiency and cardiomyopathy losartan 
showed an antagonistic effect on TGF-p (66;67). Prenatal administration of 
losartan in Fbn1C1039G mice blunted TGF-p signaling and prevented the
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emphysematous phenotype (65). A clinical trial has recently enrolled that 
studies the effect of losartan on COPD, a collective term including chronic 
bronchitis and emphysema (68). Patients diagnosed as having chronic 
bronchitis or emphysema are treated with 50-100 mg losartan or a placebo 
intervention. The progression of emphysema is monitored by high resolution 
CT-scans and additional lung function tests, serum biomarkers of inflammation, 
and inflammatory cells in bronchoalveolar lavage. The clinical trial will be 
completed at the end 2012 and, in the light of the study presented here, will be 
of particular interest to the authors.
154
Samenvatting
Longemfyseem is een progressief ziektebeeld waarbij de pulmonaire alveoli, de 
longblaasjes waar tijdens de ademhaling de gasuitwisseling plaatsvindt, 
irreversibel beschadigd zijn (1). Het roken van sigaretten is zonder twijfel de 
belangrijkste risicofactor voor het ontwikkelen van emfyseem. Het grote aantal 
rokers en de ophanden zijnde vergrijzing zullen er toe leiden dat emfyseem in 
de komende jaren een groot globaal probleem voor de gezondheidszorg zal zijn 
(2). Vanuit dit perspectief is kennis van de pathogenese van emfyseem van 
cruciaal belang. De afgelopen jaren zijn tal van pathogenetische processen 
geassocieerd met de ontwikkeling van emfyseem (samengevat in review (3)). 
Echter, ondanks dit groeiende inzicht blijft de pathogenese van emfyseem 
grotendeels onbekend. Recente studies in emfysemateuze muismodellen 
hebben nieuw licht geworpen op dit vraagstuk. In hoofdstuk 1 is een overzicht 
gegeven van deze nieuwe inzichten, waarbij de nadruk ligt op de verschillende 
componenten van de elastische vezel en hun rol in het ziekteproces. Ondanks 
dat alle gepubliceerde studies een waardevol inzicht verschaffen in de 
pathogenetische rol van deze componenten, blijft de vraag bestaan wat en 
welke component de pathogenese van emfyseem nu initieert en waarom 
sommige individuen gevoeliger zijn voor het ontwikkelen van emfyseem dan 
anderen. In een poging deze vragen op te helderen, is in deze studie de rol van 
één van de belangrijkste componenten van de elastische vezel, het eiwit 
fibrilline-1, in de pathogenese van emfyseem onderzocht.
Opzet van de studie
Het huidige moleculaire inzicht in de pathogenese van emfyseem is afkomstig 
van studies naar genetisch gemodificeerde muizen. Het is echter algemeen 
bekend dat de longen van muizen minder gevoelig zijn voor de schadelijke 
effecten van sigarettenrook. Zonder enige vorm van genetische modificatie 
moet men muizen erg lang blootstellen aan sigarettenrook voordat zij een 
emfysemateuze laesie ontwikkelen (4). De ontwikkelde laesies na deze 
ingrijpende blootstelling zijn relatief mild en ernstige luchtwegobstructie en 
destructie, zoals men die ziet bij de mens, kan moeilijk gereproduceerd worden 
(4). Daarnaast verschillen de longen van muis en mens in histologisch opzicht 
van elkaar. Zo ontbreekt bijvoorbeeld de respiratoire bronchiole in de 
muizenlong (4). Als men deze verschillen in ogenschouw neemt, dan heeft het 
bestuderen van de emfysemateuze processen in humane longbiopten de 
voorkeur. In hoofdstuk 2, 3 en 4 is daarom gebruik gemaakt van humane 
longbiopten met morfologisch emfyseem, waarbij emfyseem gedefinieerd is als 
vergroting van de alveoli en destructie van de alveolaire wanden. De biopten 
zijn afkomstig van individuen zonder duidelijke klinische kenmerken van 
emfyseem zoals bepaald door longfunctietesten. De opzet van deze studie lijkt 
op het eerste gezicht controversieel. Men moet zich echter realiseren dat 
longfunctietesten weliswaar een belangrijk hulpmiddel vormen om 
luchtwegobstructie te karakteriseren, maar dat deze tekort schieten in het 
aantonen van (beginnend) verlies van parenchymaal longweefsel (5-7). Zoals 
elders in deze studie beschreven, is de correlatie tussen longfunctietesten en 
de morfologische vaststelling van emfyseem slecht (8-11). De lage sensitiviteit
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van longfunctietesten voor de diagnose van emfyseem is waarschijnlijk het 
gevolg van de lange tijdsspanne tussen het ontstaan en de klinische 
manifestatie van de ziekte. Hiermee wordt bedoeld dat bij vaststelling van de 
diagnose emfyseem op basis van afwijkende longfunctietesten het verlies van 
longparenchym al vergevorderd is. Deze lage sensitiviteit is goed zichtbaar in 
een gepubliceerde autopsie studie. In deze studie had 30% van de individuen 
met een normale longfunctietest reeds emfyseem op basis van een 
morfologische microscopische analyse (12). Om emfyseem in een vroeg 
stadium te diagnosticeren moet men zich daarom conformeren aan de definitie 
van de American Thoracic Society (1) die emfyseem definieert als een 
abnormale permanente vergroting van de longblaasjes gecombineerd met 
destructie van de wanden. In lijn met deze definitie is emfyseem, in de in deze 
studie gebruikte humane longbiopten, gebaseerd op een vergroting van de 
longblaasjes (bepaald met behulp van de ‘Mean Linear Intercept (MLI)’) en op 
destructie van de wanden (bepaald met behulp van de ‘Destructive Index (DI)’). 
Deze opzet is uniek en stelt de auteurs in staat om het pathogenetische proces 
van emfyseem in de initiële fase, nog voorafgaand aan klinisch afwijkende 
longfunctietesten, te bestuderen.
Fibrilline-1 expressie in humane longbiopten
Hoofdstuk 2 beschrijft de expressie van enkele componenten van de 
elastische vezel te weten: type I en IV collageen, laminine en fibrilline-1 in 
humane longbiopten met verschillende gradaties van microscopisch emfyseem. 
De expressie van fibrilline-1 was afwijkend in biopten met microscopisch 
emfyseem en de ernst van deze afwijkingen correleerde significant met de drie 
morfologische parameters voor emfyseem; de DI, MLI en de ‘Panel Grading 
(PG)’. Hoofdstuk 3 beschrijft eenzelfde afwijkende fibrilline-1 expressie in een 
andere studiegroep van humane longbiopten met microscopisch emfyseem. In 
deze studiegroep was de expressie van andere belangrijke componenten van 
de elastische vezel zoals elastine, EMILINE-1 en fibuline-2 niet afwijkend. 
Humane longbiopten afkomstig van patiënten met klinisch emfyseem lieten een 
afwijkende fibrilline-1 expressie zien die overeenkwam met biopten met 
microscopisch emfyseem. Zoals eerder beschreven kan emfyseem met behulp 
van de gebruikte studieopzet in een vroeg stadium gediagnosticeerd worden.
De resultaten uit hoofdstuk 2 en 3 suggereren dan ook dat fibrilline-1 een 
belangrijke speler is in de initiële fase van emfyseem. Deze hypothese wordt 
onderschreven door studies waarbij afwijkingen in fibrilline-1 geassocieerd zijn 
met de ontwikkeling van emfyseem (13-27). De vraag rijst welke rol de 
afwijkende fibrilline-1 expressie speelt in de destructieve cascade die leidt tot 
emfyseem. Een antwoord op deze vraag kan liggen in de biomechanische en 
regulatoire rol die fibrilline-1 vervult in de elastische vezel. Verstoringen in één 
van deze, of misschien beide, processen zouden een trigger kunnen zijn tot een 
cascade van destructieve processen die uiteindelijk resulteren in emfyseem.
Regulatoire rol van fibrilline-1
Fibrilline-1 reguleert de activiteit van de groeifactor TGF-p door deze in te 
bouwen in een inactief latent complex (28-30). In recente publicaties is
gesuggereerd dat afwijkingen in extracellulaire matrixeiwitten zoals fibrilline-1 
kunnen leiden tot een verstoring van dit latente complex waardoor TGF-p 
geactiveerd wordt (29;14). In overeenstemming met deze hypothese wordt in 
hoofdstuk 4 een sterk verhoogde downstream activatie van TGF-pi in biopten 
met microscopisch emfyseem en een afwijkende fibrilline-1 expressie 
beschreven. TGF-p is een multipotent cytokine dat een overvloed aan 
processen reguleert die in het eerste opzicht kunnen worden beschreven als 
“voordelig”, zoals bijvoorbeeld celgroei en matrixsynthese (31). Daarnaast 
reguleert TGF-p ook een aantal processen die kunnen worden beschreven als 
“nadelig”, zoals bijvoorbeeld inflammatie en apoptosis (32-37). Deze nadelige 
effecten van TGF-p zijn geassocieerd met tal van pathologieën waaronder 
emfyseem (38;39;14). Zoals beschreven in hoofdstuk 4 kan de toegenomen 
TGF-p1 activatie geassocieerd worden met (emfysemateuze) processen zoals 
inflammatie en apoptosis. De beschreven resultaten zijn echter observationeel 
van aard en een grote uitdaging ligt dan ook in het bewijzen dat afwijkingen in 
fibrilline-1 inderdaad aanleiding kunnen geven tot TGF-p activatie en inductie 
van emfyseem gerelateerde processen zoals apoptose en inflammatie. In dit 
licht is het interessant om op te merken dat twee genetische muismodellen met 
een afwijkend fibrilline-1 eiwit emfyseem ontwikkelen dat veroorzaakt wordt 
door een verhoogde activiteit van TGF-p (14). Perinatale toediening van een 
polyclonaal TGF-p-neutraliserende antilichaam voorkomt de ontwikkeling van 
een emfysemateus fenotype (14).
Biomechanische rol van fibrilline-1
Het verlies van elasticiteit is kenmerkend voor emfyseem en de 
biomechanische rol van de elastische vezel in de pathogenese van emfyseem 
is daarom vanuit wetenschappelijk oogpunt interessant. In de jaren 70 is het 
idee reeds ontstaan dat het verlies van de biomechanische eigenschappen van 
de elastische vezel een belangrijke rol zou kunnen spelen in de progressie van 
emfyseem (40). Elastine lijkt grotendeels verantwoordelijk te zijn voor de 
viscoelastische en mechanische eigenschappen van de long (41). 
Controversiële literatuur suggereert echter dat fibrilline-1 ook, zij het deels, 
verantwoordelijk zou kunnen zijn voor deze biomechanische eigenschappen 
(samengevat in review (42)). Helaas lopen Young’s moduli, een maat voor 
elasticiteit, van de fibrilline-1 in de literatuur uiteen van 3 tot 5 keer lager (43-45) 
tot 100 keer hoger dan elastine (46). Vanuit het oogpunt van de auteurs is het 
daarom van wezenlijk belang om te onderzoeken wat de Young’s modulus van 
fibrilline-1 is en of het eiwit inderdaad bijdraagt aan de biomechanische 
eigenschappen van de elastische vezel. Uit eerdere publicaties is bekend dat 
biochemische veranderingen in de elastische vezel leiden tot overeenkomstige 
biomechanische veranderingen (47-49). Men kan dus speculeren dat wanneer 
de samenstelling van de elastische vezels verandert, bijvoorbeeld door een 
afwijkende expressie van fibrilline-1 zoals gezien in de humane longbiopten met 
microscopisch emfyseem, de biomechanica van de elastische vezel ook 
verandert. Als fibrilline-1 inderdaad biomechanische eigenschappen heeft die 
bijdragen aan de viscoelasticiteit van de elastische vezel, dan zal verlies of 
afbraak van fibrilline-1 de biomechanische functionaliteit van de elastische vezel
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verzwakken en aanleiding kunnen geven tot ademhalingsproblemen. De data 
beschreven in hoofdstuk 5 laten echter zien dat de aan- of afwezigheid van 
fibrilline-1 de Young’s modulus van de elastische vezel niet significant 
beïnvloedt. Bijkomend wordt aangetoond dat de Young’s modulus van fibrilline- 
1 microfibrillen overeenkomt met die van elastine en daardoor dus niet 
significant bijdraagt aan de elastische eigenschappen van de vezel. De 
hypothetische biomechanische rol die fibrilline-1 zou kunnen spelen in de 
pathogenese van emfyseem wordt hierdoor obsoleet.
Fibrilline-1 expressie in humane longfibroblasten
Met behulp van fibroblasten afkomstig van patiënten met klinisch (gevorderd) 
emfyseem kan inzicht worden verkregen in het cellulaire proces van fibrilline-1. 
Zoals beschreven in hoofdstuk 6 is de depositie van fibrilline-1 in de 
extracellulaire matrix aangedaan in emfysemateuze fibroblasten. mRNA 
expressie studies lieten zien dat deze defecte matrixdepositie niet het gevolg 
was van een afname van de expressie van het fibrilline-1 gen (FBN1). Ondanks 
het feit dat de gepresenteerde data slechts voorlopig zijn en er maar een 
beperkt aantal monsters is geïncludeerd (n = 4), komen de data uit hoofdstuk 6 
overeen met de data afkomstig van de humane longbiopten uit eerdere 
hoofdstukken. De verkregen resultaten versterken de suggestie dat fibrilline-1 
een belangrijke rol speelt in initiatie van emfyseem.
Fibrilline-1; een kandidaat gen voor emfyseem?
Elke wolk sigarettenrook bevat ongeveer 5.000 toxische stoffen waaronder 
waterstofperoxide en organische radicalen (50). Het is dan ook niet 
verwonderlijk dat roken de belangrijkste risicofactor is voor emfyseem; 90% van 
de emfyseempatiënten is roker of heeft in het verleden gerookt (51). Roken 
induceert een cascade van destructieve processen die resulteren in het 
verdwijnen van structurele elementen, zoals fibrilline-1, waarbij de alveolaire 
wanden beschadigen en het oppervlak voor gasuitwisseling significant afneemt 
(52). Ondanks het feit dat roken de belangrijkste risicofactor is, blijft de relatie 
tussen roken en emfyseem paradoxaal. Om, tot nu toe nog onbekende 
redenen, ontwikkelt slechts 15% van de rokers klinische klachten (51). Deze 
paradox suggereert dat, naast roken, andere risicofactoren van invloed zijn bij 
het ontwikkelen van emfyseem. Familiare aggregatie suggereert dat behalve 
externe risicofactoren zoals roken interne genetische risicofactoren, oftewel de 
genetische predispositie van een individu, van invloed zijn (63-56). Publicaties 
die laten zien dat mutaties in FBN1 aanleiding geven tot de ontwikkeling van 
emfyseem (13-27) en de gepresenteerde afwijkende fibrilline-1 expressie in 
biopten met microscopisch emfyseem uit deze studie, wijzen FBN1 aan als een 
mogelijk kandidaatgen voor de predispositie voor emfyseem. De auteurs stellen 
de volgende hypothese voor: een mutatie in het FBN1 gen geeft aanleiding tot 
een “verzwakt” fibrilline-1 eiwit waarvan niet rokers geen klinische klachten 
ondervinden. Echter, als dit verzwakte eiwit wordt blootgesteld aan de toxische 
stoffen aanwezig in sigarettenrook dan treedt er irreversibele schade op die 
uiteindelijk aanleiding geeft tot een emfysemateus fenotype. In hoofdstuk 7 zijn 
humane emfysemateuze longbiopten met een afwijkende fibrilline-1 expressie
onderzocht op FBN1 mutaties. Genomische DNA monsters waren afkomstig 
van 6 patiënten met microscopisch of klinisch emfyseem. In één monster werd 
een nieuwe mutatie (6576C>T) gezien. Deze mutatie codeerde echter niet voor 
een ander aminozuur en was dus “silent”. Ook de hoeveelheid FBN1 mRNA 
werd niet beïnvloed door deze mutatie.
Algemene conclusie
In deze studie is de expressie van enkele componenten van de elastische vezel 
bestudeerd in humane longbiopten met morfologisch emfyseem. Één van de 
bestudeerde componenten, fibrilline-1, vertoonde afwijkingen in deze biopten. 
De aankleuring van fibrilline-1 was gefragmenteerd en gepunctueerd in plaats 
van lineair en gestreept. Deze afwijkende fibrilline-1 kleuring was geassocieerd 
met een verstoring van de regulatoire rol van fibrilline-1, namelijk de regulatie 
van de activiteit van de groeifactor TGF-p. TGF-p is een multipotent cytokine 
dat pathogene processen zoals inflammatie en apoptosis induceert. Dit in 
ogenschouw genomen wordt door de auteurs de volgende hypothese 
voorgesteld: afwijkingen in fibrilline-1 lijden tot excessieve down-stream 
activatie van TGF-p dat door transcriptionele activatie cellulaire processen zoals 
inflammatie en apoptosis induceert die resulteren in een emfysemateus 
fenotype. De vraag is hoe het fibrilline-1 eiwit afwijkend wordt. Een mutatie in 
het FBN1 gen dat het fibrilline-1 eiwit gevoelig maakt voor o.a. de effecten van 
sigarettenrook of proteases werd niet gevonden. Deze observatie ondermijnt de 
suggestie dat fibrilline-1 een mogelijk kandidaatgen zou kunnen zijn dat een 
cascade van destructieve processen triggert die uiteindelijk leidt tot vergroting 
van de longblaasjes en verlies van elasticiteit. Ondanks dat het fibrilline-1 gen 
niet kan worden aangewezen als de primaire initiator van de 
emfysematogenese, is de afwijkende fibrilline-1 expressie die gezien wordt in 
biopten met initieel emfyseem wel indicatief voor een vroege betrokkenheid. De 
fibrilline-1-geïnduceerde activatie van TGF-p is de trigger voor tal van 
destructieve processen die zich afspelen in de luchtwegen. Sterker nog, de 
verhoogde down-stream activatie van TGF-p kan vele processen die 
geassocieerd zijn met emfyseem zoals inflammatie, apoptosis en een protease- 
disbalans, verklaren. Ondanks dat bovenstaande hypothese erg interessant is, 
kan deze studie de suggestie alleen onderbouwen met indirect analytisch 
bewijs. Deze studie geeft geen verklaring waarom de aankleuring van het 
fibrilline-1 eiwit in de long gefragmenteerd is. Een mogelijke verklaring is 
destructie van fibrilline-1 door bijvoorbeeld de matrix metalloproteases (MMPs) 
afkomstig van pulmonaire of inflammatoire cellen (57-59). Echter de 
gelatinografie experimenten gepresenteerd in hoofdstuk 4 lieten geen toe- of 
afgenomen activiteit zien van de MMPs in humane longbiopten met een 
afwijkende fibrilline-1 expressie. Er is echter een groot scala aan protelytische 
enzymen en targets en de aanwezigheid van een fibrilline-1-degraderend 
enzym in humane longbiopten kan dan ook niet worden uitgesloten.
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Toekomstvisie
Chronische obstructieve longziekten (COPD), een collectieve term die zowel 
chronische bronchitis als emfyseem omvat, is een wereldwijd probleem voor de 
gezondheidszorg. Patiënten met COPD hebben bijvoorbeeld frequent contact 
met hun (huis)arts, moeten relatief vaak worden opgenomen in het ziekenhuis 
en hebben een verhoogd risico op een vroegtijdig overlijden (4). Inzicht in de 
pathogenese van emfyseem is dan ook van belang. De pathogenese van 
emfyseem is echter complex en moeilijk te doorgronden. In de zoektocht naar 
nieuwe inzichten worden belangrijke moleculaire spelers doorlopend ontdekt. 
De auteurs zijn van mening dat de componenten van de elastische vezel van 
groot belang zijn in deze zoektocht. Deze componenten zijn niet alleen van 
belang als structurele componenten van de long, maar reguleren ook een groot 
scala aan processen waaronder de activiteit van TGF-p. Verder onderzoek in, 
bij voorkeur humane, longbiopten moet meer inzicht geven in de rol van de 
componenten van de elastische vezel en TGF-p in de pathogenese van 
emfyseem.
Medische interventie van emfyseem
Op dit moment zijn er geen succesvolle behandelingen die de progressieve 
ontwikkeling van emfyseem een halt toe roepen en is medicatie vooral gericht 
op het verlichten van de symptomen. Zoals al eerder beschreven wordt 
emfyseem gekarakteriseerd door een complexe pathologie waarin meerdere 
processen zoals inflammatie, apoptosis en destructie van de extracellulaire 
matrix een rol spelen. Deze pathogene processen staan niet op zichzelf maar 
zijn met elkaar verbonden en vormen een destructieve cascade. Vanuit het 
oogpunt van medische interventie is het interessant om deze cascade te 
onderbreken door een van deze pathogene processen te remmen of zelfs te 
voorkomen. Een belangrijk punt dat hierbij in ogenschouw moet worden 
genomen is het zeer beperkt pakket aan herstelmaatregelen dat de long kan 
aanspreken. Elastische vezels kunnen bijvoorbeeld niet geregenereerd worden 
(60). Ondanks dat elastine en de andere componenten van de elastische vezel 
opnieuw gesynthetiseerd worden, resulteert depositie van deze componenten in 
de extracellulaire matrix niet in een fysiologisch functionerende elastische vezel 
(60). De temporele en spatieële regulatie van deze componenten is naar alle 
waarschijnlijkheid moeilijk te recapituleren in een volwassen individu (60). 
Farmacologische interventie moet daarom gericht zijn op processen in de 
pathogene cascade die voorafgaan aan afbraak van de elastische vezel. 
Getracht is het inflammatoire proces bij emfyseempatiënten te remmen door het 
inhaleren van corticosteroïden. Deze behandeling is echter niet succesvol 
gebleken (61-63). Wel kan het inflammatoire proces in zeer geringe mate 
onderdrukt worden door een fosfodiesterase(PDE)-4 remmer (64). Echter, het 
doseren van hogere concentraties van deze breed-spectrum remmer is niet 
wenselijk door het optreden van bijwerkingen zoals misselijkheid en overgeven
(64). De inzichten uit deze studie, die zowel TGF-p1 als fibrilline-1 aanwijzen als 
cruciale spelers in de pathogenese van emfyseem, opent de deur tot nieuwe 
therapeutische behandelingen. Perinatale toediening van een TGF-p
neutraliserend antilichaam in homozygote muizen met een hypomorf Fbn1 allel 
reduceert de excessieve down-stream TGF-p activatie en voorkomt hiermee de 
ontwikkeling van een emfysemateus fenotype (14). Een recente publicatie van 
Habashi et al. (65) laat zien dat TGF-p antagonisme een succesvolle 
behandeling kan zijn voor emfyseem bij Marfan patiënten (en misschien ook 
kan zijn voor patiënten met roken-geïnduceerd emfyseem). Recentelijk is 
Losartan, een angiotensine II type 1 receptor antagonist, die wordt gebruikt voor 
de behandeling van hypertensie, in beeld gekomen (65). Een groot voordeel 
van Losartan is het grootschalige gebruik hiervan in de kliniek en de 
exceptionele tolerantie van patiënten voor de verschillende bijwerkingen. In 
zowel humane als diermodellen met chronische nierinsufficiëntie liet Losartan 
een antagonistisch effect zien voor TGF-p (66;67). Perinatale toediening van 
Losartan in een Fbn1C1039G muis verminderde de down-stream activatie van 
TGF-p en voorkwam hiermee de ontwikkeling van een emfysemateus fenotype
(65). Momenteel loopt er een klinische trial die het effect van Losartan in COPD 
patiënten bestudeert (68). Patiënten met de diagnose emfyseem of chronische 
bronchitis worden behandeld met 50-100 mg Losartan of placebo. In deze 
clinical trial wordt de progressie van emfyseem in beeld gebracht met behulp 
van een high-resolution CT-scan, additionele longfunctietesten, inflammatoire 
biomarkers in serum en de bepaling van inflammatoire cellen in de 
bronchoalveolaire lavage. Naar verwachting worden de resultaten van deze 
studie eind 2012 gepubliceerd en de uitkomst van deze studie zal, in het licht 
van de hier gepresenteerde data, met veel interesse door de auteurs gevolgd 
worden.
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verbonden aan de Radboud Universiteit Nijmegen, Nijmegen Center for 
Molecular Life Sciences (NCMLS). Onder begeleiding van Dr. T.H. van 
Kuppevelt werd het promotieonderzoek uitgevoerd waarvan de resultaten 
beschreven staan in dit proefschrift. Tijdens haar promotie was zij betrokken bij 
diverse onderwijstaken en het begeleiden van studenten en stagiaires. Tevens 
heeft zij haar onderzoeksresultaten mogen presenteren op internationale 
congressen, waaronder de ‘Gordon Research Conference on Elastin and 
Elastic Fibers’ (Biddeford, USA, juli 2007) en de ‘American Thoracic Society 
(ATS) International Conference 2008’ (Toronto, Canada, mei 2008). Op het 
laatstgenoemde congres heeft zij een ‘International Trainee Travel Award’ 
gewonnen. Deze award was gebaseerd op de kwaliteit van het onderzoek en 
de gepresenteerde data. Sinds december 2008 is zij werkzaam als klinisch 
chemicus i.o. in het St. Elizabeth Ziekenhuis te Tilburg. Gedurende deze 
vierjarige postacademische opleiding zal zij zich focusseren op de verschillende 
aspecten van het medisch laboratoriumonderzoek. De opleiding zal worden 
afgesloten met een registratie als laboratoriumspecialist klinische chemie.
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‘You never forget some of the best times of your life!’ Met deze wijze woorden 
van Quincy Jones aan Frank Sinatra begint dit proefschrift. En terwijl ik de 
laatste woorden van mijn proefschrift op papier zet, weet ik, hij heeft gelijk! Na 
jaren van pipetteren, coupes snijden en het uitvoeren van immunohisto- 
chemische kleuringen is het afronden van je proefschrift een onvergetelijk 
moment! Het tot stand komen van dit alles is natuurlijk niet zonder de nodige 
hulp gebeurd. Hierbij gaat mijn dank dan ook uit naar iedereen die ook maar 
enige bijdrage heeft geleverd en interesse heeft getoond in mijn 
promotieonderzoek en proefschrift.
In het bijzonder wil ik mijn promotoren prof. dr. Roland Brock en prof. dr.
Richard Dekhuijzen en mijn copromotor dr. Toin van Kuppevelt bedanken.
Beste Roland, bedankt voor de mogelijkheid tot een promotieonderzoek binnen 
de vakgroep Biochemie. Tevens wil ik je bedanken voor de goede 
samenwerking bij de afronding van mijn proefschrift. Beste Richard, jouw 
expertise op het gebied van longziekten gecombineerd met je enthousiasme 
voor fundamenteel onderzoek hebben een grote bijdrage geleverd aan dit 
proefschrift. Dank je wel daarvoor! Beste Toin, bedankt dat ik binnen de sectie 
Matrix Biochemie de mogelijkheid heb gekregen om te promoveren. Ik denk met 
veel vreugde terug aan onze artikelbesprekingen die vaak eindigde in een 
brainstormsessie waarbij de context van mijn promotieonderzoek werd 
opgerekt. Het is aan deze sessies te danken dat wij meermalen naar 
Amsterdam of Enschede togen om nieuwe technieken te ontdekken waarmee 
we de pathogenese van emfyseem konden ontrafelen. Ik wens je veel succes 
met verdere onderzoekslijnen.
Ook wil ik prof. dr. Ben Hamel bedanken voor het corrigeren van enkele van 
mijn manuscripten en voor zijn inzichten in de genetica van Marfan syndroom. 
Beste Ben, ik wens je nog veel plezier toe met jouw onderzoekslijn in Moshi 
(Tanzania), een stad die zich, naar mijn mening, mag bogen op het beste 
uitzicht op de Kilimanjaro!
De leden van de manuscriptcommissie, prof. dr. Han van Krieken, dr. Thijs 
Hendriks en dr. Gerard Pals, wil ik bedanken voor hun snelle beoordeling van 
mijn proefschrift.
Binnen mijn promotieonderzoek heb ik het geluk gehad om te mogen 
samenwerken met enkele andere wetenschappelijke afdelingen. Ik heb dit kijkje 
in andermans keuken altijd zeer inspirerend gevonden en wil de volgende 
personen dan ook bedanken. Prof. dr. Jan Feijen, prof. dr. Piet Dijkstra, dr. 
Martin Bennink en dr. Lanti Yang bedankt dat jullie mij hebben willen inwijden in 
de wondere wereld van de Atomic Force Microscopy. Onze samenwerking heeft 
licht geworpen op de biomechanische eigenschappen van de fibrilline- 
microfibrillen en heeft geresulteerd in een mooie publicatie. Prof. dr. Dirkje 
Postma en prof. dr. Wim Timens wil ik bedanken voor het beschikbaar stellen 
van de primaire longfibroblasten. Dr. Gerard Pals, beste Gerard, bedankt voor 
je samenwerking in de zoektocht naar een causale fibrilline-1 mutatie. Ik hoop
dat je met behulp van DHPLC mutatiescreening in de toekomst meer inzicht 
weet te verschaffen in de pathogenese van Marfan syndroom en andere 
gerelateerde syndromen.
De medewerkers van de sectie Matrix Biochemie wil ik bedanken voor de fijne 
samenwerking en bovenal voor alle gezelligheid. De koekjes op woensdag, de 
donderdagavonden in de Aesculaaf, de paasbrunches en natuurlijk de 
kerstdiners staan in mijn geheugen gegrift. In het bijzonder bedankt voor alle 
hilarische momenten die jullie de organisatie hebben geschonken tijdens de 
jaarlijkse kerstquiz; de onnavolgbare imitaties van een kerstkalkoen zal ik echt 
nooit vergeten! En ook de talloze takes die Paul, Guido, Arie en ik nodig hebben 
gehad om de labgeluiden op band te krijgen voor de quiz hebben mij tot tranen 
geroerd.........van het lachen.
Een aantal medewerkers van de sectie Matrix Biochemie wil ik in het bijzonder 
bedanken. Elly, bedankt voor alle hulp tijdens mijn promotieonderzoek. Ik kon 
altijd bij jou terecht met vragen over de ‘longbank’ en het gebruik van 
longfunctiedata. Ook ben ik je zeer dankbaar voor alle kilometers die jij hebt 
afgetrapt richting Dekkerswald of het Canisius-Wilhelmina Ziekenhuis om 
longweefsels voor de ‘ longbank’ te verzamelen. Ronnie, samen hebben we 
aardig wat uurtjes achter de TEM en de SEM gezeten en door jouw handigheid 
met elektronenmicroscopie leverde dit onvoorstelbare mooie beelden op. 
Bedankt voor alle hulpvaardigheid. Paul J, bedankt voor je hulp bij het 
interpreteren van de TEM beelden van elastische vezels, want wat zijn mooie 
beelden als je niet precies weet waar je naar kijkt? Els, zonder jouw hulp had ik 
in mijn laatste jaar lang niet zoveel experimenten kunnen uitvoeren. Vooral jouw 
expertise op het gebied van de qPCR zijn van onschatbare waarde geweest. 
Maar ook de gezelligheid maakte de samenwerking geslaagd, lekker kletsen 
over “de zaken des levens” (kinderen, huizen, reizen, lekker uit eten gaan en 
winkelen....wat wil een mens nog meer?). Ik ben blij dat jij straks als paranimf 
aan mijn zijde zal staan. En last, but not least mijn mede junior onderzoekers: 
Nicole, Joost, Suzan, Tessa, Paul, Martin, Gerwen, Peter, Xander en Katrien. 
Lief en leed hebben we gedeeld. En vooral alle ontspanning (papendal!) die 
volgde op zo’n inspannend promotietraject zal ik zeker niet vergeten. Ik wens 
jullie allen heel veel succes bij het afronden van jullie promotie en jullie verdere 
carrière.
Ook vrienden en familie hebben natuurlijk een belangrijke rol gespeeld in de 
totstandkoming van mijn proefschrift. Bedankt voor jullie betrokkenheid en voor 
de nodige afleiding in de vorm cappuccino’s, lunches, glaasjes Prosecco, 
discoavondjes, culinaire hoogstandjes en slechte sinterklaascadeaus. In het 
speciaal wil ik hier mijn furie-vriendinnetjes bedanken. Ik vind het heel bijzonder 
dat 10 zo’n uitlopende karakters samenkomen tot een kakofonische chaos die 
aanvoelt als een familie. Elke keer dat we samenkomen is weer een waar 
avontuur en ik hoop met jullie nog vele avonturen te mogen beleven! Beste 
Rianne, lieve Ri, bedankt dat ik altijd bij je terecht kan voor een bakkie thee, 
een slaapplaats of een luisterend oor. Ik vind het heel fijn dat jij mij 16 juni 
mentaal als paranimf wil bijstaan.
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Lieve Marloes en Wim, bedankt voor jullie belangstelling in mijn proefschrift. 
Jullie luisterende oren en helpende handen stel ik ontzettend op prijs 
Lieve Anny en Frans, mama en papa, bedankt voor jullie onvoorwaardelijke 
steun, liefde en geloof in mij. Tijdens mijn promotietraject hebben jullie menige 
frustratie bij mij weten om te buigen in enthousiasme en zonder jullie was het 
dan ook nooit gelukt! Zonder jullie klushulp waren de muren trouwens ook niet 
zo mooi geschilderd en lag de tuin er ook niet zo fraai bij!
De laatste woorden blijven over voor jou, Maarten. Samen hebben we al heel 
wat mooie landen in de wereld mogen ontdekken tijdens onze reizen. Ook dit 
promotietraject is voor ons beide een onvergetelijke reis geweest. Een reis 
waarbij we hoge bergen hebben beklommen om te kunnen genieten van 
schitterende vergezichten, maar ook een reis waarbij we soms verdwaalden 
tussen de bomen en samen de weg weer terug moesten vinden. Maar met het 
juiste reisgezelschap kan elk onontgonnen gebied worden ontdekt.
Lieve Maarten, bedankt voor je onvoorwaardelijke steun en geloof in mij. Om af 
te sluiten met de woorden van Stef Bos ‘Ik heb je  lief, Ik heb je  liever, liefste, 
Elke dag'.
172
